ICMR NIN Indian Food Composition Tables pulses fruits nutrition values calories protein fibre

~/

child nutrition AND dietary fiber

Indian food nutrition spotter raw rice toor dal chana dal moong dal green gram urad dal ragi jaggery peanuts fruits egg banana apple mango guava papaya custard apple coconut pear

~/attachments/589c3435-dc77-40e2-ab7d-a1c643ab31f3/

mkdir -p "/tmp/workspace/nutrition-spotter/src" "/tmp/workspace/nutrition-spotter/output" && python -c "from pypdf import PdfReader; p='/tmp/workspace/attachments/589c3435-dc77-40e2-ab7d-a1c643ab31f3/Elizabeth nutrition.pdf'; r=PdfReader(p); print('pages',len(r.pages)); open('/tmp/workspace/nutrition-spotter/src/elizabeth_extracted.txt','w',encoding='utf-8').write('\\n\\n'.join((x.extract_text() or '') for x in r.pages))" && wc -c "/tmp/workspace/nutrition-spotter/src/elizabeth_extracted.txt"

"Toor" in ~/nutrition-spotter/src

"Pigeon" in ~/nutrition-spotter/src

"Nutritive value" in ~/nutrition-spotter/src

"Jaggery" in ~/nutrition-spotter/src

"Papaya" in ~/nutrition-spotter/src

https://www.nin.res.in/ebooks/IFCT2017.pdf

A clear educational photographic identification chart of Indian nutrition spotter dry foods, with separate realistic panels showing raw white rice, toor dal, chana dal, split moong dal, whole green gram, white urad dal, ragi grain, sugar crystals, yellow jaggery block, shelled peanuts, and labelled short common names.

A clear educational photographic identification chart of food nutrition spotters, with separate realistic panels showing a chicken egg, banana, red apple, ripe mango, guava cut open, small papaya, custard apple, fresh coconut half, and pear. Include only short common name labels.

ICMR NIN Dietary Guidelines Indians 2024 child healthy diet fruit pulse eggs nuts food safety choking

~/

python - <<'PY' from reportlab.lib import colors from reportlab.lib.pagesizes import A4, landscape from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER, TA_LEFT from reportlab.platypus import SimpleDocTemplate, Table, TableStyle, Paragraph, Spacer, KeepTogether from reportlab.lib.units import mm from reportlab.pdfbase.ttfonts import TTFont from reportlab.pdfbase import pdfmetrics from reportlab.lib.colors import HexColor from pypdf import PdfReader import os out='/tmp/workspace/nutrition-spotter/output/Nutrition_Spotters_One_Page.pdf' os.makedirs(os.path.dirname(out), exist_ok=True) page=landscape(A4) doc=SimpleDocTemplate(out,pagesize=page,rightMargin=8*mm,leftMargin=8*mm,topMargin=7*mm,bottomMargin=7*mm) styles=getSampleStyleSheet() title=ParagraphStyle('title',parent=styles['Title'],fontName='Helvetica-Bold',fontSize=16,leading=17,textColor=HexColor('#123B5D'),alignment=TA_CENTER,spaceAfter=2) sub=ParagraphStyle('sub',parent=styles['Normal'],fontName='Helvetica',fontSize=7.2,leading=8.2,alignment=TA_CENTER,textColor=HexColor('#415466'),spaceAfter=4) head=ParagraphStyle('head',parent=styles['Normal'],fontName='Helvetica-Bold',fontSize=7.0,leading=7.7,textColor=colors.white,alignment=TA_CENTER) cell=ParagraphStyle('cell',parent=styles['Normal'],fontName='Helvetica',fontSize=6.45,leading=7.25,textColor=HexColor('#17232C')) food=ParagraphStyle('food',parent=cell,fontName='Helvetica-Bold',fontSize=6.5,leading=7.25) foot=ParagraphStyle('foot',parent=styles['Normal'],fontName='Helvetica',fontSize=5.7,leading=6.4,textColor=HexColor('#45545E'),alignment=TA_LEFT) def P(x,s=cell): return Paragraph(x,s) rows=[ ['Raw rice','350','7','0.2','Cereal; carbohydrate-rich. Pair with dal: cereal is lysine-poor.'], ['Toor dal / red gram','340','22','1.5','Pulse; protein, iron, B vitamins. Methionine-limited.'], ['Chana dal / Bengal gram','360','17','3.9','Protein, iron and fibre; economical pulse.'], ['Moong dal / green gram','340','24','4.1','Digestible pulse; sprouting adds vitamin C.'], ['Peas, dry','~315','~20','~4-5','Legume, protein and fibre. Fresh peas are much less calorie dense.'], ['Urad dal / black gram','350','24','0.9','Protein-rich; used in idli/dosa. Fermentation improves palatability.'], ['Ragi / finger millet','330','7','3.6','Millet; calcium-rich (~344 mg/100 g). Use thick, not watery porridge.'], ['Sugar','~400','0','0','Sucrose: energy only. Excess intake promotes dental caries.'], ['Jaggery / bellam','~380','~0.4','0','Energy concentrate with some iron; not treatment for IDA.'], ['Peanuts / groundnuts','560','25','3.1','Energy-dense protein and fat. Use paste/powder in young children: choking risk.'], ['Fresh coconut','444','4.5','~1','Fat-rich, energy-dense kernel; relatively high saturated fat.'], ['Egg, whole hen','~173','~13','0','High biological-value protein; B12, choline, vitamin A, iron. Fully cook.'], ['Banana','116','1.2','0.4','Soft energy-rich fruit; potassium; useful mashed in complementary feeds.'], ['Apple','59','0.2','1.0','Low-energy fruit with modest fibre; give age-appropriate texture.'], ['Mango, ripe','75','0.6','0.7','Carotene (pro-vitamin A)-rich seasonal fruit.'], ['Guava','50','0.9','5.2','Vitamin C-rich and high fibre; improves non-haem iron absorption.'], ['Papaya, ripe','32','0.6','0.8','Low-calorie, soft fruit; carotenoids and vitamin C.'], ['Custard apple / sitaphal','~104','~1.6','~2.4','Relatively energy-rich fruit. Remove all seeds.'], ['Pear','~42-57','~0.5','~3','Water-rich fruit; fibre, especially if peel is safely eaten.'], ['Avocado pear*','~215','~1.6','~6-7','Fat-rich fruit, unlike pear; monounsaturated fat and fibre.'], ] data=[[P('Spotter',head),P('kcal',head),P('Protein<br/>(g)',head),P('Fibre<br/>(g)',head),P('High-yield viva points',head)]] for r in rows: data.append([P(r[0],food),P(r[1]),P(r[2]),P(r[3]),P(r[4])]) widths=[46*mm,16*mm,18*mm,15*mm,169*mm] t=Table(data,colWidths=widths,repeatRows=1,rowHeights=[8.4*mm]+[5.35*mm]*len(rows),hAlign='CENTER') t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,0),HexColor('#1C6289')),('TEXTCOLOR',(0,0),(-1,0),colors.white), ('VALIGN',(0,0),(-1,-1),'MIDDLE'),('ALIGN',(1,1),(3,-1),'CENTER'), ('GRID',(0,0),(-1,-1),0.25,HexColor('#B8C8D3')), ('BACKGROUND',(0,1),(-1,-1),HexColor('#F8FBFC')), ('BACKGROUND',(0,1),(-1,11),HexColor('#EDF5F8')), ('BACKGROUND',(0,12),(-1,-1),HexColor('#FFF9EE')), ('LINEBELOW',(0,11),(-1,11),0.8,HexColor('#D58B29')), ('LEFTPADDING',(0,0),(-1,-1),2.3*mm),('RIGHTPADDING',(0,0),(-1,-1),2.3*mm), ('TOPPADDING',(0,0),(-1,-1),0.55*mm),('BOTTOMPADDING',(0,0),(-1,-1),0.55*mm), ])) story=[Paragraph('PAEDIATRIC NUTRITION SPOTTERS: ONE-PAGE VIVA SHEET',title),Paragraph('Approximate values per 100 g edible portion. Dry/raw values apply to rice, dals, ragi and peanuts. Cite the source and mention that variety, maturity and cooking alter values.',sub),t,Spacer(1,2.5*mm),Paragraph('<b>Rapid viva:</b> Cereal + pulse gives mutual amino-acid supplementation (rice + dal). Ragi is calcium-rich. Guava supports iron absorption through vitamin C. Sugar/jaggery are energy concentrates. Complementary feeds after 6 months should be thick and energy-dense. <b>*If the specimen is avocado.</b> &nbsp; <b>Sources:</b> Elizabeth KE, <i>Nutrition and Child Development</i>, Table 3.11, pp. 125-126; ICMR-NIN Indian Food Composition Tables (2017); ICMR-NIN Dietary Guidelines for Indians (2024).',foot)] doc.build(story) reader=PdfReader(out) print(out, 'pages=',len(reader.pages), 'bytes=',os.path.getsize(out)) PY

~/

WHO paediatric equipment endotracheal tube suction catheter IV cannula size colour coding guidance

mkdir -p "/tmp/workspace/instrument-viva/output" && python - <<'PY' from reportlab.lib.pagesizes import A4, landscape from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Table, TableStyle, Paragraph, Spacer from reportlab.lib.units import mm from pypdf import PdfReader import os out='/tmp/workspace/instrument-viva/output/Paediatric_Instrument_Spotters_One_Page.pdf' styles=getSampleStyleSheet() title=ParagraphStyle('t',parent=styles['Title'],fontName='Helvetica-Bold',fontSize=15.2,leading=16.5,textColor=HexColor('#103C5A'),alignment=TA_CENTER,spaceAfter=2) sub=ParagraphStyle('s',parent=styles['Normal'],fontSize=6.9,leading=7.7,textColor=HexColor('#465966'),alignment=TA_CENTER,spaceAfter=3) h=ParagraphStyle('h',parent=styles['Normal'],fontName='Helvetica-Bold',fontSize=6.7,leading=7.3,textColor=colors.white,alignment=TA_CENTER) c=ParagraphStyle('c',parent=styles['Normal'],fontName='Helvetica',fontSize=5.75,leading=6.32,textColor=HexColor('#182A35')) f=ParagraphStyle('f',parent=c,fontName='Helvetica-Bold') foot=ParagraphStyle('foot',parent=c,fontSize=5.35,leading=5.9,textColor=HexColor('#45545E')) def P(t,st=c): return Paragraph(t,st) items=[ ('Ambu bag + reservoir + mask','Manual positive-pressure ventilation in resuscitation. Select mask that seals nose and mouth without covering eyes. Reservoir increases delivered O₂ when attached to oxygen.'), ('Thermometer','Measures temperature. Digital axillary is commonly used in children. Clean between patients; do not use a mercury thermometer.'), ('ET tube: cuffed / uncuffed','Definitive airway and ventilation. Size is internal diameter in mm. Cuffed tube permits lower leak and ventilation monitoring; use minimal cuff pressure. Confirm with clinical assessment plus waveform capnography where available.'), ('Nebulisation mask','Delivers aerosolised drug, often salbutamol. Use a well-fitting mask in young child. MDI + spacer is usually equally effective for mild-moderate wheeze and often preferred.'), ('Laryngoscope: straight / curved','Visualises glottis for intubation. Miller straight blade lifts epiglottis directly, useful in neonates/infants. Macintosh curved blade sits in vallecula, commonly used in older children.'), ('Feeding tube: 5F, 6F, 8F','Orogastric/nasogastric feeding, gastric decompression or aspiration. French (F): 1 F = 0.33 mm external diameter. Confirm position by aspirate pH and local protocol before feeding; do not rely on air insufflation alone.'), ('Bone marrow aspiration / biopsy needle','Obtains marrow for morphology, flow cytometry, culture or biopsy. Usual paediatric site: posterior superior iliac crest. Aspiration and trephine biopsy are distinct. Maintain asepsis, analgesia/sedation and pressure dressing.'), ('Rotahaler','Capsule-based dry-powder inhaler. Patient loads and pierces capsule, then inhales rapidly and deeply. Not suitable if child cannot generate adequate inspiratory flow; capsule is not swallowed.'), ('Revolizer','Another capsule-based dry-powder inhaler. Open, insert capsule, pierce, then forceful deep inhalation. Check capsule is empty. Rinse mouth after inhaled corticosteroid.'), ('Syringe','Measures and administers medication or draws fluid. Choose appropriate volume for accuracy, use sterile single-use equipment, remove air and label prepared drugs.'), ('Oxygen tubing','Connects oxygen source to delivery device. Check source, flow, tubing patency and device fit. Oxygen is a drug: titrate to target saturation and monitor.'), ('Face mask','Delivers oxygen or assists bag-mask ventilation. Correct size permits a seal over mouth and nose. Avoid excessive pressure and avoid covering eyes.'), ('Suction catheter','Clears airway secretions. Size is in French. Use sterile technique when indicated, pre-oxygenate high-risk patients, limit duration and suction only while withdrawing. Watch for hypoxia/bradycardia/trauma.'), ('Umbilical cord clamp','Clamps cord after birth to prevent bleeding. Apply securely 2-3 cm from the abdominal wall after delayed cord clamping when appropriate. Inspect stump for bleeding or infection.'), ('IV cannula / scalp-vein set','Peripheral venous access for fluids, drugs and samples. Common IV cannula codes: 24G yellow, 22G blue, 20G pink, but colour varies by manufacturer. Scalp-vein set is for short peripheral access or blood sampling, not prolonged infusion.'), ('LP needle: Quincke / Whitacre','CSF sampling or intrathecal therapy. Quincke has cutting bevel; Whitacre is pencil-point atraumatic. Use asepsis, correct position and appropriate length; monitor for headache, bleeding, infection and neurologic symptoms.'), ('Butterfly cannula','Winged needle with short tubing for venepuncture or brief access. Secure well; avoid use for vesicants or prolonged infusion because of infiltration risk.'), ('Foley catheter, e.g. 8F','Indwelling urinary drainage and accurate output measurement. Size is French. Insert aseptically, use smallest suitable size, inflate balloon only after urine return, and remove as soon as possible to reduce CAUTI.'), ('Peak expiratory flow-rate meter','Measures peak expiratory flow for asthma monitoring in cooperative children, usually >5-6 years. Standing, maximal inspiration then one hard fast blow; take best of 3. Compare with personal best, not only predicted value.'), ('Insulin syringe','U-100 syringe: 100 units = 1 mL. Use only with matching insulin concentration. Insulin is administered subcutaneously; check dose and concentration independently.'), ('MDI, usually blue salbutamol','Pressurised metered-dose inhaler. Blue commonly indicates salbutamol in many markets, but verify label. Use spacer, one puff at a time, then 5-6 tidal breaths in young children.'), ('Tongue depressor','Examines mouth, pharynx and tonsils. Depress anterior tongue gently, avoid gagging. Single-use wooden depressor reduces cross-infection.'), ('Knee hammer','Tests deep tendon reflexes, especially patellar reflex (L3-L4, femoral nerve). Patient must be relaxed; compare sides and look for briskness/clonus.'), ('Torch','Assesses pupils, red reflex and oral/throat illumination. Red-reflex test detects leukocoria such as cataract or retinoblastoma and needs urgent referral if abnormal.'), ] data=[[P('Instrument',h),P('High-yield viva statement: identify, state use and one safety point',h)]] for a,b in items: data.append([P(a,f),P(b,c)]) page=landscape(A4) doc=SimpleDocTemplate(out,pagesize=page,leftMargin=8*mm,rightMargin=8*mm,topMargin=6*mm,bottomMargin=6*mm) t=Table(data,colWidths=[51*mm,211*mm],rowHeights=[7.2*mm]+[5.42*mm]*len(items),repeatRows=1) t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,0),HexColor('#17628B')),('TEXTCOLOR',(0,0),(-1,0),colors.white), ('GRID',(0,0),(-1,-1),0.22,HexColor('#B9CAD4')),('VALIGN',(0,0),(-1,-1),'MIDDLE'), ('BACKGROUND',(0,1),(-1,6),HexColor('#EAF5F8')),('BACKGROUND',(0,7),(-1,15),HexColor('#F7FAFC')),('BACKGROUND',(0,16),(-1,-1),HexColor('#FFF8EA')), ('LINEBELOW',(0,6),(-1,6),0.65,HexColor('#3891A6')),('LINEBELOW',(0,15),(-1,15),0.65,HexColor('#D79832')), ('LEFTPADDING',(0,0),(-1,-1),2.1*mm),('RIGHTPADDING',(0,0),(-1,-1),2.1*mm),('TOPPADDING',(0,0),(-1,-1),0.46*mm),('BOTTOMPADDING',(0,0),(-1,-1),0.46*mm), ])) story=[Paragraph('PAEDIATRIC INSTRUMENT SPOTTERS: ONE-PAGE VIVA POINTS',title),Paragraph('Give every answer as: <b>identify → use/indication → size or technique → one safety precaution.</b> Follow local institutional policies for devices, sizes and infection-control procedures.',sub),t,Spacer(1,1.4*mm),Paragraph('<b>Sources:</b> WHO service-readiness list includes paediatric ETTs, paediatric/neonatal laryngoscope equipment and airway supplies; standard paediatric emergency and procedure principles. Device-specific colours and technique may differ by manufacturer and hospital protocol. <b>Exam safety line:</b> “I will confirm patient, device size, sterility, position/function and monitoring before use.”',foot)] doc.build(story) r=PdfReader(out) print(out, len(r.pages), os.path.getsize(out)) PY

~/

paediatric clinical procedures endotracheal tube sizing lumbar puncture needle cannula colour coding peak flow guidelines

python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak, KeepTogether from reportlab.lib.units import mm from pypdf import PdfReader import os out='/tmp/workspace/instrument-viva/output/Detailed_Paediatric_Instrument_Viva_Answers.pdf' os.makedirs(os.path.dirname(out),exist_ok=True) styles=getSampleStyleSheet() TITLE=ParagraphStyle('Title2',parent=styles['Title'],fontName='Helvetica-Bold',fontSize=19,leading=23,textColor=HexColor('#123E5C'),alignment=TA_CENTER,spaceAfter=5) SUB=ParagraphStyle('Sub',parent=styles['Normal'],fontSize=9,leading=12,alignment=TA_CENTER,textColor=HexColor('#475967'),spaceAfter=12) H1=ParagraphStyle('H1',parent=styles['Heading1'],fontName='Helvetica-Bold',fontSize=14,leading=17,textColor=HexColor('#123E5C'),spaceBefore=10,spaceAfter=6) H2=ParagraphStyle('H2',parent=styles['Heading2'],fontName='Helvetica-Bold',fontSize=11,leading=14,textColor=HexColor('#126B7B'),spaceBefore=8,spaceAfter=4) BODY=ParagraphStyle('B',parent=styles['Normal'],fontName='Helvetica',fontSize=8.35,leading=11.2,textColor=HexColor('#1F2E38'),spaceAfter=3) SMALL=ParagraphStyle('S',parent=BODY,fontSize=7.25,leading=9) BOXH=ParagraphStyle('BH',parent=BODY,fontName='Helvetica-Bold',fontSize=8.2,leading=10,textColor=colors.white) BOX=ParagraphStyle('BX',parent=BODY,fontSize=7.7,leading=9.5) FOOT=ParagraphStyle('F',parent=SMALL,fontSize=6.7,leading=8,textColor=HexColor('#53636C')) def p(t,st=BODY): return Paragraph(t,st) def bullet(t): return Paragraph('• '+t,BODY) def info_table(rows): data=[[p('<b>What the examiner expects</b>',BOXH),p('<b>Answer</b>',BOXH)]] for a,b in rows:data.append([p('<b>'+a+'</b>',BOX),p(b,BOX)]) t=Table(data,colWidths=[43*mm,138*mm],hAlign='LEFT') t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),HexColor('#176A87')),('TEXTCOLOR',(0,0),(-1,0),colors.white),('GRID',(0,0),(-1,-1),.3,HexColor('#B8D0DA')),('BACKGROUND',(0,1),(0,-1),HexColor('#EAF5F8')),('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),3*mm),('RIGHTPADDING',(0,0),(-1,-1),3*mm),('TOPPADDING',(0,0),(-1,-1),2*mm),('BOTTOMPADDING',(0,0),(-1,-1),2*mm)])) return t def instrument(name, ident, uses, sizing, technique, safety, follow): return [Paragraph(name,H2),info_table([('Identify',ident),('Uses / indications',uses),('Size / key facts',sizing),('Technique point',technique),('Safety / complications',safety),('Common follow-up',follow)]),Spacer(1,4)] story=[] story += [Paragraph('DETAILED PAEDIATRIC INSTRUMENT SPOTTERS',TITLE),Paragraph('Final MD Paediatrics practical viva handbook | Identify → indication → size/parts → technique → precaution → follow-up answer',SUB), p('<b>How to score in a spotter:</b> First name the device correctly. Then state one or two indications, the relevant size or colour code, a technique principle, and one safety check. Avoid giving a size without confirming the child’s age, weight, device manufacturer and local protocol.'), p('<b>Important:</b> This is an examination revision guide, not a substitute for supervised procedural training or your hospital’s current SOP. In emergencies use local paediatric resuscitation algorithms and a length-based tape where available.'),Spacer(1,7),Paragraph('Universal safety answer for any device',H1), bullet('<b>Before:</b> confirm patient identity, indication, allergies, equipment integrity/expiry, appropriate size, monitoring and consent where applicable.'),bullet('<b>During:</b> asepsis when indicated, use age-appropriate analgesia/sedation, monitor oxygenation and clinical status.'),bullet('<b>After:</b> confirm device position or function, secure it, document size/depth/time, reassess the child and look for complications.'),Spacer(1,6),Paragraph('Quick conversion and colour-code facts',H1)] quick=[['French (F)','External diameter: 1 F = 0.33 mm. Used for feeding tubes, urinary catheters and suction catheters.'],['Gauge (G)','Higher gauge = smaller external diameter. Common peripheral cannula colours: 24G yellow, 22G blue, 20G pink, 18G green. Manufacturer codes may differ.'],['ETT size','Internal diameter in mm. Prefer length-based tape. If unavailable: uncuffed ID = age/4 + 4; cuffed ID = age/4 + 3.5, for children >1 year. Have 0.5 mm sizes above and below ready.'],['ETT depth','Use a length-based tape where possible. A rough oral-depth estimate is 3 × ETT internal diameter in cm. Always confirm clinically and with waveform capnography; radiograph as appropriate.'],['Insulin','U-100 insulin: 100 units = 1 mL. Use an insulin syringe or pen matched to the insulin concentration.']] story.append(info_table([(a,b) for a,b in quick])) story.append(PageBreak()) story.append(Paragraph('1. AIRWAY, BREATHING AND INHALATION DEVICES',H1)) story += instrument('1. Ambu bag, oxygen reservoir and face mask','A self-inflating bag-valve-mask device for manual positive-pressure ventilation. The reservoir bag attaches to the oxygen inlet and increases delivered oxygen concentration.','Apnoea, ineffective breathing, cardiopulmonary resuscitation, preoxygenation and ventilation while preparing for advanced airway.','Choose an age-appropriate bag and mask. A transparent mask allows observation of colour, secretions and fogging. Mask should cover mouth and nose, not eyes.','Open airway with appropriate head position. Use a two-person technique when possible: one creates a two-handed mask seal and jaw thrust, the other squeezes bag. Give visible chest rise, avoiding over-ventilation.','Poor seal, gastric inflation, aspiration, barotrauma and volutrauma. Do not hyperventilate. Attach oxygen, use reservoir if available, and monitor SpO₂ and clinical chest rise.','<b>Why is a two-person technique better?</b> It improves mask seal and airway patency, particularly in infants or difficult airways.' ) story += instrument('2. Thermometer','A device to measure body temperature. Digital thermometers are standard; infrared temporal devices may be used according to local policy.','Recognition and monitoring of fever or hypothermia, including sepsis assessment and post-resuscitation monitoring.','Axillary temperature is convenient but can underestimate core temperature. Rectal temperature is closer to core but has risk of trauma and is avoided in neutropenia, thrombocytopenia and certain anorectal conditions.','Use a clean device and the prescribed site. Ensure correct placement and wait for completion signal. Record value, site and method.','Do not use mercury thermometers. Clean or use disposable covers between patients. Interpret fever in clinical context, especially in young infants.','<b>What is fever?</b> In routine clinical practice, temperature ≥38.0°C is treated as fever; method and site must be stated.' ) story += instrument('3. Endotracheal tube: cuffed and uncuffed','A tube passed through the glottis into trachea to secure airway and deliver controlled ventilation. Size refers to internal diameter in millimetres.','Failure of oxygenation or ventilation, airway protection, anticipated deterioration, severe trauma, status epilepticus or anaesthesia.','Modern cuffed tubes are acceptable in children when correctly sized and cuff pressure monitored. WHO readiness lists paediatric uncuffed ETTs 3.0-5.0 mm as essential equipment.','Prepare suction, oxygen, bag-mask, laryngoscope, capnography, fixation and rescue equipment. Confirm tracheal placement by sustained waveform capnography, bilateral chest rise and auscultation; document size and lip depth.','Oesophageal or endobronchial placement, hypoxia, trauma, aspiration, tube obstruction and cuff-related mucosal injury. Keep cuff pressure low, commonly <20-25 cm H₂O per local policy.','<b>How do you choose ETT size?</b> Prefer length-based tape. If unavailable in a child >1 year: uncuffed = age/4 + 4; cuffed = age/4 + 3.5. Prepare adjacent sizes.' ) story += instrument('4. Nebulisation mask / nebuliser','Aerosol delivery system that turns liquid medication into inhalable particles, usually driven by oxygen or compressed air.','Bronchodilator delivery in acute wheeze/asthma; selected use for adrenaline in upper-airway obstruction according to protocol.','Select a snug age-appropriate mask. Gas flow depends on device, commonly 6-8 L/min for jet nebulisers. Drug dose is prescription- and protocol-specific.','Keep child upright where possible; ensure visible aerosol. Reassess work of breathing, air entry, heart rate and SpO₂.','Poor mask fit reduces delivery. Avoid routine oxygen-driven nebulisation when the child does not need oxygen if air-driven source is available. Clean equipment to prevent infection.','<b>MDI-spacer or nebuliser?</b> For many mild-moderate asthma exacerbations, salbutamol by pressurised MDI with spacer is at least as effective and faster; nebuliser is used when indicated by severity or local protocol.' ) story += instrument('5. Laryngoscope blades: straight and curved','Laryngoscope handle with light source and blade, used to visualise larynx during tracheal intubation.','Endotracheal intubation, foreign-body or airway assessment by trained personnel.','Straight Miller blade: lifts epiglottis directly, useful in neonates and young infants. Curved Macintosh blade: placed in vallecula to indirectly lift epiglottis, common in older children. Blade size is age/child dependent.','Check light and batteries before induction. Position child, optimize preoxygenation, insert blade without levering on teeth, and aim to minimize attempts.','Dental/oral trauma, hypoxia from prolonged attempts, haemodynamic instability. A failed airway plan, suction and alternate device must be ready.','<b>Why are straight blades useful in infants?</b> Infant epiglottis is relatively long, floppy and more cephalad; direct lift can give a better view.' ) story.append(PageBreak());story.append(Paragraph('2. TUBES, SUCTION, VASCULAR AND URINARY ACCESS',H1)) story += instrument('6. Feeding tube: NG/OG, 5F, 6F, 8F','A flexible tube passed nasally or orally into the stomach. Used for feeding, medication, decompression or aspirate.','Enteral feeding when oral intake is unsafe/inadequate; gastric decompression in bowel obstruction or during ventilation; gastric aspirate when indicated.','Size is French. 5F and 6F are small neonatal tubes; 8F is common in infants/children depending on indication. 1F = 0.33 mm external diameter.','Measure and mark insertion length using institutional method. Before every feed or medicine, check external length and confirm gastric position by aspirate pH per local policy.','Misplacement into airway, aspiration, nasal trauma, blockage and pressure injury. Do not use auscultation after air insufflation as sole confirmation. Obtain radiograph if placement is uncertain or policy requires it.','<b>NG versus OG?</b> OG is often preferred in small infants on nasal CPAP or with nasal obstruction; NG can be more secure for longer use in an otherwise stable child.' ) story += instrument('7. Suction catheter','Flexible sterile catheter connected to suction apparatus to remove airway secretions.','Clear secretions from upper airway, ETT or tracheostomy in a child unable to clear them.','Size is in French. For ETT suction, catheter external diameter should generally be less than about half the ETT internal diameter to limit occlusion and hypoxia.','Set appropriate suction pressure per local policy. Insert without suction to predetermined depth, then apply suction only while withdrawing. Keep duration brief.','Hypoxaemia, bradycardia, mucosal trauma, bleeding, atelectasis and raised intracranial pressure. Preoxygenate or increase support in high-risk ventilated children and monitor throughout.','<b>Why no suction on insertion?</b> It reduces mucosal injury and prevents the catheter from adhering to tissue.' ) story += instrument('8. Peripheral IV cannula and scalp-vein set','A peripheral intravenous catheter provides venous access for fluid, medication, blood products or sampling. A scalp-vein set, also called a butterfly needle, has wings and short tubing.','Resuscitation fluids, IV drugs, blood sampling and transfusion. Butterfly is mainly for venepuncture or brief access.','Common cannula codes: 24G yellow, 22G blue, 20G pink, 18G green. Use the smallest gauge that meets clinical need. Colour coding varies by brand.','Apply tourniquet, use aseptic non-touch technique, obtain flashback, advance catheter, release tourniquet, flush, secure, label date/time and monitor site.','Infiltration/extravasation, phlebitis, haematoma, infection and nerve/arterial injury. Stop infusion immediately if pain, swelling, blanching or coolness occurs. Do not use butterfly for prolonged infusions or vesicants unless specific protocol supports it.','<b>Which cannula for shock?</b> Obtain two large-bore peripheral IVs if feasible; intraosseous access should not be delayed if IV access cannot be rapidly established.' ) story += instrument('9. Foley urinary catheter, e.g. 8F','An indwelling urethral catheter with retention balloon for continuous bladder drainage.','Accurate urine output in critical illness, urinary retention, perioperative drainage, neurogenic bladder management or selected urine sampling.','Size in French. Use the smallest appropriate catheter. 8F may be suitable for a child but selection is age, urethral size and indication dependent.','Use strict asepsis. Lubricate, insert gently until urine returns, then advance as directed before inflating balloon with sterile water using volume specified on catheter. Secure without traction.','CAUTI, urethral trauma, haematuria, false passage, bladder spasm and accidental removal. Never inflate balloon before confirming intravesical placement. Remove as soon as indication ends.','<b>How can CAUTI be prevented?</b> Avoid unnecessary catheterisation, aseptic insertion, closed drainage system, unobstructed dependent drainage and early removal.' ) story += instrument('10. Umbilical cord clamp','Plastic clamp used to occlude the umbilical cord after delivery and prevent bleeding.','Routine newborn cord care after cord division.','Clamp is placed securely several centimetres from abdominal wall after delayed cord clamping where appropriate. Exact timing follows neonatal resuscitation/obstetric policy.','Inspect cord and clamp for bleeding before leaving newborn. Keep stump clean and dry; provide cord-care advice.','Bleeding from inadequate clamp, infection/omphalitis and accidental traction. Redness spreading onto abdominal wall, purulent discharge or systemic illness require urgent assessment.','<b>What is delayed cord clamping?</b> Deferring clamping after birth, commonly at least 1 minute in vigorous newborns, subject to maternal/newborn condition and local protocol.' ) story.append(PageBreak());story.append(Paragraph('3. PROCEDURAL INSTRUMENTS',H1)) story += instrument('11. Lumbar puncture needle: Quincke and Whitacre','Spinal needle used to obtain CSF, measure opening pressure when appropriate or administer intrathecal treatment. Quincke has a cutting bevel; Whitacre is a pencil-point atraumatic needle.','Suspected meningitis/encephalitis after stabilisation, selected neurologic/inflammatory disorders, intrathecal chemotherapy and spinal anaesthesia in relevant settings.','Needle gauge and length depend on age and body habitus. Atraumatic needles are associated with lower post-dural puncture headache when available and appropriate.','Position lateral decubitus or sitting. Identify L3-L4 or L4-L5, maintain strict asepsis, local anaesthesia/analgesia and monitoring. Label tubes in correct sequence.','Do not perform with cardio-respiratory instability requiring immediate resuscitation, signs of impending herniation, infection at site or uncorrected significant bleeding risk. Consider neuroimaging only when clinically indicated, not routinely.','<b>Why LP below L2?</b> The spinal cord ends above this level in children, so L3-L4 or L4-L5 reduces risk of cord injury.' ) story += instrument('12. Bone marrow aspiration and trephine biopsy needle','Needles used to aspirate marrow particles and/or obtain a core biopsy for histology.','Evaluation of unexplained cytopenias, suspected leukaemia/lymphoma, marrow infiltration, storage disorders, HLH and selected infections.','Aspiration provides cytology, differential count, flow cytometry and microbiology. Trephine biopsy provides marrow architecture and cellularity. Posterior superior iliac crest is usual paediatric site.','Use sterile technique, adequate analgesia and often procedural sedation. Collect specimens promptly in correct tubes, make slides and apply firm pressure dressing after procedure.','Pain, bleeding, infection, inadequate sample and rare injury to nearby structures. Check platelet count/coagulation risk where relevant and observe post-procedure.','<b>Why both aspirate and biopsy?</b> Aspirate shows individual cell morphology; biopsy shows architecture, fibrosis, cellularity and focal infiltrates.' ) story += instrument('13. Syringe','Graduated barrel and plunger used to withdraw or administer fluids/drugs.','Medication delivery, blood sampling, flushing lines, aspiration and dilution.','Select smallest syringe that permits accurate measurement: 1 mL syringe for tiny volumes, 2-5 mL for small doses, larger syringes for flushing/aspiration. Luer-lock helps prevent disconnection.','Read volume at leading edge of plunger stopper. Expel excess air if required, label prepared syringe with drug, concentration, dose, patient and time.','Wrong-route, wrong-concentration and needlestick errors. Use needleless systems where available; never recap needles routinely and dispose immediately into sharps container.','<b>Why use a 1 mL syringe?</b> It gives more accurate measurement of very small paediatric volumes.' ) story += instrument('14. Insulin syringe','A calibrated syringe specifically for insulin, normally marked in units.','Subcutaneous insulin administration in diabetes or hyperkalaemia protocols when ordered.','For U-100 insulin: 100 units = 1 mL, so 1 unit = 0.01 mL. Syringe must match insulin concentration. Many modern services use pens rather than syringes.','Check insulin type, concentration, dose, timing, blood glucose and meal plan. Use subcutaneous injection sites and rotate sites.','The major risk is dose error causing hypoglycaemia or hyperglycaemia. Never substitute a non-insulin syringe without a deliberate, double-checked volume conversion.','<b>What must be checked before insulin?</b> Patient, insulin type, concentration, units, timing, current glucose, feeding status and independent double-check according to policy.' ) story.append(PageBreak());story.append(Paragraph('4. ASTHMA DEVICES, MONITORING AND EXAMINATION TOOLS',H1)) story += instrument('15. Rotahaler','A capsule-based dry-powder inhaler. The capsule contains powder and is pierced inside device.','Maintenance inhaled therapy in a cooperative child able to generate adequate inspiratory flow.','Capsules are device-specific and must not be swallowed. Child needs a fast, deep inspiratory effort, unlike spacer use.','Open device, insert capsule, pierce as designed, exhale away from device, seal lips and inhale deeply/forcefully. Hold breath if able, then check capsule is empty.','Not reliable in very young children or severe acute exacerbation because inspiratory flow may be insufficient. Rinse mouth after inhaled corticosteroids to reduce oral candidiasis.','<b>What is the disadvantage in small children?</b> It requires adequate inspiratory flow and coordination, so MDI with spacer is generally preferred.' ) story += instrument('16. Revolizer','A single-dose capsule dry-powder inhaler, similar in principle to Rotahaler.','Delivery of prescribed dry-powder inhaled medication in older cooperative children/adolescents.','The capsule is loaded and pierced, then inhaled through device. It is not an oral capsule.','Demonstrate: open, insert capsule, pierce, breathe out away from mouthpiece, inhale rapidly/deeply, hold breath, repeat if powder remains.','Same precautions as other DPIs: poor technique, inadequate inspiratory flow and failure to rinse after steroid use. Keep device dry.','<b>How do you check technique?</b> Ask the child to demonstrate. Check capsule placement, forceful inhalation, breath hold and whether powder remains.' ) story += instrument('17. Metered-dose inhaler (MDI), often blue salbutamol','Pressurised canister that delivers a metered aerosol dose. In many settings a blue inhaler is salbutamol, but always read the label because colour is not universal.','Reliever bronchodilator delivery, usually salbutamol, for wheeze/asthma according to an action plan or acute-care protocol.','Use with valved holding chamber/spacer in children. One actuation at a time. In young children, mask spacer and several tidal breaths are used.','Shake, attach to spacer, child exhales, actuate one puff into chamber, then takes a slow deep breath and holds if possible or 5-6 tidal breaths in young child. Repeat prescribed puffs one at a time.','Poor coordination without spacer, failure to shake or prime, multiple puffs fired together, empty canister and excessive use without review. Observe for tremor/tachycardia after β₂ agonist.','<b>Why is spacer important?</b> It reduces oropharyngeal deposition, improves lung delivery and removes need for precise actuation-inhalation coordination.' ) story += instrument('18. Peak expiratory flow rate (PEFR) meter','Portable meter measuring maximum flow achieved during a forceful expiration from full inspiration.','Monitoring variable airflow obstruction in cooperative children with asthma; supports action plans and assessment of response in selected patients.','Usually reliable in children around 5-6 years or older if they can perform reproducibly. Interpret using the child’s personal best where available.','Stand or sit upright, reset marker, full breath in, tight seal, then one short hard fast blow. Repeat three times and record the highest reading.','Technique-dependent and not a substitute for clinical assessment. Avoid comparing readings across different meter brands. In acute severe asthma, do not delay treatment for PEFR.','<b>What are action-plan zones?</b> Commonly green 80-100% of personal best, yellow 50-79%, red <50%, but follow the child’s written action plan.' ) story += instrument('19. Tongue depressor','Flat disposable wooden or plastic blade for oral and pharyngeal examination.','Inspect oral cavity, tongue, tonsils and posterior pharynx; may help obtain throat swab.','Use single-use device. In a cooperative child, ask them to open mouth and say “aaah.”','Depress the anterior two-thirds of tongue gently, not the posterior third, and inspect systematically with good light.','Gagging, vomiting, bite injury and cross-infection. Do not force examination in a child with suspected epiglottitis or impending airway obstruction.','<b>Why avoid examination in suspected epiglottitis?</b> Agitation and pharyngeal stimulation can precipitate complete airway obstruction.' ) story += instrument('20. Knee hammer','Reflex hammer used to elicit deep tendon reflexes.','Neurologic examination: tone, reflexes, symmetry and clonus assessment.','Patellar reflex tests predominantly L3-L4 via femoral nerve. Achilles reflex tests S1-S2 via tibial nerve.','Position limb relaxed and partially supported. Strike tendon briskly, not muscle. Compare sides and use reinforcement manoeuvre when needed in older child.','Do not interpret reflexes in isolation. Anxiety, poor relaxation and examination technique alter response.','<b>What does hyperreflexia suggest?</b> An upper motor neuron lesion, though age and anxiety must be considered; clonus strengthens this interpretation.' ) story += instrument('21. Torch','Small focused light source for clinical inspection.','Pupil examination, red reflex screening, mouth/throat illumination, skin inspection and transillumination in selected contexts.','For pupil testing use a dim environment. For red reflex use an ophthalmoscope ideally, but torch assists general inspection only.','Assess pupils for size, symmetry and direct/consensual light response. For red reflex, view through ophthalmoscope from about arm’s length in a dark room.','Avoid prolonged bright light exposure. Leukocoria, asymmetrical/dull red reflex or absent red reflex needs urgent ophthalmology assessment.','<b>What conditions cause leukocoria?</b> Retinoblastoma, congenital cataract, Coats disease, retinal detachment and severe retinopathy of prematurity among others.' ) story.append(PageBreak());story.append(Paragraph('5. COMMON EXAM FOLLOW-UPS AND RAPID TABLES',H1)) story.append(Paragraph('Airway size and confirmation',H2)) size_data=[['Question','Viva answer'],['How do I select ETT?','Length-based tape is preferred. If unavailable and age >1 year: uncuffed ID = age/4 + 4; cuffed ID = age/4 + 3.5. Prepare 0.5 mm smaller and larger.'],['How confirm ETT placement?','Continuous waveform capnography is the most reliable bedside confirmation in a perfusing patient. Also check chest rise, bilateral air entry, tube depth, no epigastric sounds and clinical improvement.'],['If suddenly difficult to ventilate through ETT?','Use DOPES: Displacement, Obstruction, Pneumothorax, Equipment failure, and breath Stacking. Call for help and give oxygen.'],['ETT cuff concern?','Use a properly sized modern cuffed tube, minimal effective cuff pressure and monitor pressure. Avoid prolonged high cuff pressure.']] story.append(info_table([(a,b) for a,b in size_data])) story.append(Spacer(1,6));story.append(Paragraph('Key device distinctions',H2)) dist=[['Device','Best one-line distinction'],['Nebuliser vs MDI-spacer','Nebuliser continuously generates aerosol; MDI with spacer delivers measured puffs and is preferred for many mild-moderate asthma episodes.'],['Rotahaler/Revolizer vs MDI-spacer','Dry-powder devices require forceful inspiratory flow; MDI-spacer works with tidal breaths and is suited to younger children.'],['Quincke vs Whitacre LP needle','Quincke is cutting-bevel; Whitacre is pencil-point atraumatic and may reduce post-dural puncture headache.'],['Aspiration vs trephine biopsy','Aspiration yields cells for morphology/flow; trephine yields core architecture/cellularity/fibrosis.'],['NG vs OG tube','NG for longer use in stable child; OG often preferred in tiny infants receiving nasal CPAP or with nasal obstruction.'],['IV cannula vs butterfly','Cannula is for ongoing infusion; butterfly is mainly for venepuncture/brief access.']] story.append(info_table([(a,b) for a,b in dist])) story.append(Spacer(1,7));story.append(Paragraph('References and scope',H1)) story += [p('1. World Health Organization. Harmonized Health Facility Assessment, core readiness questionnaire, 2023. Lists paediatric airway equipment, including ETTs, laryngoscope equipment and connectors.' ,FOOT),p('2. Sheffield Children’s NHS Foundation Trust. EMBrACE Airway Management Guideline, 2024. Paediatric airway equipment, ETT sizing and positioning principles.' ,FOOT),p('3. Standard paediatric emergency, neonatal and procedure texts. Follow institutional protocols for medication doses, equipment sizes, procedural sedation, asepsis and monitoring.' ,FOOT),p('<b>Revision warning:</b> Device colours, connector types, recommended sizes and local procedural details can differ by manufacturer and hospital. In a viva, say “I would confirm the manufacturer instructions and my unit protocol.”',FOOT)] def footer(canvas,doc): canvas.saveState();canvas.setFont('Helvetica',7);canvas.setFillColor(HexColor('#61727A'));canvas.drawString(14*mm,10*mm,'Detailed Paediatric Instrument Spotters | Revision guide');canvas.drawRightString(196*mm,10*mm,f'Page {doc.page}');canvas.restoreState() doc=SimpleDocTemplate(out,pagesize=A4,leftMargin=14*mm,rightMargin=14*mm,topMargin=12*mm,bottomMargin=16*mm) doc.build(story,onFirstPage=footer,onLaterPages=footer) r=PdfReader(out) print('OUTPUT',out,'pages',len(r.pages),'bytes',os.path.getsize(out)) PY

python - <<'PY' from pypdf import PdfReader p='/tmp/workspace/instrument-viva/output/Detailed_Paediatric_Instrument_Viva_Answers.pdf' r=PdfReader(p) text='\n'.join(page.extract_text() or '' for page in r.pages) checks=['Ambu bag','Endotracheal tube','Lumbar puncture','Peak expiratory flow','References and scope'] print('pages',len(r.pages),'size',__import__('os').path.getsize(p)) for x in checks: print(x, x in text) print('extracted_chars',len(text)) PY

India National Immunization Schedule 2025 UIP vaccine doses routes sites open vial policy PCV MR JE rotavirus IPV

https://nccmis.mohfw.gov.in/document/RI_Manual_For_Health_Wo…

childhood vaccination AND safety

python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak, KeepTogether from reportlab.lib.units import mm from pypdf import PdfReader import os out='/tmp/workspace/vaccine-viva/output/MD_Paediatrics_Gold_Medal_Vaccine_Viva.pdf' os.makedirs(os.path.dirname(out),exist_ok=True) S=getSampleStyleSheet() T=ParagraphStyle('T',parent=S['Title'],fontName='Helvetica-Bold',fontSize=19,leading=23,alignment=TA_CENTER,textColor=HexColor('#173E5B'),spaceAfter=5) ST=ParagraphStyle('ST',parent=S['Normal'],fontSize=8.8,leading=11,alignment=TA_CENTER,textColor=HexColor('#536572'),spaceAfter=10) H1=ParagraphStyle('H1',parent=S['Heading1'],fontName='Helvetica-Bold',fontSize=14,leading=17,textColor=HexColor('#123E5B'),spaceBefore=9,spaceAfter=6) H2=ParagraphStyle('H2',parent=S['Heading2'],fontName='Helvetica-Bold',fontSize=11.3,leading=14,textColor=HexColor('#086A76'),spaceBefore=7,spaceAfter=4) B=ParagraphStyle('B',parent=S['Normal'],fontName='Helvetica',fontSize=8.15,leading=10.65,textColor=HexColor('#1D2C34'),spaceAfter=3) SM=ParagraphStyle('SM',parent=B,fontSize=7.1,leading=8.8) TH=ParagraphStyle('TH',parent=B,fontName='Helvetica-Bold',fontSize=7.45,leading=8.6,textColor=colors.white,alignment=TA_CENTER) TB=ParagraphStyle('TB',parent=B,fontSize=7.35,leading=9.0) TF=ParagraphStyle('TF',parent=TB,fontName='Helvetica-Bold') FT=ParagraphStyle('FT',parent=SM,fontSize=6.5,leading=7.7,textColor=HexColor('#4D6069')) def p(x,st=B):return Paragraph(x,st) def bl(x):return Paragraph('• '+x,B) def table(rows, widths=(43*mm,138*mm)): d=[[p('<b>Viva heading</b>',TH),p('<b>Gold-medal answer</b>',TH)]]+[[p('<b>'+a+'</b>',TF),p(b,TB)] for a,b in rows] t=Table(d,colWidths=list(widths),hAlign='LEFT',repeatRows=1) t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),HexColor('#176B86')),('GRID',(0,0),(-1,-1),.25,HexColor('#B7CDD5')),('BACKGROUND',(0,1),(0,-1),HexColor('#EAF5F8')),('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),2.5*mm),('RIGHTPADDING',(0,0),(-1,-1),2.5*mm),('TOPPADDING',(0,0),(-1,-1),1.8*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.8*mm)])) return t def vac(name, identify, composition, schedule, dose, efficacy, ae, contra, pearl): return [Paragraph(name,H2),table([('Identification / type',identify),('Composition & mechanism',composition),('Schedule: India',schedule),('Dose, route, site & storage',dose),('Protection / effectiveness',efficacy),('Adverse events',ae),('Contraindications / precautions',contra),('Gold-medal pearl',pearl)]) ,Spacer(1,4)] def footer(c,d): c.saveState();c.setFont('Helvetica',7);c.setFillColor(HexColor('#63747C'));c.drawString(13*mm,9*mm,'MD Paediatrics Vaccine Spotters | India-focused, verify current local programme circular');c.drawRightString(197*mm,9*mm,'Page %d'%d.page);c.restoreState() story=[Paragraph('VACCINE SPOTTERS: MD PAEDIATRICS GOLD-MEDAL VIVA',T),Paragraph('A detailed India-focused answer bank for the vaccine list in your photograph. Use this sequence in every spotter: identify → type/antigen → schedule → dose/route/site → AEFI → contraindications → programme and cold-chain point.',ST), p('<b>Scope and accuracy note.</b> The national schedule is the Government of India Universal Immunization Programme (UIP), based on the 2024 Routine Immunization Manual and current official citizen guidance. Private-practice schedules may follow IAP/ACVIP recommendations and licensed product inserts. Brand, vial-cap colour and vial-label colour are <b>not reliable identifiers</b>; read the vial label, antigen, batch, expiry, VVM, diluent and manufacturer instructions.'), Paragraph('A. Core immunology and programme answers',H1), bl('<b>Live attenuated vaccines:</b> BCG, OPV, MR/MMR, varicella, live JE and some rotavirus products. They replicate, induce humoral and cellular immunity, and are generally contraindicated in severe immunodeficiency and pregnancy. Live parenteral vaccines not given on the same day should usually be separated by at least 4 weeks.'), bl('<b>Inactivated, toxoid, subunit, conjugate and recombinant vaccines:</b> cannot replicate and are safe in immunodeficiency, but often require primary series and boosters. Examples: IPV, PCV, Hib, Hepatitis A/B, rabies, DPT components, TCV and inactivated influenza.'), bl('<b>Conjugate vaccine principle:</b> polysaccharide covalently linked to a carrier protein produces T-cell-dependent immunity, immune memory, affinity maturation and effectiveness in children under 2 years. PCV, Hib and TCV are key examples.'), bl('<b>Valid dose principle:</b> minimum age and minimum interval matter. A delayed series is continued, never restarted. Mild illness, low-grade fever, antibiotic use, prematurity, breastfeeding and malnutrition are usually not contraindications.'), bl('<b>AEFI response:</b> manage anaphylaxis immediately with IM adrenaline in the anterolateral thigh, maintain airway/oxygen/circulation, document and report through the AEFI system. Do not casually label a child “vaccine allergic”.'), Paragraph('UIP schedule: rapid recall',H1)] uis=[['Age','Vaccines under UIP'],['Birth','BCG, OPV-0, Hepatitis B birth dose, preferably within 24 h.'],['6 weeks','OPV-1, Pentavalent-1, Rotavirus-1, fIPV-1, PCV-1.'],['10 weeks','OPV-2, Pentavalent-2, Rotavirus-2.'],['14 weeks','OPV-3, Pentavalent-3, fIPV-2, Rotavirus-3, PCV-2.'],['9-12 months','MR-1, PCV booster, fIPV-3, Vitamin A; JE-1 only in endemic districts.'],['16-24 months','DPT booster-1, OPV booster, MR-2, JE-2 in endemic districts, Vitamin A second dose then 6-monthly up to 5 years.'],['5-6 years','DPT booster-2.'],['10 and 16 years','Td.']] story.append(table([(a,b) for a,b in uis])) story.append(Paragraph('B. The vaccine spotters',H1)) story += vac('1. Seasonal influenza vaccine, often quadrivalent influenza vaccine (QIV)','Usually an inactivated influenza vaccine (IIV), split virion or subunit. It may be supplied in a prefilled syringe. Do not identify solely by brand such as Vaxigrip Tetra.','Contains antigens from four currently recommended influenza strains, typically two influenza A and two influenza B lineages. Antigen composition is updated to match circulating strains.','Recommended annually from 6 months of age in most private-paediatric schedules and for high-risk children. If first-ever influenza vaccination is at age <9 years, give 2 doses at least 4 weeks apart; then annual single dose.','0.5 mL IM, anterolateral thigh in young child or deltoid in older child. Store 2-8°C. Do not freeze.','Reduces laboratory-confirmed influenza and severe outcomes; effectiveness varies with strain match, age and season. Best given before local influenza season but may be given later.','Local pain, fever, malaise. Rare anaphylaxis. Guillain-Barré syndrome association is very rare; balance individually if GBS occurred within 6 weeks of prior influenza vaccine.','Severe allergic reaction to a previous dose/component is contraindication. Egg allergy is not a contraindication to IIV; vaccinate in a setting equipped to treat anaphylaxis. Defer in moderate/severe acute illness.','Influenza vaccine does not cause influenza because injected IIV is non-live. LAIV is a different intranasal live vaccine and is not the usual paediatric spotter in India.' ) story += vac('2. Pneumococcal conjugate vaccine (PCV)','A conjugate vaccine, commonly PCV10 or PCV13 in India depending on programme/product. The vial may be a liquid prefilled syringe; it is not identified by cap colour alone.','Capsular polysaccharides from selected Streptococcus pneumoniae serotypes conjugated to carrier protein. Produces T-cell-dependent immune response and memory.','UIP: 6 weeks, 14 weeks and booster at 9-12 months. Private schedules may use 2+1 or 3+1 depending on age at start and product. Catch-up is age and product specific.','0.5 mL IM. In UIP, right anterolateral mid-thigh for infant doses/booster. Store 2-8°C; do not freeze.','Prevents vaccine-serotype invasive pneumococcal disease, pneumonia and some otitis media; herd protection reduces nasopharyngeal carriage. It does not cover all serotypes.','Injection-site reaction, fever, irritability; rare febrile seizure temporally related to fever.','Anaphylaxis after prior dose or to component. Defer moderate/severe acute illness. Safe in immunocompromise but response may be reduced; high-risk children may require additional pneumococcal vaccination under specialist guidance.','Differentiate PCV from PPSV23: PCV is conjugate, immunogenic in infants and gives memory; PPSV23 is unconjugated polysaccharide and is generally for selected high-risk children aged ≥2 years.' ) story += vac('3. Measles-rubella (MR) vaccine','Live attenuated, lyophilised vaccine requiring reconstitution with the supplied manufacturer-matched diluent. Usually amber/light-protected presentation.','Live attenuated measles and rubella viruses. Generates durable humoral and cellular immunity.','UIP: MR-1 at 9-12 months and MR-2 at 16-24 months. Catch-up can be provided up to 5 years under programme guidance. Private practice often uses MMR instead of MR at scheduled ages.','0.5 mL subcutaneous, right upper arm in UIP. Protect from light. After reconstitution, use within 4 hours or end of session, whichever earlier. Store diluent as instructed and never interchange diluent.','Prevents measles, a highly contagious disease with pneumonia, encephalitis and SSPE risk, and rubella including congenital rubella syndrome.','Fever and rash 5-12 days later; transient lymphadenopathy. Rare febrile seizure and thrombocytopenia.','Severe immunodeficiency, pregnancy, anaphylaxis to prior dose/component. Recent blood products/IVIG can impair response: schedule depends on product/dose. Minor illness is not contraindication.','MR is not MMR. MR protects against measles and rubella only. It is a reconstituted live vaccine: under UIP open-vial policy, discard after 4 hours/session end.' ) story += vac('4. Bacille Calmette-Guérin (BCG)','Live attenuated Mycobacterium bovis vaccine. A lyophilised vial reconstituted with supplied diluent.','Induces predominantly cell-mediated immunity, reducing severe childhood tuberculosis such as TB meningitis and miliary TB more consistently than pulmonary TB.','UIP: at birth or as early as possible until 1 year of age. No routine revaccination and no tuberculin test is required before vaccination.','<1 month: 0.05 mL intradermal. ≥1 month to <1 year: 0.1 mL intradermal. Site: left upper arm, at insertion of deltoid. Proper intradermal injection produces a wheal. Store 2-8°C, protect from light; reconstituted vaccine use within 4 h/session end.','Strong protection against disseminated and meningeal TB in young children, variable protection against pulmonary TB.','Local papule in 2-6 weeks, ulceration, healing and scar. Ipsilateral axillary lymphadenitis may occur. Rare suppurative lymphadenitis, osteitis or disseminated BCG disease.','Severe cellular immunodeficiency, symptomatic HIV/AIDS, known SCID, and serious acute illness are contraindications. Do not give deep SC or IM.','A normal BCG scar is not an absolute proof of protection, and absence of scar alone is not an indication for routine revaccination under UIP.' ) story.append(PageBreak()) story += [Paragraph('B. Vaccine spotters continued',H1)] story += vac('5. Japanese encephalitis (JE) vaccine','In UIP endemic districts, presentation may be live attenuated SA 14-14-2 or inactivated Vero-cell-derived JE vaccine. Correct identification requires label, not vial colour.','Live vaccine contains attenuated JE virus. Inactivated vaccine contains killed antigen and requires a different programme/cold-chain handling.','UIP only in designated endemic districts: JE-1 at 9-12 months and JE-2 at 16-24 months. A child who received campaign JE vaccine should still receive routine JE doses as eligible.','0.5 mL IM in UIP schedule, anterolateral left mid-thigh, subject to product label. Live JE is reconstituted and has 4-hour discard rule; inactivated JE follows open-vial policy where applicable.','Prevents JE, a mosquito-borne flaviviral encephalitis with high mortality and neurologic sequelae. It is a geographic-risk programme vaccine, not universally indicated throughout India.','Local reaction, fever. Rare hypersensitivity or neurologic events require AEFI assessment.','For live JE: severe immunodeficiency and pregnancy are contraindications. For any JE vaccine: anaphylaxis to prior dose/component. Follow product-specific age limits.','Ask examiner: “Is this a live or killed JE product?” The answer determines contraindications and whether the open-vial policy applies.' ) story += vac('6. Haemophilus influenzae type b (Hib) vaccine','A conjugate vaccine, usually Hib polysaccharide conjugated to tetanus toxoid or another protein carrier. It may be a component of pentavalent/hexavalent combination vaccines.','Polyribosylribitol phosphate (PRP) capsular polysaccharide conjugated to protein carrier, giving T-dependent memory response.','UIP: delivered as part of pentavalent at 6, 10 and 14 weeks. Private schedule commonly has 3 primary doses plus booster at 15-18 months, depending on product and age at start.','0.5 mL IM. If given in pentavalent under UIP, left anterolateral thigh. Store 2-8°C, do not freeze.','Prevents invasive Hib disease, especially meningitis, epiglottitis, pneumonia and sepsis. It does not protect against non-typeable H. influenzae.','Local reaction, fever, irritability; serious adverse events rare.','Anaphylaxis to prior dose/component. Safe in immunocompromise, though antibody response may vary.','Why Hib after infancy? Risk falls with age and natural exposure; catch-up schedule depends on current age, previous doses and high-risk condition.' ) story += vac('7. Hepatitis A vaccine','Either inactivated whole-virus vaccine or live attenuated hepatitis A vaccine, depending on product. Both are used in private schedules; not part of UIP.','Inactivated vaccine induces antibody response without replication and needs 2 doses. Live attenuated vaccine replicates and is generally a single-dose schedule, subject to local recommendations/product label.','Private practice: commonly start at 12 months. Inactivated HAV: 2 doses 6 months apart. Live HAV: one dose at ≥12 months where licensed. Use current IAP/product schedule.','Usually 0.5 mL IM for inactivated HAV, thigh/deltoid. Live HAV route depends on product insert. Store 2-8°C, do not freeze.','Prevents symptomatic hepatitis A, including severe disease which increases with age. It is not post-exposure immunoglobulin replacement in every situation.','Local pain, fever, headache. Serious AEFI uncommon.','Severe allergy to prior dose/component. Live HAV is contraindicated in severe immunodeficiency and pregnancy.','Do not confuse hepatitis A with hepatitis B: HAV is fecal-oral, does not cause chronic hepatitis; HBV is blood/body-fluid transmitted and can become chronic.' ) story += vac('8. Hepatitis B vaccine','Recombinant subunit vaccine containing hepatitis B surface antigen (HBsAg), usually adsorbed on aluminium salt.','Induces anti-HBs antibodies; prevents acute and chronic HBV, cirrhosis and hepatocellular carcinoma.','UIP: birth dose as soon as possible, ideally within 24 h; then within pentavalent at 6, 10 and 14 weeks. For infants born to HBsAg-positive mothers, give HepB within 12 h plus HBIG at a separate site as per guidelines.','0.5 mL IM, anterolateral left mid-thigh for birth dose in UIP. Never gluteal. Store 2-8°C and do not freeze. Shake if labelled adsorbed suspension.','Very high efficacy after complete series. Timely birth dose is central to preventing perinatal chronic HBV infection.','Injection-site pain, low fever; anaphylaxis extremely rare.','Anaphylaxis to prior dose/component, including yeast hypersensitivity in relevant products. Not contraindicated in prematurity, breastfeeding or maternal HBV infection.','HepB birth dose must be given even if there is only one newborn at the session. Do not wait for weight gain or BCG availability.' ) story += vac('9. Rabies vaccine','Modern cell-culture rabies vaccine, inactivated. Human diploid cell, purified chick embryo cell or Vero-cell vaccine may be used. It is a post-exposure biologic, not routine UIP vaccine.','Inactivated rabies virus induces neutralising antibody. Rabies immunoglobulin provides immediate passive antibody when indicated.','Post-exposure prophylaxis (PEP) is based on exposure category. Category II: vaccine. Category III: meticulous wound care + vaccine + rabies immunoglobulin infiltration into/around wounds. Pre-exposure prophylaxis is for selected high-risk groups.','Use only WHO-recommended routes and regimens: intradermal or intramuscular according to national guideline and product. IM vaccine is injected in deltoid or anterolateral thigh in small children, never gluteal.','Rabies is nearly 100% fatal after symptoms, but PEP is highly effective when wound management, vaccine and RIG are correctly given promptly.','Local pain, fever, headache; severe allergy is rare.','There are <b>no contraindications to life-saving PEP</b>, including pregnancy, infancy, immunocompromise or concurrent illness. In immunocompromised patients, use IM regimen and assess antibody response according to guidelines.','The first and most important action is immediate wound washing with soap and running water for at least 15 minutes, then virucidal antiseptic if available. Do not suture primarily unless essential and after RIG infiltration.' ) story += vac('10. Inactivated poliovirus vaccine (IPV/fIPV)','Inactivated trivalent poliovirus vaccine. In UIP, fractional IPV (fIPV) is an intradermal fractional dose.','Killed poliovirus types 1, 2 and 3. Produces excellent serum immunity, but less intestinal mucosal immunity than OPV.','UIP: fIPV at 6 and 14 weeks plus fIPV third dose at 9-12 months. This is co-administered at the MR/PCV visit.','fIPV: 0.1 mL intradermal, right upper arm. Full-dose IPV is 0.5 mL IM depending on product/private schedule. Store 2-8°C; do not freeze.','Protects against paralytic poliomyelitis without vaccine-associated paralytic polio. Combined OPV plus IPV strategy supports eradication and mucosal protection.','Local reaction, fever uncommon; severe events rare.','Anaphylaxis to previous dose or antibiotics/components such as neomycin, streptomycin or polymyxin B where applicable. Safe in immunodeficiency.','OPV is live and gives intestinal immunity; IPV is killed and safe in severe immunodeficiency. Explain why both can be used in eradication programmes.' ) story.append(PageBreak());story += [Paragraph('B. Vaccine spotters continued',H1)] story += vac('11. DPT vaccine','Combination against diphtheria, pertussis and tetanus. May be DTwP (whole-cell pertussis) or DTaP (acellular pertussis). UIP pentavalent contains whole-cell pertussis formulation.','Diphtheria and tetanus toxoids, plus whole-cell or acellular pertussis antigens. Toxoids generate antitoxin antibodies; pertussis requires repeated doses/boosters.','UIP primary protection is within pentavalent at 6, 10, 14 weeks. DPT boosters: 16-24 months and 5-6 years. Td at 10 and 16 years. Private schedules may use DTaP/DTwP based on policy/cost/availability.','0.5 mL IM. UIP DPT booster: left anterolateral thigh at 16-24 months; left upper arm at 5-6 years. Store 2-8°C, do not freeze.','Prevents diphtheria, pertussis and tetanus. Protection against pertussis wanes, hence boosters and maternal vaccination strategies.','Pain, swelling, fever, persistent crying. Whole-cell pertussis has more reactogenicity than acellular. Rare hypotonic-hyporesponsive episode or febrile seizure.','True contraindication to pertussis-containing vaccine: encephalopathy within 7 days of a prior pertussis vaccine not attributable to another cause. Progressive/unstable neurologic disorder is a precaution until stabilised.','Do not confuse <b>high fever or prolonged crying</b> with absolute contraindication. They are precautions for future pertussis-containing doses and merit assessment, not automatic abandonment of all immunisation.' ) story += vac('12. Pentavalent vaccine','Fixed combination: DPT + Hepatitis B + Hib. Under UIP it is an adsorbed liquid combination vaccine.','Contains diphtheria and tetanus toxoids, whole-cell pertussis, recombinant HBsAg and Hib conjugate. Reduces injections and missed opportunities.','UIP: 6, 10 and 14 weeks. If starting after 1 year, use DPT rather than pentavalent per programme catch-up guidance. Minimum interval between primary doses is 4 weeks.','0.5 mL IM, left anterolateral mid-thigh in UIP. Store 2-8°C, do not freeze; inspect for freezing damage where relevant.','Provides primary protection against five diseases while improving programme adherence. It does not replace booster DPT and does not include IPV/PCV/rotavirus.','Local pain, fever, irritability; adverse effects reflect constituent antigens, especially pertussis component.','Same as relevant components: anaphylaxis to prior dose/component; encephalopathy after pertussis-containing dose is contraindication to further pertussis component.','If the examiner shows a pentavalent vial, state all five antigens without hesitation and add that it is covered by UIP open-vial policy if conditions are met.' ) story += vac('13. Varicella vaccine','Live attenuated Oka strain varicella-zoster vaccine, usually lyophilised and reconstituted.','Replicating attenuated VZV induces immunity against chickenpox; it lowers severe disease and complications.','Private schedule: first dose at 12-15 months, second dose at 4-6 years or at least 3 months later in children <13 years. In children ≥13 years, 2 doses at least 4 weeks apart. Not UIP.','0.5 mL SC, usually upper arm; some products permit IM. Store/reconstitute exactly per product guidance, protect from light; use promptly after reconstitution.','Very effective against any varicella and more effective against severe varicella. Breakthrough illness can occur but is usually mild.','Local reaction, fever, mild varicella-like rash. Rare transmission of vaccine virus from a vaccinee with rash to susceptible high-risk contact.','Severe immunodeficiency, pregnancy, anaphylaxis to gelatin/neomycin where relevant. Avoid salicylates for 6 weeks after vaccination as a precaution.','In a child exposed to varicella, vaccine within 3-5 days can modify/prevent disease in eligible susceptible contacts; high-risk contacts may need VZIG and specialist advice.' ) story += vac('14. MMR vaccine','Live attenuated measles, mumps and rubella vaccine. It requires reconstitution, like MR, but has an additional mumps component.','Live attenuated measles, mumps and rubella viruses. Mumps prevention reduces parotitis and complications including meningitis, orchitis and hearing loss.','Private schedule commonly: MMR-1 at 9 months, MMR-2 at 15 months, and MMR-3 at 4-6 years, though schedules vary. UIP supplies MR, not MMR.','0.5 mL SC, upper arm. Protect from light. Use reconstituted product promptly, commonly within 4 hours/session end according to manufacturer/local policy.','Provides protection against three viral diseases; measles component supports elimination efforts and rubella component prevents congenital rubella syndrome.','Fever/rash 5-12 days later, parotid swelling, transient arthralgia (more in adults), rare febrile seizure and thrombocytopenia. No credible evidence links MMR to autism.','Severe immunodeficiency, pregnancy, anaphylaxis to prior dose/component. Defer after certain blood products/IVIG. Egg allergy is not a contraindication to MMR.','Answer a common myth clearly: extensive epidemiologic evidence does not support an association between MMR vaccine and autism.' ) story += vac('15. Rotavirus vaccine (RVV)','Live attenuated oral vaccine. Products differ: some are monovalent 2-dose, others are pentavalent/Indian formulations given as 3 doses. Presentation and VVM placement matter for open-vial policy.','Replicating attenuated rotavirus induces mucosal and systemic immunity against severe rotavirus gastroenteritis.','UIP: 6, 10, 14 weeks, 3-dose RVV. Private schedule follows product: RV1 is 2 doses; several others are 3 doses. Observe product-specific upper age limits.','Oral drops, not injected. UIP product is commonly 5 drops. Give directly into mouth toward inner cheek. If child spits/regurgitates, do not repeat the dose.','Strongly reduces severe rotavirus diarrhoea, dehydration and hospitalisation; does not prevent all diarrhoeal illness.','Mild diarrhoea, vomiting, irritability. Very rare intussusception risk, greatest shortly after early doses; benefits exceed risk in eligible infants.','History of intussusception, SCID and severe allergy are contraindications. Postpone moderate/severe gastroenteritis or serious illness. Mild diarrhoea does not always require deferral, but follow local guidance.','Open-vial policy depends on product: RVV with VVM on label may qualify; VVM on cap/stem does not. This is a favourite programme-viva question.' ) story += vac('16. Oral polio vaccine (OPV/bOPV)','Live attenuated oral vaccine. In current programmes bOPV contains poliovirus types 1 and 3.','Replicates in intestine, inducing mucosal IgA and systemic immunity, reducing transmission. Rarely can revert to neurovirulence in under-immunised populations.','UIP: OPV-0 at birth, then OPV-1/2/3 at 6/10/14 weeks and booster at 16-24 months. Supplementary immunisation activity doses are additional and do not replace routine schedule.','2 oral drops. Store in cold chain as per VVM/freeze requirements. Avoid contamination of dropper; administer directly into mouth.','Excellent intestinal immunity and community transmission interruption, central to eradication. Risk of vaccine-associated paralytic poliomyelitis is extremely rare.','Usually no significant AEFI. Rare VAPP and circulating vaccine-derived poliovirus in populations with low coverage.','Severe primary immunodeficiency is a contraindication to OPV; IPV is preferred. A child with diarrhoea can receive OPV, but an additional dose may be considered later according to programme guidance.','OPV birth dose is a “zero dose”: it does not count as part of the primary 3-dose OPV series.' ) story.append(PageBreak());story += [Paragraph('B. Vaccine spotters continued',H1)] story += vac('17. Typhoid conjugate vaccine (TCV)','Vi capsular polysaccharide conjugated to a carrier protein, commonly tetanus toxoid. It is a conjugate vaccine and not the older plain Vi polysaccharide vaccine.','Conjugation makes response T-cell dependent, enabling use in young children, immune memory and longer protection than plain polysaccharide vaccine.','Private schedule: single 0.5 mL IM dose from 6 months or 9 months depending on product/national recommendation. IAP schedules commonly use at 9-12 months. Booster policy varies by product/programme and evolving guidance. Not routine UIP nationally.','0.5 mL IM, anterolateral thigh or deltoid. Store 2-8°C, do not freeze. Often supplied in prefilled syringe.','Prevents typhoid fever due to Salmonella Typhi. It does not protect against paratyphoid; sanitation, safe water and food hygiene remain essential.','Local reaction, fever, malaise; severe events rare.','Anaphylaxis to prior dose/component. Defer moderate/severe acute illness.','TCV vs Vi polysaccharide: TCV works in infants and has immunologic memory. Vi polysaccharide is generally for age ≥2 years and needs repeat dosing.' ) story += vac('18. Sterile water for injection / diluent','Not a vaccine. It is a sterile diluent that may accompany lyophilised vaccines such as BCG, MR/MMR, varicella and some JE products.','Its function is to reconstitute vaccine exactly as specified. It does not confer immunity. Sterile water for injection is not interchangeable with normal saline or another vaccine’s diluent.','No schedule. Use only with its matched vaccine and in the supplied volume.','Use aseptically. Check label, manufacturer, batch, expiry and integrity. Use only manufacturer-supplied matched diluent for reconstitution.','No vaccine protection. The relevant AEFI/contraindications belong to the reconstituted vaccine, not sterile water itself.','Wrong diluent, wrong volume, contaminated diluent, using frozen or inappropriate diluent, or mixing diluents across manufacturers can cause programme errors and invalid doses.','A spotter labelled “sterile water” should trigger the statement: “This is a diluent, not a vaccine. I must never use it interchangeably; I will reconstitute only with the matched manufacturer-provided diluent.”' ) story.append(Paragraph('C. High-yield programme viva',H1)) prog=[('Cold-chain range','Most routine vaccines are stored at +2°C to +8°C at service level. Never freeze freeze-sensitive adsorbed vaccines, such as DPT-containing vaccines, HepB, pentavalent, PCV, IPV and Td. Freeze damage is irreversible and not detected by VVM.'),('Vaccine vial monitor (VVM)','A heat-exposure indicator. Use vial if inner square is lighter than outer circle. Do not use if inner square is the same colour as or darker than outer circle. VVM does not indicate expiry, freezing, contamination or reconstitution time.'),('Open-vial policy, UIP','Eligible for reuse up to 28 days if conditions are met: DPT, Td, HepB, OPV, pentavalent, IPV, PCV, killed JE and RVV with VVM on label. Not applicable: reconstituted BCG, MR, live JE; RVV with VVM on cap/stem; single-dose presentations. Discard reconstituted BCG/MR/live JE after 4 h or at session end.'),('Injection-site rules','Use separate syringes and different sites. In UIP infants: pentavalent left anterolateral thigh, PCV right anterolateral thigh, fIPV right upper arm, MR right upper arm. Never inject vaccines into buttock because of sciatic injury and variable fat deposition.'),('Co-administration','Most routine vaccines can be given at same visit at separate sites. Do not mix vaccines in same syringe unless licensed as a fixed combination. Live injectable vaccines given on different days should usually be separated by 4 weeks.'),('Prematurity','Vaccinate by chronological age, not corrected age, with full age-appropriate dose. HepB birth-dose decisions in very low-birth-weight infant can depend on maternal HBsAg status and national policy, but do not omit protection.'),('HIV/immunodeficiency','Inactivated vaccines are generally safe but response may be reduced. Live vaccines require assessment of severity and immune status. BCG is contraindicated in symptomatic HIV/severe cellular immunodeficiency; OPV avoided in severe primary immunodeficiency.'),('AEFI vs adverse event','An AEFI is any untoward medical event after immunisation, not necessarily caused by vaccine. Classify after investigation: vaccine product-related, quality defect-related, immunisation error-related, anxiety-related or coincidental.'),('Anaphylaxis treatment','IM adrenaline 1 mg/mL (1:1000), 0.01 mg/kg, maximum 0.5 mg, into anterolateral thigh; repeat every 5 minutes if needed while managing ABC and transferring urgently. This is emergency management, not an indication to delay treatment.'),('Catch-up','Do not restart a series irrespective of delay. Administer due vaccines at same visit whenever possible while respecting minimum ages and intervals. Document clearly and update the immunisation card.')] story.append(table(prog)) story += [Paragraph('D. Examiner traps and model answers',H1),bl('<b>“Can a child with cough and cold be vaccinated?”</b> Yes, if illness is mild and child is otherwise stable. Mild fever, antibiotics and convalescence are not contraindications.'),bl('<b>“Can vaccines be given during breastfeeding?”</b> Yes. Breastfeeding is not a contraindication to infant or maternal routine vaccination.'),bl('<b>“What is a true contraindication?”</b> Anaphylaxis after prior dose/component; for live vaccines, severe immunodeficiency and pregnancy. Pertussis vaccine has specific contraindication of unexplained encephalopathy within 7 days of a prior dose.'),bl('<b>“If child missed vaccines?”</b> Continue from where they stopped. Do not repeat earlier doses or restart the schedule.'),bl('<b>“Why no routine serology after vaccination?”</b> Protective thresholds and assay interpretation vary; routine serology is not required except selected situations such as post-vaccination testing for infants born to HBsAg-positive mothers or immunocompromised hosts.'),Paragraph('References',H1),p('1. Government of India, Ministry of Health and Family Welfare. <i>Routine Immunization Manual for Health Workers</i>, 2024. National Immunization Schedule, injection sites, open-vial policy, cold-chain and AEFI guidance.' ,FT),p('2. Government of India/U-WIN. <i>General Information on Routine Vaccines under Universal Immunization Programme for Citizens</i>. Official vaccine profiles and contraindication information.' ,FT),p('3. WHO. Harmonized Health Facility Assessment, 2023. Vaccine and programme readiness context. 4. IMA/IAP immunisation charts and current licensed product inserts should be consulted for private-practice schedules and product-specific dose/age restrictions.' ,FT),p('<b>Final exam line:</b> “I will verify the product label, expiry, VVM, appropriate diluent, cold-chain status, age eligibility, contraindications, route, site, dose and documentation before administration.”',FT)] doc=SimpleDocTemplate(out,pagesize=A4,leftMargin=14*mm,rightMargin=14*mm,topMargin=12*mm,bottomMargin=15*mm) doc.build(story,onFirstPage=footer,onLaterPages=footer) r=PdfReader(out) print(out,'pages=',len(r.pages),'bytes=',os.path.getsize(out)) PY

~/vaccine-viva/

python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak from reportlab.lib.units import mm from pypdf import PdfReader import os out='/tmp/workspace/vaccine-viva/output/MD_Paediatrics_Gold_Medal_Vaccine_Viva.pdf' S=getSampleStyleSheet(); T=ParagraphStyle('T',parent=S['Title'],fontName='Helvetica-Bold',fontSize=18,leading=22,alignment=TA_CENTER,textColor=HexColor('#173E5B'),spaceAfter=4) ST=ParagraphStyle('ST',parent=S['Normal'],fontSize=8.5,leading=10.5,alignment=TA_CENTER,textColor=HexColor('#536572'),spaceAfter=9) H1=ParagraphStyle('H1',parent=S['Heading1'],fontName='Helvetica-Bold',fontSize=13.5,leading=16,textColor=HexColor('#123E5B'),spaceBefore=8,spaceAfter=5) H2=ParagraphStyle('H2',parent=S['Heading2'],fontName='Helvetica-Bold',fontSize=10.8,leading=13,textColor=HexColor('#086A76'),spaceBefore=7,spaceAfter=3) B=ParagraphStyle('B',parent=S['Normal'],fontName='Helvetica',fontSize=8,leading=10.3,textColor=HexColor('#1D2C34'),spaceAfter=2) TB=ParagraphStyle('TB',parent=B,fontSize=7.25,leading=8.75); TF=ParagraphStyle('TF',parent=TB,fontName='Helvetica-Bold'); TH=ParagraphStyle('TH',parent=TB,fontName='Helvetica-Bold',textColor=colors.white,alignment=TA_CENTER) FT=ParagraphStyle('FT',parent=B,fontSize=6.5,leading=7.6,textColor=HexColor('#4D6069')) def p(x,st=B): return Paragraph(x,st) def table(rows): d=[[p('Viva heading',TH),p('Gold-medal answer',TH)]]+[[p(a,TF),p(b,TB)] for a,b in rows] t=Table(d,colWidths=[43*mm,138*mm],repeatRows=1) t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),HexColor('#176B86')),('BACKGROUND',(0,1),(0,-1),HexColor('#EAF5F8')),('GRID',(0,0),(-1,-1),.25,HexColor('#B7CDD5')),('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),2.5*mm),('RIGHTPADDING',(0,0),(-1,-1),2.5*mm),('TOPPADDING',(0,0),(-1,-1),1.7*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.7*mm)])) return t def card(name,typ,sched,dose,adverse,contra,pearl): return [Paragraph(name,H2),table([('Identification/type',typ),('India schedule',sched),('Dose, route, site',dose),('AEFI and precautions',adverse),('Contraindications',contra),('Gold-medal pearl',pearl)]),Spacer(1,4)] def footer(c,d): c.saveState();c.setFont('Helvetica',7);c.setFillColor(HexColor('#63747C'));c.drawString(13*mm,9*mm,'MD Paediatrics Vaccine Spotters | Verify current local circular and product insert');c.drawRightString(197*mm,9*mm,'Page %d'%d.page);c.restoreState() story=[Paragraph('VACCINE SPOTTERS: MD PAEDIATRICS GOLD-MEDAL VIVA',T),Paragraph('India UIP focused. Answer each station: identification → antigen/type → schedule → dose/route/site → AEFI → contraindications → cold-chain/programme point.',ST),p('<b>Critical identification warning:</b> cap colour, vial colour and brand are not dependable identifiers. Read the product label, antigen, batch, expiry, VVM and diluent. The schedule below is Government of India UIP; IAP/private schedules and licensed inserts may differ.'),Paragraph('1. Master answers before you start',H1),table([('Live vaccines','BCG, OPV, MR/MMR, varicella, live JE and certain RVV products. Generally contraindicated in severe cellular immunodeficiency and pregnancy. If two live injectable vaccines are not given on the same day, separate by 4 weeks.'),('Conjugate principle','Polysaccharide linked to protein carrier gives T-cell-dependent response, memory and infant efficacy. Examples: Hib, PCV, TCV.'),('Delay/catch-up','A delayed series is continued, never restarted. Mild URTI, low-grade fever, antibiotic therapy, breastfeeding, prematurity and malnutrition are usually not contraindications.'),('Anaphylaxis','IM adrenaline 1 mg/mL, 0.01 mg/kg, maximum 0.5 mg, anterolateral thigh. Repeat every 5 min if necessary while ABC support and urgent transfer occur.'),('VVM','Use if inner square is lighter than outer circle. Do not use if same colour/darker. VVM indicates cumulative heat, not expiry, freezing or contamination.')]),Paragraph('2. UIP schedule: rapid recall',H1),table([('Birth','BCG, OPV-0, Hepatitis B birth dose, preferably within 24 hours.'),('6 weeks','OPV-1, Pentavalent-1, RVV-1, fIPV-1, PCV-1.'),('10 weeks','OPV-2, Pentavalent-2, RVV-2.'),('14 weeks','OPV-3, Pentavalent-3, fIPV-2, RVV-3, PCV-2.'),('9-12 months','MR-1, PCV booster, fIPV-3, Vitamin A. JE-1 only in endemic districts.'),('16-24 months','DPT booster-1, OPV booster, MR-2, JE-2 in endemic districts; Vitamin A.'),('5-6 / 10 / 16 years','DPT booster-2 at 5-6 years; Td at 10 and 16 years.')]),PageBreak(),Paragraph('3. Vaccine-wise gold-medal viva answers',H1)] V=[ ('Influenza vaccine / QIV','Usually inactivated split-virion or subunit quadrivalent influenza vaccine. It is not a live injection.','Annual from 6 months in private/high-risk practice. First season in child <9 years: 2 doses at least 4 weeks apart; thereafter one annual dose.','0.5 mL IM, thigh in young child or deltoid. 2-8°C, do not freeze.','Pain, fever, myalgia; rare anaphylaxis. Effectiveness depends on seasonal strain match.','Anaphylaxis to previous dose/component. Egg allergy is not a contraindication to IIV. Defer moderate/severe acute illness.','IIV cannot cause influenza. Antigen formulation is updated annually.'), ('Pneumococcal conjugate vaccine (PCV)','Conjugate vaccine, PCV10/PCV13 depending programme/product. It prevents vaccine-serotype invasive pneumococcal disease.','UIP 6 and 14 weeks, booster 9-12 months. Catch-up is age/product specific.','0.5 mL IM. UIP right anterolateral thigh. Store 2-8°C, do not freeze.','Local pain, fever, irritability. Safe in immunocompromise though response can be reduced.','Anaphylaxis to prior dose/component.','PCV has memory and works in infants; PPSV23 is plain polysaccharide, used only in selected high-risk children ≥2 years.'), ('Measles-rubella (MR)','Live attenuated, lyophilised measles and rubella vaccine. Requires matched manufacturer-supplied diluent.','UIP at 9-12 months and 16-24 months. UIP uses MR, not MMR.','0.5 mL SC, right upper arm. Protect from light. Reconstituted vaccine: discard after 4 h or session end.','Fever/rash 5-12 d later, rare febrile seizure, thrombocytopenia.','Severe immunodeficiency, pregnancy, anaphylaxis to previous dose/component; defer after certain blood products/IVIG.','MR prevents CRS through rubella protection. Never interchange diluents.'), ('BCG','Live attenuated Mycobacterium bovis, lyophilised/reconstituted. Reduces severe childhood TB, especially TB meningitis and miliary TB.','At birth or as early as possible until age 1 year. No routine revaccination.','0.05 mL ID if <1 month; 0.1 mL ID from ≥1 month to <1 year. Left upper arm. 2-8°C, protect light; use within 4 h after reconstitution.','Papule, ulcer, scar and ipsilateral nodes may be normal. Rare suppurative lymphadenitis, osteitis, disseminated BCG.','Symptomatic HIV/AIDS, SCID/severe cellular immunodeficiency, serious illness.','A proper intradermal wheal should appear. Absence of scar alone is not an indication for revaccination.'), ('Japanese encephalitis (JE)','In UIP endemic districts: live attenuated or inactivated Vero-cell product. Identify exact type on label.','JE-1 9-12 months, JE-2 16-24 months in endemic districts only.','Usually 0.5 mL IM, left anterolateral thigh under UIP, subject to product insert.','Fever/local reaction. Live product has live-vaccine precautions.','Anaphylaxis to component; live JE contraindicated in severe immunodeficiency/pregnancy.','Live JE is reconstituted and discarded after 4 h; killed JE can fall under open-vial policy.'), ('Hib vaccine','PRP polysaccharide conjugated to carrier protein, often TT. Prevents invasive Hib meningitis, epiglottitis, pneumonia and sepsis.','UIP as Pentavalent at 6,10,14 weeks. Private schedules often add booster at 15-18 months.','0.5 mL IM; in UIP pentavalent, left anterolateral thigh.','Local pain, fever. Serious AEFI rare.','Anaphylaxis to prior dose/component.','Conjugation is why Hib protects infants and creates immune memory.'), ('Hepatitis A','Inactivated whole-virus or live attenuated product, private schedule, not UIP. HAV does not cause chronic hepatitis.','Start ≥12 months. Inactivated: 2 doses 6 months apart. Live: single dose where licensed.','Usually 0.5 mL IM for inactivated product. Follow live product insert.','Local pain, fever, headache.','Severe allergy; live HAV contraindicated in severe immunodeficiency/pregnancy.','Differentiate from HBV: HAV is fecal-oral and never chronic; HBV is blood/body-fluid transmitted and can become chronic.'), ('Hepatitis B','Recombinant HBsAg subunit vaccine, typically aluminium-adsorbed.','Birth dose within 24 h, then in pentavalent at 6,10,14 weeks. HBsAg-positive mother: HepB within 12 h plus HBIG at separate site.','0.5 mL IM, left anterolateral thigh for birth dose in UIP. Never gluteal. 2-8°C, do not freeze.','Pain/low fever; anaphylaxis extremely rare.','Anaphylaxis to prior dose/component, including yeast where relevant.','Birth dose must not be delayed for low birth weight or non-availability of other birth vaccines.'), ('Rabies vaccine','Modern cell-culture inactivated rabies vaccine. PEP vaccine is not UIP routine immunisation.','PEP immediately after exposure. Category II: wound care + vaccine. Category III: wound care + vaccine + RIG infiltrated into/around wounds.','WHO/national IM or ID regimen. IM deltoid or anterolateral thigh in small child, never gluteal.','Local symptoms, fever, headache.','No contraindication to life-saving PEP, including pregnancy, infancy, illness or immunocompromise.','First action is vigorous wound wash with soap/running water for ≥15 minutes. Do not withhold PEP awaiting animal observation.'), ('IPV / fractional IPV','Inactivated trivalent poliovirus vaccine. fIPV is intradermal fractional dose.','UIP fIPV at 6,14 weeks and 9-12 months.','fIPV 0.1 mL ID, right upper arm. Full IPV product is 0.5 mL IM. 2-8°C, do not freeze.','Local reaction/fever uncommon.','Anaphylaxis to previous dose/components such as neomycin, streptomycin, polymyxin B as relevant.','IPV protects from paralysis without VAPP; OPV gives superior intestinal immunity. Both have roles in eradication.'), ('DPT / DTwP / DTaP','Diphtheria and tetanus toxoids with whole-cell or acellular pertussis. UIP uses whole-cell pertussis in pentavalent.','Primary doses via pentavalent 6,10,14 weeks. DPT boosters at 16-24 months and 5-6 years; Td 10/16 years.','0.5 mL IM. DPT booster left thigh at 16-24 months; left upper arm at 5-6 years.','Pain, fever, persistent crying; DTwP more reactogenic. Rare HHE/febrile seizure.','Encephalopathy within 7 d of pertussis vaccine without other cause contraindicates further pertussis component.','High fever/prolonged crying are precautions, not automatic permanent contraindications to all vaccination.'), ('Pentavalent','DPT + Hepatitis B + Hib combination.','UIP 6,10,14 weeks. If starting after 1 year, UIP uses DPT series rather than pentavalent.','0.5 mL IM left anterolateral thigh. 2-8°C, do not freeze.','AEFI reflect components: local reaction, fever, irritability.','Anaphylaxis; pertussis-component encephalopathy rule applies.','It decreases injections and missed opportunities. It is eligible under UIP open-vial policy if conditions are satisfied.'), ('Varicella','Live attenuated Oka strain VZV, lyophilised/reconstituted. Private schedule.','Dose 1 at 12-15 months, dose 2 at 4-6 years or ≥3 months later if <13 years; ≥13 years: 2 doses ≥4 weeks apart.','0.5 mL SC upper arm, product-specific storage/reconstitution.','Local reaction, fever, mild varicella-like rash; rare vaccine-virus transmission if rash occurs.','Severe immunodeficiency, pregnancy, severe allergy to gelatin/neomycin where relevant.','Post-exposure vaccine within 3-5 days can prevent/modify disease in eligible susceptible contacts.'), ('MMR','Live attenuated measles, mumps and rubella. It differs from UIP MR by its mumps component.','Private: commonly 9 months, 15 months, 4-6 years; schedule can differ by IAP/product.','0.5 mL SC upper arm. Protect light; use promptly after reconstitution.','Fever/rash, rare febrile seizure/thrombocytopenia; transient parotid swelling.','Severe immunodeficiency, pregnancy, prior anaphylaxis; defer after certain blood products. Egg allergy is not contraindication.','There is no credible association between MMR and autism.'), ('Rotavirus vaccine (RVV)','Live attenuated oral vaccine. Product can be 2-dose or 3-dose; UIP uses 3-dose schedule.','UIP 6,10,14 weeks. Product-specific upper age limits apply in private practice.','Oral, UIP commonly 5 drops. If spit/regurgitated, do not repeat.','Mild vomiting/diarrhoea. Very rare intussusception risk.','Prior intussusception, SCID, anaphylaxis. Postpone moderate/severe gastroenteritis/illness.','Open vial policy depends on VVM placement: VVM on label may qualify; VVM on cap/stem does not.'), ('OPV / bOPV','Live attenuated oral polio vaccine. bOPV contains types 1 and 3.','UIP OPV-0 birth, OPV 1/2/3 at 6/10/14 weeks, booster 16-24 months.','2 drops oral. Observe VVM/cold chain.','Usually minimal AEFI; extremely rare VAPP/cVDPV in low-coverage contexts.','Severe primary immunodeficiency: use IPV, not OPV.','Birth OPV is zero dose and does not count toward primary series. SIA doses are additional, not substitutes.'), ('Typhoid conjugate vaccine (TCV)','Vi capsular polysaccharide conjugated to carrier protein, often tetanus toxoid. Private schedule, not UIP nationally.','Usually one 0.5 mL IM dose from 6-9 months depending product; IAP commonly 9-12 months. Booster guidance is product/policy specific.','0.5 mL IM thigh/deltoid, 2-8°C.','Local pain, fever, malaise.','Anaphylaxis to prior dose/component.','TCV works in young infants and gives memory. It does not protect against paratyphoid.'), ('Sterile water / diluent','Not a vaccine. It is the matched diluent for lyophilised vaccine such as BCG, MR/MMR, varicella or some JE products.','No vaccine schedule. Use only with its own matched vaccine and specified volume.','Aseptic reconstitution only; verify manufacturer, batch/expiry and integrity.','Errors include wrong diluent, contamination, wrong volume or mixing diluents across manufacturers.','Not applicable as vaccine contraindication.','Never use normal saline or another vaccine’s diluent. Reconstituted live products follow strict discard timing.')] for i,x in enumerate(V): story+=card(*x) if i in [3,8,13]:story.append(PageBreak()) story += [PageBreak(),Paragraph('4. Programme, cold-chain and examiner-trap answers',H1),table([('Open-vial policy','Reuse up to 28 d if all conditions met: DPT, Td, HepB, OPV, pentavalent, IPV, PCV, killed JE and RVV with VVM on label. Not applicable: BCG, MR, live JE, RVV with VVM on cap/stem, or single-dose products. Reconstituted BCG/MR/live JE must be discarded after 4 h or session end.'),('Cold chain','Store vaccines at +2 to +8°C at session level. Freeze-sensitive: DPT-containing, Td, HepB, pentavalent, PCV, IPV. VVM cannot detect freeze damage. Use shake test only per programme policy where indicated.'),('Injection sites','Separate syringes and sites. UIP infant: Pentavalent left thigh, PCV right thigh, fIPV right upper arm, MR right upper arm. Avoid buttock due to sciatic injury and variable fat deposition.'),('Co-administration','Give most vaccines together at separate sites. Never mix in syringe unless manufacturer-licensed fixed combination. Live injectable vaccines different days: usually ≥4 weeks apart.'),('Prematurity','Give by chronological age, full dose. Do not miss vaccines for low birth weight. HepB birth management may depend on maternal HBsAg and national policy.'),('AEFI definition','Any adverse event after immunisation, not necessarily caused by vaccine. Categories: product-related, quality defect-related, immunisation error-related, anxiety-related and coincidental.'),('Most common false contraindications','Mild illness, low fever, antibiotics, prematurity, stable neurological disease, malnutrition, breastfeeding, family history of seizures, allergy unrelated to vaccine component.'),('Catch-up line','“I will not restart the schedule. I will give all age-eligible vaccines today, respect minimum intervals, document clearly and schedule next dose.”')]),Paragraph('References',H1),p('Government of India, MoHFW. <i>Routine Immunization Manual for Health Workers</i>, 2024. Government of India/U-WIN. <i>General Information on Routine Vaccines under UIP for Citizens</i>. WHO vaccine-position papers and current product inserts should be checked for updated age limits, formulation-specific routes and special-risk schedules.',FT),p('<b>Final ideal examiner response:</b> “Before administration I verify child identity, eligibility, contraindications, product label, expiry, VVM, cold chain, matched diluent, dose, route, site, asepsis, documentation and observation for AEFI.”',FT)] doc=SimpleDocTemplate(out,pagesize=A4,leftMargin=14*mm,rightMargin=14*mm,topMargin=12*mm,bottomMargin=15*mm) doc.build(story,onFirstPage=footer,onLaterPages=footer) r=PdfReader(out);print(out,len(r.pages),os.path.getsize(out)) PY

python - <<'PY' from pypdf import PdfReader import os p='/tmp/workspace/vaccine-viva/output/MD_Paediatrics_Gold_Medal_Vaccine_Viva.pdf' r=PdfReader(p) t='\n'.join((x.extract_text() or '') for x in r.pages) for term in ['Influenza vaccine','Pneumococcal conjugate','Measles-rubella','Rabies vaccine','Typhoid conjugate','Sterile water','Open-vial policy']: print(term,term in t) print('pages',len(r.pages),'bytes',os.path.getsize(p),'chars',len(t)) PY

India routine immunization manual 2024 national immunization schedule vaccine doses routes sites open vial policy

WHO Pocket Book Hospital Care for Children injectable medicines gentamicin midazolam vancomycin dexamethasone dopamine noradrenaline

pediatric medication safety AND systematic review

mkdir -p "/tmp/workspace/drug-viva/output" && python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak from reportlab.lib.units import mm from pypdf import PdfReader import os out='/tmp/workspace/drug-viva/output/MD_Paediatrics_Gold_Medal_Injectable_Drug_Viva.pdf' S=getSampleStyleSheet() T=ParagraphStyle('T',parent=S['Title'],fontName='Helvetica-Bold',fontSize=18,leading=22,alignment=TA_CENTER,textColor=HexColor('#173E5B'),spaceAfter=4) ST=ParagraphStyle('ST',parent=S['Normal'],fontSize=8.4,leading=10.4,alignment=TA_CENTER,textColor=HexColor('#52646E'),spaceAfter=8) H1=ParagraphStyle('H1',parent=S['Heading1'],fontName='Helvetica-Bold',fontSize=13.4,leading=16,textColor=HexColor('#123E5B'),spaceBefore=7,spaceAfter=5) H2=ParagraphStyle('H2',parent=S['Heading2'],fontName='Helvetica-Bold',fontSize=10.7,leading=13,textColor=HexColor('#086A76'),spaceBefore=7,spaceAfter=3) B=ParagraphStyle('B',parent=S['Normal'],fontName='Helvetica',fontSize=7.9,leading=10.1,textColor=HexColor('#1C2B35'),spaceAfter=2) TB=ParagraphStyle('TB',parent=B,fontSize=7.2,leading=8.65); TF=ParagraphStyle('TF',parent=TB,fontName='Helvetica-Bold'); TH=ParagraphStyle('TH',parent=TB,fontName='Helvetica-Bold',textColor=colors.white,alignment=TA_CENTER) FT=ParagraphStyle('FT',parent=B,fontSize=6.45,leading=7.6,textColor=HexColor('#4D5F68')) def p(x,st=B):return Paragraph(x,st) def table(rows): d=[[p('Viva heading',TH),p('Gold-medal answer',TH)]]+[[p(a,TF),p(b,TB)] for a,b in rows] t=Table(d,colWidths=[44*mm,137*mm],repeatRows=1) t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),HexColor('#176B86')),('BACKGROUND',(0,1),(0,-1),HexColor('#EAF5F8')),('GRID',(0,0),(-1,-1),.25,HexColor('#B9CED6')),('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),2.5*mm),('RIGHTPADDING',(0,0),(-1,-1),2.5*mm),('TOPPADDING',(0,0),(-1,-1),1.7*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.7*mm)])) return t def card(name, cl, uses, dose, prep, monitor, danger, pearl): return [Paragraph(name,H2),table([('Class / mechanism',cl),('Key paediatric uses',uses),('Dose: examination answer',dose),('Preparation / administration',prep),('Monitoring',monitor),('Toxicity, cautions, antidote',danger),('Gold-medal viva pearl',pearl)]),Spacer(1,4)] def footer(c,d): c.saveState();c.setFont('Helvetica',7);c.setFillColor(HexColor('#63747C'));c.drawString(13*mm,9*mm,'MD Paediatrics Injectable Drug Spotters | Confirm concentration and local formulary before prescribing');c.drawRightString(197*mm,9*mm,'Page %d'%d.page);c.restoreState() story=[Paragraph('INJECTABLE DRUG SPOTTERS: MD PAEDIATRICS GOLD-MEDAL VIVA',T),Paragraph('Based on the medicine list in your image. Use: identify → class/mechanism → indication → dose → preparation → monitoring → adverse effects/antidote. All doses require verification against your hospital formulary, age, weight, gestation, renal/hepatic function and the exact product concentration.',ST),p('<b>High-alert warning:</b> Vasopressors/inotropes, insulin, concentrated electrolytes, sedatives, anticonvulsants and IV antibiotics can cause severe harm if concentration or infusion rate is wrong. Never quote a dose without stating route, maximum dose, dilution and monitoring. This is a viva revision document, not a stand-alone prescribing chart.'),Paragraph('1. Universal gold-medal answers',H1),table([('Before giving any injectable drug','Confirm child, weight in kg, indication, allergy, exact concentration, dose calculation in mg/kg, route, compatibility, line patency, renal/hepatic status, monitoring and independent double-check for high-alert medicines.'),('Dose calculation','Dose (mg) = ordered mg/kg × weight. Volume (mL) = dose (mg) ÷ available concentration (mg/mL). State the maximum dose and reassess need before repeat dose.'),('Dilution','Read product insert and institutional compatibility chart. “One ampoule” is never a dose. Label syringe/infusion with drug, total amount, final concentration, patient, time and preparer.'),('Extravasation','Stop infusion, leave cannula in place initially, aspirate if possible, elevate limb, document and use drug-specific protocol. Vasopressor extravasation requires urgent local management.'),('Renal adjustment','Gentamicin, vancomycin and many beta-lactams require dose interval or dose adjustment in renal dysfunction. Use serum levels for drugs with narrow therapeutic index when indicated.'),('Medication error prevention','Use smart pump/drug library, standard concentrations, leading zero before decimal, never trailing zero, verbal read-back, separate look-alike/sound-alike medicines and barcode/independent double check where available.')]),Paragraph('2. Antimicrobials and diagnostic injection',H1)] cards=[ ('1. Purified protein derivative (tuberculin), Mantoux test','Standardised PPD antigen causing delayed type IV hypersensitivity in sensitised T cells. It is a diagnostic immunologic test, not a vaccine.','Screening/supportive evaluation of TB infection in selected clinical contexts. It cannot distinguish latent TB from active disease and does not rule out TB in severe illness/immunosuppression.','Mantoux: 0.1 mL intradermal PPD, usually 5 TU, on volar forearm. Read induration, not erythema, at 48-72 h. Interpret cut-off by risk category/national TB guidance.','Use a 1 mL tuberculin syringe with 26-27G needle. Intradermal wheal 6-10 mm should form. Do not inject SC.','Measure transverse induration in mm with palpation. Record exact mm, date, product and lot, not only “positive/negative”.','Local itching/vesicle possible. False negative: very recent infection, very young age, severe TB, malnutrition, viral illness, steroids/immunosuppression. False positive: BCG effect or non-tuberculous mycobacteria.','The correct response is “0.1 mL intradermal, read induration at 48-72 h.” A positive test means immunologic sensitisation, not active TB diagnosis.'), ('2. Gentamicin injection','Aminoglycoside: binds 30S ribosomal subunit, causes misreading of mRNA. Bactericidal, concentration-dependent killing with post-antibiotic effect.','Neonatal sepsis in combination with ampicillin; Gram-negative sepsis, complicated UTI, and synergistic treatment in selected infections. In meningitis, use recommended beta-lactam backbone because CSF penetration is limited.','Common non-neonatal dose: 7.5 mg/kg/day IV/IM once daily or divided per local protocol. Neonatal dosing is gestation- and postnatal-age based, commonly extended-interval. Quote local neonatal chart, not an adult regimen.','Administer IV over about 30 min if infusion used; compatible dilution depends on product/institution. Avoid mixing in same syringe/line without compatibility check.','Creatinine/urine output, fluid status, hearing/vestibular symptoms where relevant. Therapeutic drug monitoring: use local peak/trough or nomogram protocol, especially neonates, prolonged therapy, renal impairment or unstable physiology.','Nephrotoxicity, cochleo-vestibular ototoxicity, neuromuscular blockade. Risk rises with renal impairment, dehydration, prolonged course, high trough and other nephrotoxins. No specific antidote.','Once-daily dosing exploits concentration-dependent killing and may reduce nephrotoxicity. The critical safety metric is avoiding persistently high trough concentration.'), ('3. Midazolam injection','Short-acting benzodiazepine, positive allosteric modulator of GABA-A receptor; anticonvulsant, anxiolytic, sedative and amnestic.','Acute seizures/status epilepticus, procedural sedation, intubation adjunct and ICU sedation.','Seizure rescue: IV 0.1-0.2 mg/kg slowly; intranasal/buccal 0.2 mg/kg commonly used where protocol supports. Sedation doses must be titrated in monitored setting. Always state local protocol and maximum.','Give IV slowly and titrate. For intranasal use, use a mucosal atomisation device if available. Ensure resuscitation equipment, suction, oxygen and trained staff before administration.','Continuous respiratory rate, SpO₂, level of consciousness, BP and capnography for deep sedation where available. Observe after last dose.','Respiratory depression, apnoea, hypotension, paradoxical agitation. Flumazenil reverses benzodiazepine effect but can precipitate seizures, especially in chronic benzodiazepine exposure or mixed overdose, so use selectively.','In status epilepticus, avoid repeated benzodiazepine doses without escalating to second-line antiseizure therapy: cumulative respiratory depression is a major danger.'), ('4. Vancomycin injection','Glycopeptide: binds D-Ala-D-Ala terminus, inhibiting cell-wall synthesis. Bactericidal against most Gram-positive organisms.','Suspected/confirmed MRSA, resistant pneumococcal meningitis combined with cefotaxime/ceftriaxone, catheter-related infection and severe Gram-positive sepsis per antibiogram.','Typical child dose 10-15 mg/kg IV every 6 h, adjusted for age, renal function and level-guided targets. Neonatal dosing is gestation/postnatal age specific. For serious invasive MRSA, target exposure is AUC-guided where available.','Infuse slowly, generally at no more than 10 mg/min and over at least 60 min for typical doses. Never rapid IV push. Use compatibility chart.','Renal function, urine output, infusion reaction; therapeutic monitoring. Modern preferred target in serious MRSA is AUC24/MIC 400-600 when feasible, rather than trough alone.','Nephrotoxicity, neutropenia with prolonged use, ototoxicity uncommon, and vancomycin infusion reaction (flushing/pruritus/hypotension) from rapid infusion, not IgE allergy. Slow infusion and treat symptoms.','Vancomycin infusion reaction is rate related. Do not label it “anaphylaxis” unless clinical criteria for true immediate allergy are met.'), ('5. Dexamethasone injection','Long-acting potent glucocorticoid with anti-inflammatory and anti-edema effects; minimal mineralocorticoid effect.','Bacterial meningitis adjunct when indicated and given before/with first antibiotic dose; croup; cerebral edema from selected causes; oncology and adrenal-related indications per protocol.','Croup: 0.15-0.6 mg/kg PO/IM/IV once, maximum commonly 10-16 mg depending protocol. Meningitis: 0.15 mg/kg IV every 6 h for 2-4 days is a commonly used regimen, started before/with antibiotics.','IV/IM formulation and dilution depend on product. Give meningitis dose before or with first antimicrobial, not after substantial antibiotic delay.','Clinical response, glucose, BP, GI bleeding risk, infection, mood/behaviour. Short course generally well tolerated.','Hyperglycaemia, hypertension, gastritis/GI bleeding, infection masking, mood change. Avoid routine steroid use in viral encephalitis or uncomplicated sepsis without specific indication.','The timing in bacterial meningitis matters: adjunctive steroid is most useful before or with the first antibiotic, and may reduce hearing loss in Hib meningitis.'), ('6. Ampicillin injection','Aminopenicillin beta-lactam. Binds PBPs and inhibits bacterial cell-wall synthesis. Time-dependent bactericidal activity.','Empiric early neonatal sepsis with gentamicin, suspected Listeria, enterococcal infections and susceptible streptococci.','Neonatal dose depends on gestation, postnatal age and whether meningitis is suspected. In older children, common severe-infection dosing is 50 mg/kg/dose IV every 6 h; meningitis requires higher local-guideline dose.','Reconstitute/dilute according to vial strength and local policy; administer IV slowly/infuse as directed. Obtain cultures before antibiotics if this does not delay care.','Clinical response, cultures/susceptibility, renal function with prolonged/high dose, rash/diarrhoea.','Immediate hypersensitivity/anaphylaxis, rash, diarrhoea/C. difficile, seizures at very high concentrations/renal failure. Do not confuse non-allergic ampicillin rash with anaphylaxis.','Ampicillin is included in neonatal meningitis coverage because it covers Listeria, unlike third-generation cephalosporins alone.'), ('7. Cefotaxime injection','Third-generation cephalosporin. Beta-lactam with strong Gram-negative activity and good CSF penetration when meninges inflamed.','Neonatal/paediatric bacterial meningitis, severe sepsis, pneumonia and intra-abdominal infections according to local antibiogram. In neonates it is often preferred to ceftriaxone where hyperbilirubinaemia/calcium concerns exist.','Severe infection commonly 50 mg/kg/dose IV every 6-8 h; meningitis may use 50 mg/kg every 6 h, maximum dependent on guideline. Neonatal interval is age/gestation dependent.','Reconstitute and infuse per product/local policy. Do not unnecessarily combine with another beta-lactam. De-escalate when culture result available.','Culture response, renal/hepatic function in prolonged therapy, diarrhoea, cytopenias if long course.','Allergy, diarrhoea/C. difficile, cytopenia with prolonged use, biliary issues less prominent than ceftriaxone. Cross-reactivity risk depends on beta-lactam allergy phenotype.','In children >1 month with suspected bacterial meningitis, empirical vancomycin plus cefotaxime/ceftriaxone is standard in many guidelines until susceptibility known.'), ('8. Phenobarbitone / phenobarbital injection','Barbiturate that enhances GABA-A-mediated inhibition; at higher concentration directly activates GABA-A. Long half-life.','First-line antiseizure medicine for neonatal seizures in many protocols; status epilepticus second-line/adjunct; refractory seizures.','Neonatal loading 20 mg/kg IV, with additional 10 mg/kg increments if needed to total usually 40 mg/kg under monitoring. Maintenance commonly 3-5 mg/kg/day. Give slow IV, often ≤1 mg/kg/min.','Use cardiac/respiratory monitoring during loading. Do not mix with incompatible medicines. Consider serum level for prolonged therapy or poor control, interpreting in clinical context.','Respiratory depression, hypotension, sedation, feeding difficulty, paradoxical irritability, cognitive/neurodevelopment concerns with prolonged exposure. No specific antidote; support airway/ventilation.','Failure to stop seizures after phenobarbital loading should trigger etiologic evaluation: glucose, calcium, sodium, infection, stroke/hemorrhage and EEG monitoring, not just repeated sedation.'), ('9. Paracetamol / acetaminophen injection','Central analgesic-antipyretic with complex central COX/peroxidase pathway effects; minimal peripheral anti-inflammatory effect.','Moderate pain and fever when oral/rectal route unavailable, including perioperative setting.','IV: 15 mg/kg/dose every 6 h in many children, or 12.5 mg/kg every 4 h. Use age/weight-specific product chart in neonates. Do not exceed total daily maximum, commonly 60-75 mg/kg/day in children, lower in neonates/hepatic impairment.','Product is commonly 10 mg/mL. Confirm concentration before calculating. Infuse over 15 min. Count all oral, rectal and IV paracetamol sources.','Pain/temperature, liver risk factors, total 24-h dose, hepatic function in prolonged/repeated high-risk use.','Hepatotoxicity from overdose or repeated supratherapeutic dosing. Antidote: N-acetylcysteine, guided by toxicology protocol and timed level where acute ingestion.','The commonest error is duplicate prescribing across routes. Always total the dose from all formulations.'), ('10. Biphasic isophane insulin / premixed insulin','Fixed mixture of short/rapid-acting insulin and intermediate-acting isophane (NPH) insulin. The exact ratio, e.g. 30/70, must be identified.','Selected diabetes regimens where a simpler fixed mixture is appropriate. It is not preferred for DKA infusion and often offers less flexibility than basal-bolus therapy in children.','Dose is individualised in units/kg/day by paediatric diabetes team. Never give a generic spotter dose. For DKA, use regular insulin IV infusion according to DKA protocol, not biphasic insulin.','Gently roll/suspend cloudy NPH-containing preparation. Confirm product, strength, device and units. Give SC, not IV. Time meal appropriately.','Capillary glucose, ketones/sick-day status, meal intake, injection technique, hypo symptoms, lipohypertrophy.','Hypoglycaemia, weight gain, lipodystrophy, hypokalaemia with high dose. Treat conscious hypoglycaemia with rapid carbohydrate; severe/unconscious with IV dextrose or IM glucagon per protocol.','“Cloudy insulin” means NPH component. Never use a premixed insulin for initial DKA management.'), ('11. Hydrocortisone injection','Glucocorticoid with substantial mineralocorticoid activity.','Adrenal crisis, stress dosing in known adrenal insufficiency/CAH, anaphylaxis adjunct, severe asthma in selected protocols, and refractory shock only when adrenal insufficiency/corticosteroid-responsive shock is suspected.','Adrenal crisis: 2 mg/kg IV/IM immediately, maximum 100 mg, then age/weight-based stress regimen. Alternative age doses often cited: 25 mg <1 year, 50 mg 1-5 years, 100 mg ≥6 years, then repeat/infuse by protocol.','Do not delay in suspected adrenal crisis for cortisol sampling if unstable; obtain samples first only if feasible without delay. Give isotonic fluid and correct hypoglycaemia concurrently.','BP, glucose, electrolytes, clinical perfusion, infection and GI effects.','Hyperglycaemia, hypertension, fluid retention, GI bleeding, infection masking. Steroids are adjuncts in anaphylaxis, never replace IM adrenaline.','In adrenal crisis, hydrocortisone treats both glucocorticoid deficiency and provides mineralocorticoid activity at stress doses.'), ('12. Calcium gluconate injection','Calcium salt. Stabilises myocardial membrane in severe hyperkalaemia; replaces calcium in symptomatic hypocalcaemia. It does not lower serum potassium.','Symptomatic hypocalcaemia, hyperkalaemia with ECG changes, calcium-channel blocker toxicity, hypermagnesaemia in selected contexts.','10% calcium gluconate: 0.5-1 mL/kg IV slowly (50-100 mg/kg calcium gluconate), maximum often 20 mL, with ECG monitoring. Dose/product must be distinguished from calcium chloride, which has about three times more elemental calcium per mL.','Dilute as per local protocol and administer slowly through secure IV. Central access is preferred for calcium chloride; avoid mixing with bicarbonate or phosphate in same line.','Continuous ECG during emergency use; ionised calcium, perfusion and extravasation site.','Bradycardia, arrhythmia, tissue necrosis with extravasation, hypercalcaemia. Use caution with digoxin toxicity and avoid rapid push.','In hyperkalaemia calcium buys time by stabilising cardiac membrane. It must be followed by potassium-shifting/removal therapies.'), ('13. Furosemide / frusemide injection','Loop diuretic: inhibits Na-K-2Cl transporter in thick ascending limb; causes natriuresis, kaliuresis and venodilation.','Pulmonary edema/fluid overload, heart failure, renal fluid overload, hypercalcaemia adjunct. Not routine “renal-dose” therapy in shock.','Common IV dose 0.5-1 mg/kg/dose; may increase to 2 mg/kg depending response and renal function. In neonates use specific protocol. Give slowly, maximum rate commonly 0.5 mg/kg/min.','Ensure adequate intravascular volume and perfusion before diuresis. Assess cause of edema and avoid reflex diuresis in dehydration.','Urine output, weight, BP, electrolytes (K, Na, Mg, Ca), renal function, acid-base balance, hearing with high dose/rapid injection.','Hypovolaemia, hypotension, hypokalaemic metabolic alkalosis, hyponatraemia, ototoxicity, nephrocalcinosis in preterm infants.','Poor response may reflect low renal perfusion, hypoalbuminaemia, renal failure, inadequate dose or ongoing salt/fluid intake. Treat underlying physiology, not just urine output.'), ('14. Dopamine injection','Catecholamine with dose-dependent dopaminergic, beta-1 and alpha-1 actions, though receptor selectivity is variable and “renal-dose dopamine” is obsolete.','Selected shock with low cardiac output/hypotension where local PICU protocol uses dopamine. Increasingly replaced by epinephrine/norepinephrine depending shock phenotype.','Continuous IV infusion only. Typical paediatric range 5-20 micrograms/kg/min, titrated to perfusion and BP. Do not give bolus.','Dilute to a standard concentration and administer by infusion pump via central line when possible; peripheral use requires frequent site checks.','Continuous ECG, BP, perfusion, lactate trend, urine output, glucose and peripheral circulation.','Tachyarrhythmia, increased myocardial oxygen demand, vasoconstriction/extravasation necrosis. Treat extravasation urgently with local protocol, often phentolamine where available.','Do not say “2-5 micrograms/kg/min improves renal perfusion.” Renal-dose dopamine has no proven renal-protective role.'), ('15. Noradrenaline / norepinephrine concentrate','Predominantly alpha-1 agonist with beta-1 activity. Increases systemic vascular resistance and MAP.','Vasodilatory/distributive shock, especially septic shock with low SVR after fluid resuscitation; first-line vasoactive in many adult and paediatric septic shock pathways when vasoplegia dominates.','Continuous infusion, commonly start 0.05-0.1 microgram/kg/min and titrate, range often 0.05-1 microgram/kg/min depending unit protocol. No bolus.','Use smart pump and standard concentration. Central line preferred, but do not delay life-saving initiation if monitored peripheral access is the only immediate option; check site frequently.','Continuous BP, ECG, perfusion, lactate, urine output and extremity ischemia.','Arrhythmia, hypertension, digital/mesenteric ischemia, extravasation necrosis.','Choice of vasoactive drug follows physiology: norepinephrine for vasoplegia, epinephrine for low cardiac output with hypotension. Reassess with bedside echo where available.'), ('16. Adrenaline / epinephrine injection','Mixed alpha- and beta-adrenergic agonist. Alpha causes vasoconstriction; beta-1 inotropy/chronotropy; beta-2 bronchodilation and reduced mast-cell mediator release.','Anaphylaxis, cardiac arrest, severe asthma/croup in specified forms, and vasoactive support in cold septic shock/low cardiac output per PICU protocol.','Anaphylaxis: 1 mg/mL (1:1000) 0.01 mg/kg IM in anterolateral thigh, maximum 0.5 mg; repeat every 5 min if required. Cardiac arrest: 0.01 mg/kg IV/IO of 0.1 mg/mL (1:10,000), max 1 mg.','State concentration explicitly: 1 mg/mL vs 0.1 mg/mL. IM thigh is first-line in anaphylaxis. IV adrenaline for anaphylaxis is only for refractory shock in expert monitored setting.','Airway, SpO₂, BP, ECG, perfusion, glucose, potassium. Observe biphasic reaction risk after anaphylaxis.','Tachycardia, arrhythmia, hypertension, ischemia, tremor, hyperglycaemia/lactataemia. No absolute contraindication in anaphylaxis.','The common fatal error is wrong concentration/route. Say the concentration aloud before giving adrenaline.'), ('17. Phenytoin / fosphenytoin injection','Voltage-gated sodium-channel blocker. Fosphenytoin is prodrug, dosed in phenytoin equivalents (PE).','Status epilepticus after benzodiazepine, focal seizures and selected seizure disorders. Fosphenytoin often preferred if available due to safer infusion and compatibility.','Phenytoin loading: 20 mg/kg IV, with additional 5-10 mg/kg if needed, maximum per protocol. Give phenytoin no faster than 1 mg/kg/min in children or 50 mg/min, whichever lower. Fosphenytoin rate may be faster, per PE protocol.','Phenytoin is alkaline and poorly compatible: dilute only in normal saline, use in-line filter and dedicated line. Do not mix with dextrose because precipitation occurs.','ECG, BP, respiratory status during infusion; serum level for ongoing therapy, albumin/free concentration in hypoalbuminaemia/renal failure.','Hypotension, arrhythmia, tissue injury/purple glove syndrome, extravasation, CNS depression. Fosphenytoin reduces local toxicity but still needs monitoring.','Phenytoin is not a first choice for neonatal seizures and is not appropriate for absence/myoclonic epilepsy. In convulsive status, do not delay second-line treatment after benzodiazepine.'), ('18. Sterile water for injection','Sterile, non-pyrogenic water used as a diluent or reconstitution fluid. It is not a resuscitation fluid and not a vaccine.','Reconstitution/dilution only where manufacturer instructions specifically permit.','No independent therapeutic dose. Never prescribe “sterile water IV” as a free-water bolus.','Use only matched volume and aseptic technique. Check product label. For drug reconstitution, use exactly the diluent recommended by manufacturer/local compatibility policy.','Monitor depends on reconstituted medication.','Direct IV administration may cause severe haemolysis/hyponatraemia due to hypotonicity. Wrong diluent can precipitate/inactivate drug or cause major dosing error.','Best viva line: “Sterile water is a diluent, not an IV fluid. I must not inject it IV without an appropriately diluted medicine.”'), ('19. Dobutamine injection','Predominantly beta-1 agonist with some beta-2/alpha effects: increases inotropy and cardiac output, may lower SVR.','Low cardiac output with adequate/increased SVR, myocardial dysfunction, postoperative cardiac support, selected cold shock with myocardial dysfunction.','Continuous infusion, commonly 2-20 micrograms/kg/min, titrated to cardiac output and perfusion. No bolus.','Standard concentration via pump; central line preferred. Use bedside echo and haemodynamic phenotype to guide selection.','ECG, BP, perfusion, lactate, urine output, echocardiographic function where available.','Tachyarrhythmia, hypotension due to vasodilation, increased myocardial oxygen consumption, extravasation injury.','Dobutamine may worsen hypotension in profound vasoplegia; pair/select alternative vasopressor based on SVR and myocardial function.'), ('20. Diazepam injection','Benzodiazepine, GABA-A positive allosteric modulator. Lipid soluble with rapid CNS entry but redistribution and risk of respiratory depression.','Acute convulsive seizure/status epilepticus when IV access available; muscle spasm/sedation in selected settings.','IV 0.15-0.2 mg/kg slowly, maximum commonly 10 mg. Rectal dose commonly 0.5 mg/kg where protocol supports. Do not repeat multiple doses without escalation plan.','Give slow IV through secure line. Formulation contains propylene glycol/ethanol and can cause venous irritation. Ensure airway support, oxygen and suction ready.','Respiratory rate, SpO₂, BP, consciousness. Observe for recurrence due to redistribution.','Apnoea, respiratory depression, hypotension, thrombophlebitis and paradoxical agitation. Flumazenil is selective reversal but can precipitate seizures.','Midazolam is often preferred by non-IV routes. Benzodiazepines are first-line for status but repeated dosing without airway planning is unsafe.')] for i,c in enumerate(cards): story+=card(*c) if i in [4,9,14]:story.append(PageBreak()) story += [PageBreak(),Paragraph('3. Rapid examiner questions: model answers',H1),table([('Why therapeutic drug monitoring for gentamicin/vancomycin?','Large interpatient pharmacokinetic variation, narrow safety margin and exposure-related toxicity. Gentamicin toxicity correlates with sustained trough exposure; vancomycin serious MRSA therapy is increasingly AUC-guided.'),('Which drugs need continuous ECG/BP monitoring?','Adrenaline infusion, noradrenaline, dopamine, dobutamine, calcium gluconate in emergency use, phenytoin/fosphenytoin loading, phenobarbital loading and deeply sedating benzodiazepines.'),('Which are vesicants/high extravasation risk?','Vasopressors, calcium salts, phenytoin and concentrated electrolytes. Stop infusion, leave catheter initially, aspirate, elevate, notify and follow agent-specific extravasation protocol.'),('What is the first drug in anaphylaxis?','IM adrenaline, 1 mg/mL, 0.01 mg/kg into anterolateral thigh. Antihistamines and steroids are adjuncts, not substitutes.'),('What is wrong with “renal-dose dopamine”?','It does not prevent/treat acute kidney injury and is not recommended for renal protection.'),('What must you say about insulin?','Specify insulin preparation and concentration, dose in units, route, timing with food, glucose monitoring and hypoglycaemia plan. Premixed insulin must not be used for DKA infusion.'),('Antidotes to remember','Paracetamol: N-acetylcysteine. Benzodiazepines: flumazenil only selectively. Insulin hypoglycaemia: glucose/glucagon. Most antibiotic, vasopressor and anticonvulsant toxicities have no specific antidote and require supportive care.')]),Paragraph('References and safety note',H1),p('WHO <i>Pocket Book of Hospital Care for Children</i>, 2nd ed. WHO essential medicines and standard paediatric emergency principles. Local PICU, neonatal, antimicrobial stewardship, diabetes and toxicology protocols should supersede this sheet where they differ. Exact product concentrations, infusion rates and neonatal dose intervals are institution-specific.',FT),p('<b>Final gold-medal line:</b> “I will check the child’s current weight, indication, age/gestation, renal and hepatic function, exact vial concentration, standard dilution, infusion pump setting, line compatibility and monitoring before administration, and I will document response and adverse effects.”',FT)] doc=SimpleDocTemplate(out,pagesize=A4,leftMargin=14*mm,rightMargin=14*mm,topMargin=12*mm,bottomMargin=15*mm) doc.build(story,onFirstPage=footer,onLaterPages=footer) r=PdfReader(out);print(out,len(r.pages),os.path.getsize(out)) PY

~/drug-viva/

python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak from reportlab.lib.units import mm from pypdf import PdfReader import os out='/tmp/workspace/drug-viva/output/MD_Paediatrics_Gold_Medal_Injectable_Drug_Viva.pdf' S=getSampleStyleSheet(); T=ParagraphStyle('t',parent=S['Title'],fontName='Helvetica-Bold',fontSize=18,leading=22,alignment=TA_CENTER,textColor=HexColor('#133E5B')); ST=ParagraphStyle('st',parent=S['Normal'],fontSize=8.4,leading=10.5,alignment=TA_CENTER,textColor=HexColor('#52646e'),spaceAfter=8); H1=ParagraphStyle('h1',parent=S['Heading1'],fontName='Helvetica-Bold',fontSize=13,leading=16,textColor=HexColor('#123E5B'),spaceBefore=8,spaceAfter=5); H2=ParagraphStyle('h2',parent=S['Heading2'],fontName='Helvetica-Bold',fontSize=10.5,leading=13,textColor=HexColor('#076A77'),spaceBefore=7,spaceAfter=3); B=ParagraphStyle('b',parent=S['Normal'],fontName='Helvetica',fontSize=7.85,leading=10.1,textColor=HexColor('#1D2B34')); C=ParagraphStyle('c',parent=B,fontSize=7.12,leading=8.7); L=ParagraphStyle('l',parent=C,fontName='Helvetica-Bold'); TH=ParagraphStyle('th',parent=C,fontName='Helvetica-Bold',textColor=colors.white,alignment=TA_CENTER); F=ParagraphStyle('f',parent=B,fontSize=6.4,leading=7.7,textColor=HexColor('#4b5f69')) def p(x,s=B):return Paragraph(x,s) def tab(rows): d=[[p('Viva heading',TH),p('Gold-medal answer',TH)]]+[[p(a,L),p(b,C)] for a,b in rows] t=Table(d,colWidths=[44*mm,137*mm],repeatRows=1);t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),HexColor('#176B86')),('BACKGROUND',(0,1),(0,-1),HexColor('#EAF5F8')),('GRID',(0,0),(-1,-1),.25,HexColor('#B9CED6')),('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),2.4*mm),('RIGHTPADDING',(0,0),(-1,-1),2.4*mm),('TOPPADDING',(0,0),(-1,-1),1.6*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.6*mm)]));return t def drug(n,cls,use,dose,admin,monitor,tox,pearl):return [Paragraph(n,H2),tab([('Class / mechanism',cls),('Indications',use),('Dose: exam answer',dose),('Administration',admin),('Monitoring',monitor),('Toxicity / caution',tox),('Gold-medal pearl',pearl)]),Spacer(1,4)] def footer(c,d):c.saveState();c.setFont('Helvetica',7);c.setFillColor(HexColor('#60727B'));c.drawString(13*mm,9*mm,'MD Paediatrics Injectable Drug Spotters | Confirm local formulary and vial concentration');c.drawRightString(197*mm,9*mm,'Page %d'%d.page);c.restoreState() story=[Paragraph('INJECTABLE DRUG SPOTTERS: MD PAEDIATRICS GOLD-MEDAL VIVA',T),Paragraph('Your image list: tuberculin, gentamicin, midazolam, vancomycin, dexamethasone, ampicillin, cefotaxime, phenobarbitone, paracetamol, premixed insulin, hydrocortisone, calcium gluconate, furosemide, dopamine, noradrenaline, adrenaline, phenytoin, sterile water, dobutamine and diazepam.',ST),p('<b>Safety:</b> These are revision doses, not a prescription chart. Verify age, weight, gestation, renal/hepatic function, exact concentration, local standard dilution, compatibility and maximum dose. Use independent check and pump for high-alert infusions.'),Paragraph('Universal viva framework',H1),tab([('Dose calculation','Dose in mg = mg/kg × kg. Volume = prescribed mg ÷ vial concentration in mg/mL. State maximum dose. “One ampoule” is never a dose.'),('High-alert medicines','Insulin, concentrated electrolytes, catecholamines, sedatives and anticonvulsants: independent double-check, labelled syringe/infusion, pump and continuous monitoring where indicated.'),('Extravasation','Stop infusion, leave cannula initially, aspirate if possible, elevate, document and use drug-specific protocol. Vasopressor, calcium and phenytoin extravasation are urgent.'),('Antidotes','Paracetamol: N-acetylcysteine. Benzodiazepines: flumazenil only selectively. Insulin hypoglycaemia: glucose/glucagon. Most antibiotic/inotrope toxicity needs supportive care.')])] D=[ ('1. Tuberculin / PPD','Purified protein derivative; delayed type-IV hypersensitivity diagnostic test, not vaccine.','Supportive evidence of TB infection in context. Cannot distinguish latent from active TB.','0.1 mL, commonly 5 TU, intradermal on volar forearm; read at 48-72 h.','1 mL tuberculin syringe, 26-27G. Intradermal wheal should form.','Measure transverse <b>induration</b> in mm, not erythema.','False negative with severe TB, young age, malnutrition, immunosuppression, recent viral illness; false positive with BCG/NTM.','A positive Mantoux indicates sensitisation, not active TB. Record exact mm and risk-based interpretation.'), ('2. Gentamicin','Aminoglycoside, 30S inhibitor; concentration-dependent bactericidal killing.','Neonatal sepsis with ampicillin, Gram-negative sepsis/UTI, selected synergy.','Non-neonatal commonly 7.5 mg/kg/day IV/IM once daily or divided. Neonates require gestation/postnatal-age extended-interval chart.','IV infusion commonly over 30 min; check compatibility.','Creatinine, urine output, fluid status, drug levels in neonates/prolonged therapy/renal dysfunction.','Nephrotoxicity, cochleovestibular ototoxicity, neuromuscular blockade. Avoid high troughs/nephrotoxins.','Once-daily dosing exploits concentration dependence; persistent high trough predicts toxicity.'), ('3. Midazolam','Short-acting benzodiazepine, GABA-A positive allosteric modulator.','Acute seizures, procedural sedation, intubation/ICU sedation.','Seizure: IV 0.1-0.2 mg/kg slowly; intranasal/buccal commonly 0.2 mg/kg by protocol.','Titrate slowly with airway equipment, oxygen, suction and trained staff present.','Continuous RR, SpO₂, consciousness, BP; capnography for deep sedation when available.','Apnoea, respiratory depression, hypotension, paradoxical agitation. Flumazenil may precipitate seizure.','After 2 adequate benzodiazepine doses in status, escalate to second-line antiseizure drug, not repeated sedation.'), ('4. Vancomycin','Glycopeptide, binds D-Ala-D-Ala and inhibits cell wall synthesis.','MRSA, resistant pneumococcal meningitis with cefotaxime/ceftriaxone, severe Gram-positive infection.','Typical child 10-15 mg/kg IV q6h, adjusted for renal function/age/levels. Neonatal regimen is age specific.','Infuse slowly, generally ≥60 min and ≤10 mg/min. Never rapid IV push.','Creatinine, urine output, infusion reaction; AUC24/MIC 400-600 for serious MRSA where available.','Nephrotoxicity, neutropenia; rate-related flushing/pruritus/hypotension is vancomycin infusion reaction.','“Red man” is rate-related histamine-mediated infusion reaction, not automatically IgE allergy.'), ('5. Dexamethasone','Potent long-acting glucocorticoid, negligible mineralocorticoid effect.','Croup, bacterial meningitis adjunct, selected cerebral edema/oncology indications.','Croup 0.15-0.6 mg/kg once, max local protocol. Meningitis commonly 0.15 mg/kg IV q6h, started before/with antibiotics.','Give meningitis dose before or with first antimicrobial.','Clinical response, glucose, BP, GI/infection effects.','Hyperglycaemia, hypertension, gastritis, infection masking, mood effects.','In bacterial meningitis, timing matters: steroid should precede/accompany initial antibiotic.'), ('6. Ampicillin','Aminopenicillin beta-lactam, PBP/cell-wall inhibitor, time-dependent killing.','Neonatal sepsis with gentamicin; Listeria and enterococcal infection.','Older child severe infection often 50 mg/kg/dose IV q6h; meningitis/neonatal doses are protocol specific.','Reconstitute per vial; obtain cultures if this does not delay care.','Culture response, rash, diarrhoea, renal function in prolonged course.','Anaphylaxis, rash, diarrhoea, seizures in renal failure/high levels.','Ampicillin is needed in neonatal meningitis coverage because it covers Listeria.'), ('7. Cefotaxime','Third-generation cephalosporin with CSF penetration in inflamed meninges.','Meningitis, severe sepsis, pneumonia, intra-abdominal infection per antibiogram.','Commonly 50 mg/kg/dose IV q6-8h; meningitis often q6h. Neonatal interval age/gestation dependent.','Reconstitute/infuse per local chart; de-escalate to culture.','Response, diarrhoea, cytopenia/renal/hepatic function in prolonged use.','Allergy, C. difficile, cytopenia with prolonged course.','In suspected meningitis beyond neonatal period, vancomycin plus cefotaxime/ceftriaxone is common empiric therapy.'), ('8. Phenobarbitone','Barbiturate enhancing GABA-A inhibition; long half-life.','First-line neonatal seizure drug; status epilepticus adjunct.','Neonatal load 20 mg/kg IV, additional 10 mg/kg to usual total 40 mg/kg if required; maintenance 3-5 mg/kg/day.','Slow IV, often ≤1 mg/kg/min, with cardio-respiratory monitoring.','RR, BP, consciousness, feeding; levels when prolonged/poor response.','Sedation, apnoea, hypotension, feeding difficulty.','If seizures persist, investigate glucose, calcium, sodium, sepsis, stroke and use EEG, rather than repeated sedation alone.'), ('9. Paracetamol IV','Central analgesic-antipyretic with minimal peripheral anti-inflammatory action.','Fever/moderate pain when oral/rectal route unavailable.','15 mg/kg IV q6h or 12.5 mg/kg q4h; neonatal and hepatic-risk limits lower. Max total daily dose commonly 60-75 mg/kg/day.','Common product 10 mg/mL, infuse over 15 min. Include all routes in daily total.','Temperature/pain, 24-h total, liver risk factors/function.','Hepatotoxicity in overdose/repeated excess. Antidote N-acetylcysteine.','Most frequent error is duplicate oral + IV prescribing.'), ('10. Biphasic isophane/premixed insulin','Fixed mixture short/rapid insulin plus intermediate NPH. Exact ratio must be named.','Selected diabetes regimens. Not initial therapy for DKA.','Individualised units/kg/day by diabetes team. No generic spotter dose.','Roll cloudy NPH product gently, give SC, match food timing.','Glucose, ketones, food intake, injection sites, hypo symptoms.','Hypoglycaemia, hypokalaemia, weight gain, lipohypertrophy.','Never use premixed insulin for DKA infusion: DKA uses regular insulin infusion by protocol.'), ('11. Hydrocortisone','Glucocorticoid with mineralocorticoid activity.','Adrenal crisis/stress dosing, CAH, anaphylaxis adjunct, selected asthma/shock.','Adrenal crisis: 2 mg/kg IV/IM stat, max 100 mg; common age doses 25 mg <1y, 50 mg 1-5y, 100 mg ≥6y, then protocol regimen.','Do not delay in unstable suspected adrenal crisis; fluids and dextrose as needed.','BP, glucose, electrolytes, perfusion.','Hyperglycaemia, hypertension, fluid retention, GI bleeding.','At stress doses it supplies both glucocorticoid and mineralocorticoid effect. In anaphylaxis it never replaces IM adrenaline.'), ('12. Calcium gluconate 10%','Calcium salt: membrane stabilisation in hyperkalaemia; calcium replacement. Does not lower K.','Symptomatic hypocalcaemia; hyperkalaemia with ECG changes; CCB toxicity.','0.5-1 mL/kg IV slowly, max often 20 mL, with ECG. This is 50-100 mg/kg calcium gluconate.','Secure IV, slow administration; do not mix with bicarbonate/phosphate.','Continuous ECG, ionised calcium, extravasation site.','Bradyarrhythmia if rapid, tissue necrosis, hypercalcaemia. Caution in digoxin toxicity.','Differentiate calcium gluconate from calcium chloride: chloride delivers ~3 times more elemental calcium per mL.'), ('13. Furosemide','Loop diuretic, blocks Na-K-2Cl in thick ascending limb.','Fluid overload/pulmonary edema, heart failure, hypercalcaemia adjunct.','0.5-1 mg/kg IV; up to 2 mg/kg depending response/renal function.','Give slow IV, commonly no faster than 0.5 mg/kg/min. Ensure perfusion first.','I/O, weight, BP, K/Na/Mg/Ca, renal function.','Hypovolaemia, hypokalaemic alkalosis, hypotension, ototoxicity, nephrocalcinosis in preterm.','Do not give “renal-dose” furosemide to a shocked/dehydrated child without correcting circulation.'), ('14. Dopamine','Catecholamine; beta-1/alpha effects, variable dose-response.','Selected low-output/hypotensive shock only under PICU protocol; less preferred in many current pathways.','Continuous IV 5-20 micrograms/kg/min, titrated. No bolus.','Pump, standard concentration, central line preferred; peripheral site checks.','ECG, BP, perfusion, lactate, urine output.','Tachyarrhythmia, ischemia, extravasation necrosis.','“Renal-dose dopamine” has no proven renal protective role.'), ('15. Noradrenaline','Predominantly alpha-1 with beta-1 activity: raises SVR/MAP.','Vasoplegic/distributive septic shock after appropriate fluid resuscitation.','Start commonly 0.05-0.1 micrograms/kg/min, titrate; range often 0.05-1 micrograms/kg/min.','Pump, standard concentration, central preferred; monitored peripheral start should not delay life-saving therapy.','Continuous BP/ECG, perfusion, lactate, urine, limb ischemia.','Arrhythmia, hypertension, digital/mesenteric ischemia, extravasation.','Vasoactive choice follows phenotype: norepinephrine for vasoplegia, epinephrine for low cardiac output/hypotension.'), ('16. Adrenaline / epinephrine','Mixed alpha/beta agonist.','Anaphylaxis, arrest, selected croup/asthma, cold shock/low output per protocol.','Anaphylaxis: 1 mg/mL, 0.01 mg/kg IM thigh, max 0.5 mg, repeat 5 min. Arrest: 0.01 mg/kg of 0.1 mg/mL IV/IO, max 1 mg.','Say concentration aloud: 1 mg/mL versus 0.1 mg/mL. IM thigh is first line for anaphylaxis.','Airway, SpO₂, BP, ECG, glucose/K.','Arrhythmia, hypertension, tremor, lactic acidosis. No absolute contraindication in anaphylaxis.','Wrong concentration/route is the classic lethal error.'), ('17. Phenytoin / fosphenytoin','Voltage-gated sodium-channel blocker; fosphenytoin prodrug, dosed in PE.','Status epilepticus after benzodiazepine, focal seizures.','Phenytoin load 20 mg/kg IV, further 5-10 mg/kg as needed. Max rate 1 mg/kg/min or 50 mg/min, whichever lower.','Dilute phenytoin only in normal saline, with filter/dedicated line; never dextrose.','ECG, BP, RR, drug/free level if prolonged, albumin.','Hypotension, arrhythmia, purple glove/extravasation.','Not first choice for neonatal seizures or absence/myoclonic epilepsy.'), ('18. Sterile water for injection','Sterile nonpyrogenic diluent, not IV fluid or vaccine.','Reconstitution/dilution only when product instructions permit.','No independent therapeutic dose.','Use matched volume and aseptic method; verify label.','Depends on reconstituted drug.','Direct IV use can cause haemolysis/hyponatraemia; wrong diluent can inactivate/precipitate drug.','“Sterile water is a diluent, never a free-water IV bolus.”'), ('19. Dobutamine','Predominantly beta-1 inotrope, may lower SVR.','Low cardiac output/myocardial dysfunction with adequate/high SVR; selected cold shock.','Continuous infusion 2-20 micrograms/kg/min, titrated. No bolus.','Pump, central preferred; bedside echo guides selection.','ECG, BP, perfusion, lactate, urine, echo.','Tachyarrhythmia, hypotension, extravasation.','May worsen profound vasoplegia: choose drug from haemodynamic phenotype, not habit.'), ('20. Diazepam','Benzodiazepine, GABA-A modulator.','Acute convulsive seizure when IV access; selected spasm/sedation.','IV 0.15-0.2 mg/kg slow, max commonly 10 mg; rectal commonly 0.5 mg/kg by protocol.','Slow IV with airway support ready; irritant propylene-glycol formulation.','RR, SpO₂, BP, consciousness.','Apnoea, hypotension, thrombophlebitis, paradoxical agitation.','Midazolam is often preferred non-IV. Repeated benzodiazepine dosing without airway strategy is unsafe.')] for i,x in enumerate(D): story+=drug(*x) if i in [4,9,14]:story.append(PageBreak()) story += [PageBreak(),Paragraph('Rapid examiner questions',H1),tab([('Why TDM for gentamicin/vancomycin?','Highly variable pharmacokinetics, narrow safety margin and exposure-related toxicity. Gentamicin high trough is harmful; serious MRSA vancomycin therapy is ideally AUC-guided.'),('Which require continuous monitoring?','Catecholamine infusions, calcium in emergency use, phenytoin/fosphenytoin load, phenobarbitone load and deep benzodiazepine sedation.'),('First drug in anaphylaxis?','IM adrenaline 1 mg/mL, 0.01 mg/kg into anterolateral thigh. Steroid/antihistamine are adjuncts only.'),('Universal finishing line','“I will verify weight, indication, concentration, dose, dilution, pump setting, compatibility, line patency, renal/hepatic status, monitoring, response and adverse effects.”')]),Paragraph('References',H1),p('WHO <i>Pocket Book of Hospital Care for Children</i>, 2nd edition; standard paediatric emergency, neonatal, antimicrobial stewardship, diabetes and toxicology practice. Local PICU, neonatal and drug-information protocols supersede this revision guide where different. The recommended 2024 systematic-review search did not identify a directly relevant recent synthesis that changes these medication-safety principles.',F)] doc=SimpleDocTemplate(out,pagesize=A4,leftMargin=14*mm,rightMargin=14*mm,topMargin=12*mm,bottomMargin=15*mm);doc.build(story,onFirstPage=footer,onLaterPages=footer) r=PdfReader(out);print(out,len(r.pages),os.path.getsize(out)) PY

python - <<'PY' from pypdf import PdfReader import os p='/tmp/workspace/drug-viva/output/MD_Paediatrics_Gold_Medal_Injectable_Drug_Viva.pdf' r=PdfReader(p); t='\n'.join((x.extract_text() or '') for x in r.pages) terms=['Tuberculin','Gentamicin','Midazolam','Vancomycin','Calcium gluconate','Noradrenaline','Sterile water','Diazepam'] print('pages',len(r.pages),'bytes',os.path.getsize(p),'chars',len(t)) for x in terms: print(x, x in t) PY

~/

ICMR NIN Indian Food Composition Tables 2017 food nutrients calories protein fibre ragi pulses fruits

child nutrition AND dietary diversity

python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak from reportlab.lib.units import mm from pypdf import PdfReader import os out='/tmp/workspace/nutrition-spotter/output/Detailed_MD_Paediatrics_Nutrition_Spotters_Viva.pdf' os.makedirs(os.path.dirname(out),exist_ok=True) S=getSampleStyleSheet() T=ParagraphStyle('T',parent=S['Title'],fontName='Helvetica-Bold',fontSize=18,leading=22,alignment=TA_CENTER,textColor=HexColor('#153E5A'),spaceAfter=4) ST=ParagraphStyle('ST',parent=S['Normal'],fontSize=8.5,leading=10.4,alignment=TA_CENTER,textColor=HexColor('#52646D'),spaceAfter=9) H1=ParagraphStyle('H1',parent=S['Heading1'],fontName='Helvetica-Bold',fontSize=13.5,leading=16,textColor=HexColor('#123E5B'),spaceBefore=8,spaceAfter=5) H2=ParagraphStyle('H2',parent=S['Heading2'],fontName='Helvetica-Bold',fontSize=10.7,leading=13,textColor=HexColor('#086A76'),spaceBefore=7,spaceAfter=3) B=ParagraphStyle('B',parent=S['Normal'],fontName='Helvetica',fontSize=7.95,leading=10.1,textColor=HexColor('#1D2B34')) C=ParagraphStyle('C',parent=B,fontSize=7.15,leading=8.65); L=ParagraphStyle('L',parent=C,fontName='Helvetica-Bold'); TH=ParagraphStyle('TH',parent=C,fontName='Helvetica-Bold',textColor=colors.white,alignment=TA_CENTER); F=ParagraphStyle('F',parent=B,fontSize=6.4,leading=7.5,textColor=HexColor('#4D6069')) def p(x,s=B):return Paragraph(x,s) def tab(rows,w=(43*mm,138*mm)): d=[[p('Viva heading',TH),p('Gold-medal answer',TH)]]+[[p(a,L),p(b,C)] for a,b in rows] t=Table(d,colWidths=list(w),repeatRows=1);t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),HexColor('#176A87')),('BACKGROUND',(0,1),(0,-1),HexColor('#EAF5F8')),('GRID',(0,0),(-1,-1),.25,HexColor('#B8CED6')),('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),2.4*mm),('RIGHTPADDING',(0,0),(-1,-1),2.4*mm),('TOPPADDING',(0,0),(-1,-1),1.6*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.6*mm)]));return t def food(n,vals,group,ident,uses,clinical,pearl): return [Paragraph(n,H2),tab([('Nutrient value / 100 g',vals),('Food group & identification',group+' '+ident),('Paediatric nutrition use',uses),('Clinical cautions / counselling',clinical),('Gold-medal viva pearl',pearl)]),Spacer(1,4)] def footer(c,d): c.saveState();c.setFont('Helvetica',7);c.setFillColor(HexColor('#60727B'));c.drawString(13*mm,9*mm,'MD Paediatrics Nutrition Spotters | Values are approximate and source-dependent');c.drawRightString(197*mm,9*mm,'Page %d'%d.page);c.restoreState() story=[Paragraph('DETAILED NUTRITION SPOTTERS: MD PAEDIATRICS GOLD-MEDAL VIVA',T),Paragraph('Foods listed in your original spotter image. Answer in this order: identify → food group → kcal/protein/fibre per 100 g → key micronutrient → child-feeding use → caution. Nutrient values below are primarily from Elizabeth KE, <i>Nutrition and Child Development</i>, Table 3.11, pp. 125-126, with selected clarifications from ICMR-NIN IFCT 2017.',ST),p('<b>How to state values safely:</b> “These are approximate values per 100 g edible portion. For rice, pulses, ragi, sugar and peanuts the values are for raw/dry food; cooking adds water and reduces nutrient density per 100 g prepared food. Variety, dehusking, maturity and processing change values.”'),Paragraph('1. Core viva principles',H1),tab([('Food groups','Cereals/millets: mainly energy. Pulses/legumes/nuts: protein and micronutrients. Fruits/vegetables: protective foods, vitamins, minerals, fibre and phytochemicals. Sugar/jaggery/oils: energy concentrates.'),('Protein quality','Cereals are relatively lysine-limited; pulses are relatively methionine-limited. Rice-dal, roti-dal, khichdi, idli/dosa give mutual amino-acid supplementation.'),('Complementary feeding','Start at completed 6 months while continuing breastfeeding. Give thick, mashed, responsive, diverse home foods. Avoid thin watery gruels because energy per spoon is low. Add oil/ghee, milk or smooth groundnut paste in suitable amounts to increase energy density.'),('Micronutrient logic','Vitamin C-rich guava, amla/citrus and papaya improve non-haem iron absorption from pulses/ragi. Ragi contributes calcium. Egg gives high biological-value protein, B12 and choline.'),('Safety','Prevent choking: no whole peanuts, remove custard-apple seeds, cut/soften fruits appropriately. Food hygiene, handwashing and age-appropriate texture are essential.'),('Jaggery myth','Jaggery contains some iron but is an energy concentrate. It does not treat iron-deficiency anaemia; use dietary diversification and therapeutic iron when indicated.')]),Paragraph('2. Cereals, millets, pulses and energy foods',H1)] D=[ ('1. Raw rice','350 kcal; protein 7 g; fibre 0.2 g; carbohydrate 78 g; iron 0.7 mg.','Cereal/grain. Polished white rice is low-fibre; raw rice grain is hard, white/translucent and oval.','Major inexpensive carbohydrate source. Rice porridge/khichdi is acceptable if made thick and enriched with pulse, fat and vegetables.','Rice alone has poor protein quality and low micronutrient density. Polished rice has less fibre/micronutrients than less-refined rice.','Say: “Rice is an energy food, not a complete food. Combine it with a pulse to correct lysine limitation.”'), ('2. Toor dal / arhar / red gram','340 kcal; protein 22 g; fibre 1.5 g; carbohydrate 58 g; iron 2.7 mg.','Pulse/legume. Yellow split pigeon pea.','Protein, iron and B vitamins; staple in dal, sambar and khichdi. Useful affordable complementary-food component after cooking/mashing.','Plant iron is non-haem and phytate can reduce absorption. Add vitamin C-rich fruit/vegetable; soaking/germination/fermentation improve acceptability.','Pulse protein is methionine-limited. Cereal-pulse combination improves net protein quality.'), ('3. Chana dal / Bengal gram','360 kcal; protein 17 g; fibre 3.9 g; carbohydrate 60 g; iron 4.6 mg.','Pulse/legume. Split, husked chickpea, yellow and thick.','Useful protein/fibre source. Roasted chana powder can enrich porridge; cooked mashed chana may be introduced in age-appropriate form.','Whole/split forms may cause choking if not adequately cooked/mashed. Fibre may be poorly tolerated during acute diarrhoea in some children.','Bengal gram is relatively fibre rich among the listed pulses and offers iron, but it is not a substitute for iron therapy in IDA.'), ('4. Moong dal / split green gram','340 kcal; protein 24 g; fibre 4.1 g; carbohydrate 57 g; iron 4.4 mg.','Pulse. Split dehusked green gram, usually yellow. Whole green gram is the intact green seed.','Easily digested in customary practice; commonly used in khichdi and convalescent feeds. Sprouting the whole seed increases vitamin C and may improve mineral availability.','“Easily digestible” does not mean nutritionally complete. Avoid making a dilute moong-water feed for undernourished children.','Moong has high listed protein and fibre. Sprouting is a food-processing answer, not a magic increase in calories.'), ('5. Whole green gram / green moong','340 kcal; protein 24 g; fibre 4.1 g; carbohydrate 57 g; iron 4.4 mg.','Pulse. Intact small green oval seed; same basic pulse as moong dal before splitting/dehusking.','Use boiled/mushed, sprouted and cooked in chilla/khichdi. Adds protein, folate and fibre.','Raw sprouts can carry microbial risk. For infants/young children, wash well and cook rather than offer raw sprouts.','If shown whole and split moong, identify that the whole seed retains its green husk while moong dal is split/dehusked.'), ('6. Dry peas','~315 kcal; protein ~20 g; fibre ~4-5 g.','Legume. Dry mature peas are wrinkled, round and hard. Distinguish from fresh green peas.','Protein and complex carbohydrate source. Fresh peas are softer and suitable mashed after cooking.','Dry peas require soaking/cooking. Fresh peas have lower calorie density per 100 g owing to high water content.','In a viva, clarify whether the specimen is dry pea or fresh green pea before quoting nutrient values.'), ('7. Urad dal / black gram, including white urad','350 kcal; protein 24 g; fibre 0.9 g; carbohydrate 60 g; iron 3.8 mg.','Pulse. Whole black gram has black skin; white/idli urad is dehusked, usually split.','Protein-rich and important in idli/dosa batter. Fermentation improves palatability and can improve nutrient bioavailability.','Do not equate fermented food with high iron bioavailability or sterility. Use good hygiene and adequate cooking.','Idli/dosa illustrates cereal-pulse complementation: rice plus urad improves amino-acid balance.'), ('8. Ragi / finger millet','330 kcal; protein 7 g; fibre 3.6 g; carbohydrate 72 g; iron 3.9 mg; calcium about 344 mg.','Millet. Tiny reddish-brown grains, also called finger millet/nachni.','Important calcium-rich cereal. Ragi porridge can be a useful complementary food if thick and enriched.','Do not make a very dilute ragi gruel. Phytate reduces mineral bioavailability; fermentation/malting may improve acceptability and availability.','Ragi is the key calcium spotter. It is not a high-quality protein food on its own, so combine with pulse/milk/egg.'), ('9. Sugar','~400 kcal; protein 0 g; fibre 0 g.','Refined carbohydrate, essentially sucrose crystals.','Adds energy and palatability but no meaningful protein, fibre, vitamin or mineral value.','Avoid routine added sugar in young children. Promotes dental caries and displacement of nutrient-dense foods; excess can worsen unhealthy weight gain.','Call it an “empty-calorie energy concentrate,” not a protective food.'), ('10. Jaggery / bellam / gur','~380 kcal; protein ~0.4 g; fibre 0 g; contains some iron.','Unrefined sugar product, yellow-brown to dark-brown block/powder.','Energy enhancer in some preparations; a small amount can improve palatability.','High free sugar. Not treatment for iron deficiency, and not a health food for daily unrestricted use. Dental hygiene is important.','Elizabeth notes jaggery is iron-rich relative to sugar, but the correct advanced answer is that iron quantity/bioavailability is inadequate to manage IDA.'), ('11. Peanuts / groundnuts','560 kcal; protein 25 g; fibre 3.1 g; fat about 40 g.','Nut/oilseed. Tan seed with reddish skin or shelled kernel.','Energy- and protein-dense. Smooth peanut paste or fine powder can enrich complementary foods and help increase energy density.','Whole peanuts are a choking hazard. Allergic reactions are possible. Store dry to reduce fungal/aflatoxin risk; avoid mouldy nuts.','Groundnut is among the most calorie-dense and protein-rich spotters. It supplies fat, so it can help energy deficit but requires safe texture.'), ('12. Fresh coconut','444 kcal; protein 4.5 g; fibre about 1 g; fat about 41 g.','Nut/oilseed. White kernel within hard shell.','Energy-rich food; grated coconut may enrich family foods in selected settings.','High saturated fat. Coconut water is not nutritionally equivalent to kernel and should not be used as a substitute for ORS in diarrhoea.','Fresh coconut is a fat-rich energy food, not a significant protein source. Elizabeth notes coconut oil contains medium-chain triglycerides but is deficient in essential fatty acids.')] for i,x in enumerate(D): story+=food(*x) if i in [5,11]:story.append(PageBreak()) story += [PageBreak(),Paragraph('3. Egg and fruit spotters',H1)] FDS=[ ('13. Hen egg, whole','~173 kcal; protein ~13 g; fibre 0 g; fat ~13 g.','Animal-source food. Shell with albumen and yolk.','Excellent-quality protein with high biological value; provides B12, choline, vitamin A and iron. A highly useful complementary food when fully cooked.','Cook thoroughly. Egg allergy can occur but early introduction of well-cooked egg is generally encouraged in appropriate complementary feeding. Avoid raw/undercooked egg in young children.','Egg protein has high biological value. It is an efficient way to improve protein quality of a predominantly cereal-pulse diet.'), ('14. Banana','116 kcal; protein 1.2 g; fibre 0.4 g; carbohydrate 27 g.','Fruit. Soft starchy/sweet fruit, high edible portion.','Cheap, soft and energy-rich relative to many fruits; useful mashed after 6 months and in feeding during recovery. Provides potassium.','Does not cause cough or cold. Avoid force-feeding; use age-appropriate texture. Excess banana alone does not constitute a balanced diet.','Banana is a fruit but is more energy-dense than watery fruits. It is useful for calories, not a major protein or iron source.'), ('15. Apple','59 kcal; protein 0.2 g; fibre 1.0 g; carbohydrate 13 g.','Fruit. Firm pome fruit.','Provides modest fibre and variety. Grate, stew, puree or give soft small pieces depending on age.','Raw hard apple chunks are a choking hazard in young children. Wash; peel if texture is unsuitable.','Do not call apple an iron-rich fruit. Its main value is fibre, water and dietary variety.'), ('16. Mango, ripe','75 kcal; protein 0.6 g; fibre 0.7 g; carbohydrate 17 g.','Fruit. Ripe yellow-orange fleshed drupe.','Seasonal energy-rich fruit; carotenoids provide provitamin A. Use as mashed pulp or safe slices.','Avoid added sugar in mango drinks; whole fruit is preferable to juice.','Mango is a key provitamin-A fruit. ICMR-NIN lists ripe mango among foods with substantial carotene.'), ('17. Guava','50 kcal; protein 0.9 g; fibre 5.2 g; carbohydrate 11 g.','Fruit. Green/yellow fruit with pink/white seeded pulp.','High vitamin C and fibre. Vitamin C enhances absorption of non-haem iron from pulses/cereals.','Seeds and hard pieces may be unsuitable for small children. Use ripe soft guava, pulp or safe preparation.','Guava is the best vitamin C/fibre answer in this set. Pair it with plant-iron foods to improve absorption.'), ('18. Papaya, ripe','32 kcal; protein 0.6 g; fibre 0.8 g; carbohydrate 7.2 g.','Fruit. Orange soft flesh with black seeds.','Soft, low-energy fruit with carotenoids and vitamin C; useful as an age-appropriate fruit component.','Remove seeds. It is not an energy-dense food, so do not use papaya alone to rehabilitate a severely undernourished child.','Papaya is a protective food, not a calorie concentrate. It is convenient for young children because it is soft.'), ('19. Custard apple / sitaphal','~104 kcal; protein ~1.6 g; fibre ~2.4 g.','Fruit. Segmented green outer skin with sweet white pulp and multiple black seeds.','Relatively energy-rich fruit, useful for dietary variety and energy.','Remove every seed before giving to a child. Seeds are not edible and can pose choking/aspiration risk.','Compared with papaya or apple, custard apple is more energy dense, but it is still not a significant protein source.'), ('20. Pear','~42-57 kcal; protein ~0.5 g; fibre ~3 g.','Fruit. Bell-shaped pome fruit.','Hydrating fruit with fibre; offer mashed/soft pieces appropriately.','Hard raw pieces can choke toddlers. Wash/prepare safely.','If examiner says “pear-shaped fruit,” inspect carefully: ordinary pear and avocado pear have very different nutrient profiles.'), ('21. Avocado pear, if the spotter is avocado','~215 kcal; protein ~1.6 g; fibre ~6-7 g; fat about 20-23 g.','Fruit. Pear-shaped, green/dark skin, buttery flesh and one large central seed.','Unlike most fruits, avocado is fat-rich and energy dense. Useful for increasing energy and healthy-fat contribution in complementary feeds.','Mash well; remove seed/skin. Calorie density is useful but portion still must fit overall balanced diet.','Avocado is a fruit with high fat, not a nut. Distinguish it from ordinary pear immediately.')] for i,x in enumerate(FDS): story+=food(*x) if i==4:story.append(PageBreak()) story += [PageBreak(),Paragraph('4. Integrative viva: applications in child nutrition',H1),tab([('Energy-dense foods in this set','Peanut, coconut, sugar, jaggery, dry cereals/pulses, custard apple, banana and avocado. For a child with poor weight gain, choose nutrient-dense enrichers such as oil/ghee, smooth peanut paste, milk/egg and cereal-pulse combinations rather than sugar alone.'),('Best protein sources','Peanut 25 g/100 g; moong and urad 24 g; toor 22 g; dry peas ~20 g; chana 17 g; egg ~13 g but highest protein quality. Protein adequacy depends on total energy too: low energy intake causes protein to be used for energy.'),('Fibre-rich choices','Guava, moong, chana, ragi, peanut, pear and avocado. Excess fibre can reduce energy density and may impair mineral absorption if diet is otherwise marginal, so do not indiscriminately add bran/fibre to a faltering infant diet.'),('Iron strategy','Use pulses/ragi/green leafy vegetables/animal food with vitamin C-rich guava/amla/citrus/papaya. Avoid tea with meals. For iron-deficiency anaemia, provide therapeutic iron and investigate cause, not merely jaggery.'),('Calcium strategy','Ragi contributes calcium; milk and dairy are more bioavailable calcium sources. Vitamin D status and sunlight exposure according to safe local practices matter for calcium utilisation.'),('During diarrhoea','Continue breastfeeding and feeding. Use ORS for rehydration. Offer small frequent energy-rich foods. Banana/rice can be part of diet, but rice water, coconut water or plain sweet drinks must not replace ORS.'),('During severe acute malnutrition','Do not improvise high-protein/high-salt feeds in medically complicated SAM. Follow WHO/national protocol: stabilisation, cautious feeding, correction of electrolytes/infection and therapeutic feeds. After stabilisation, improve energy/protein density and dietary diversity.'),('Dietary diversity','A practical daily plate requires cereals/millets, pulses or egg/flesh food, milk/dairy where appropriate, vegetables, fruit, nuts/seeds in safe form and limited fats/oils/sugar. ICMR-NIN 2024 emphasises variety and food-group balance.'),('Complementary feeding line','At 6 months start thick semisolid home foods 2-3 times/day, increasing frequency/texture with age, continue breastfeeding to 2 years and beyond, use responsive feeding and include animal-source food or cereal-pulse mixture, vegetables and fruit.')]),Paragraph('5. Rapid examiner traps',H1),tab([('“Is jaggery a treatment for anaemia?”','No. It contains some iron but cannot replace therapeutic iron or a complete diagnostic work-up.'),('“Does banana cause cold?”','No evidence supports that. It is a soft energy-rich fruit suitable in age-appropriate diet.'),('“Why not watery gruel?”','It has low energy density. The child cannot eat sufficient volume to meet needs; prepare thick feeds and enrich them.'),('“Can I give whole peanuts to a toddler?”','No. Use smooth paste or powder mixed into food because whole nuts cause choking.'),('“Rice and dal are both vegetarian: why combine?”','They complement limiting amino acids, improving protein quality.'),('“Which is best for vitamin C here?”','Guava. Use it to improve non-haem iron absorption.'),('“Which is best for calcium?”','Ragi among these spotters; however, bioavailability and overall diet matter.'),('“Why fruit rather than juice?”','Whole fruit retains fibre, promotes satiety and avoids excess free sugar/rapid intake.')]),Paragraph('References',H1),p('1. Elizabeth KE. <i>Nutrition and Child Development</i>. Section 3: Applied Nutrition, Table 3.11, Nutritive value of common foods/100 g, pp. 125-126 in the user-provided PDF. 2. ICMR-NIN. <i>Indian Food Composition Tables</i>, 2017. 3. ICMR-NIN. <i>Dietary Guidelines for Indians</i>, 2024. Values vary by variety, edible fraction, moisture and preparation.',F),p('Recent evidence search note: the available 2024-2026 systematic-review results on dietary diversity were not direct nutrient-composition sources and do not alter the food-composition or core feeding principles above.',F)] doc=SimpleDocTemplate(out,pagesize=A4,leftMargin=14*mm,rightMargin=14*mm,topMargin=12*mm,bottomMargin=15*mm);doc.build(story,onFirstPage=footer,onLaterPages=footer) r=PdfReader(out);print(out,len(r.pages),os.path.getsize(out)) PY

python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate,Paragraph,Table,TableStyle,Spacer,PageBreak from reportlab.lib.units import mm from pypdf import PdfReader import os out='/tmp/workspace/nutrition-spotter/output/Detailed_MD_Paediatrics_Nutrition_Spotters_Viva.pdf' S=getSampleStyleSheet(); T=ParagraphStyle('t',parent=S['Title'],fontName='Helvetica-Bold',fontSize=18,leading=22,alignment=TA_CENTER,textColor=HexColor('#153E5A')); ST=ParagraphStyle('st',parent=S['Normal'],fontSize=8.5,leading=10.5,alignment=TA_CENTER,textColor=HexColor('#52646D'),spaceAfter=8); H1=ParagraphStyle('h1',parent=S['Heading1'],fontName='Helvetica-Bold',fontSize=13,leading=16,textColor=HexColor('#123E5B'),spaceBefore=8,spaceAfter=5); H2=ParagraphStyle('h2',parent=S['Heading2'],fontName='Helvetica-Bold',fontSize=10.4,leading=13,textColor=HexColor('#086A76'),spaceBefore=7,spaceAfter=3); B=ParagraphStyle('b',parent=S['Normal'],fontName='Helvetica',fontSize=7.85,leading=10.1,textColor=HexColor('#1D2B34')); C=ParagraphStyle('c',parent=B,fontSize=7.1,leading=8.65); L=ParagraphStyle('l',parent=C,fontName='Helvetica-Bold'); TH=ParagraphStyle('th',parent=C,fontName='Helvetica-Bold',textColor=colors.white,alignment=TA_CENTER); F=ParagraphStyle('f',parent=B,fontSize=6.35,leading=7.6,textColor=HexColor('#4D6069')) def p(x,s=B):return Paragraph(x,s) def tab(rows): d=[[p('Viva heading',TH),p('Gold-medal answer',TH)]]+[[p(a,L),p(b,C)] for a,b in rows];t=Table(d,colWidths=[44*mm,137*mm],repeatRows=1);t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),HexColor('#176A87')),('BACKGROUND',(0,1),(0,-1),HexColor('#EAF5F8')),('GRID',(0,0),(-1,-1),.25,HexColor('#B8CED6')),('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),2.4*mm),('RIGHTPADDING',(0,0),(-1,-1),2.4*mm),('TOPPADDING',(0,0),(-1,-1),1.6*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.6*mm)]));return t def fd(n,v,g,u,c,pe):return [Paragraph(n,H2),tab([('Nutrients /100 g',v),('Group & identification',g),('Paediatric use',u),('Counselling / caution',c),('Gold-medal pearl',pe)]),Spacer(1,4)] def foot(c,d):c.saveState();c.setFont('Helvetica',7);c.setFillColor(HexColor('#60727B'));c.drawString(13*mm,9*mm,'MD Paediatrics Nutrition Spotters | Approximate values per 100 g edible portion');c.drawRightString(197*mm,9*mm,'Page %d'%d.page);c.restoreState() story=[Paragraph('DETAILED NUTRITION SPOTTERS: MD PAEDIATRICS GOLD-MEDAL VIVA',T),Paragraph('Foods from your original spotter list. Use this answer structure: identify → food group → kcal/protein/fibre per 100 g → micronutrient → child-feeding use → safety point. Raw/dry values apply to cereals, pulses, ragi, peanuts, sugar and jaggery.',ST),p('<b>Sources:</b> Elizabeth KE, <i>Nutrition and Child Development</i>, Table 3.11, pp. 125-126, plus ICMR-NIN Indian Food Composition Tables 2017. Values vary by variety, edible portion, dehusking and cooking.'),Paragraph('Core viva principles',H1),tab([('Cereal-pulse synergy','Cereals are relatively lysine-limited; pulses are relatively methionine-limited. Rice-dal, khichdi, roti-dal and idli/dosa improve amino-acid quality.'),('Complementary feeding','At completed 6 months, continue breastfeeding and give thick, mashed, responsive home foods. Avoid watery gruels. Enrich with oil/ghee, milk, egg or smooth groundnut paste as suitable.'),('Iron absorption','Pulses/ragi provide non-haem iron. Guava, amla/citrus and papaya provide vitamin C and improve absorption. Jaggery cannot treat iron-deficiency anaemia.'),('Safety','Use safe texture: no whole peanuts, remove custard-apple seeds, and grate/stew/cut firm fruit for young children. Raw sprouts require hygiene and are preferably cooked for young children.')]),Paragraph('Cereals, millets, pulses and energy foods',H1)] D=[ ('Raw rice','350 kcal; protein 7 g; fibre 0.2 g; CHO 78 g; iron 0.7 mg.','Cereal. Hard white/translucent oval grain, usually polished.','Major energy source; khichdi/porridge can be useful if thick and enriched with dal, fat and vegetables.','Rice alone is low in fibre/micronutrients and lysine-limited. Polished rice is less nutrient dense than less-refined rice.','“Rice is an energy food, not a complete food. Pair it with dal.”'), ('Toor dal / red gram','340 kcal; protein 22 g; fibre 1.5 g; CHO 58 g; iron 2.7 mg.','Pulse. Yellow split pigeon pea/arhar.','Affordable protein, iron and B vitamins; useful cooked and mashed in khichdi/dal.','Plant iron is non-haem. Pair with vitamin C; soak/cook adequately.','Pulse is methionine-limited, hence cereal-pulse complementation.'), ('Chana dal / Bengal gram','360 kcal; protein 17 g; fibre 3.9 g; CHO 60 g; iron 4.6 mg.','Pulse. Yellow thick split chickpea.','Protein/fibre source; roasted chana flour can enrich feeds.','Cook/mash well to prevent choking; fibre is not a replacement for energy density.','Iron-containing food, but not therapeutic treatment for IDA.'), ('Moong dal / green gram','340 kcal; protein 24 g; fibre 4.1 g; CHO 57 g; iron 4.4 mg.','Pulse. Split moong is yellow; whole green gram retains green husk.','Common in khichdi/convalescent feeds. Whole seed can be sprouted then cooked.','Do not give dilute “dal water” for malnutrition; use whole cooked pulse.','Sprouting improves vitamin C and may reduce phytate, but does not make food calorie dense.'), ('Dry peas','~315 kcal; protein ~20 g; fibre ~4-5 g.','Legume. Hard, mature, wrinkled round peas.','Protein/complex carbohydrate source after soaking and thorough cooking.','Clarify dry versus fresh pea before quoting values. Fresh peas have lower kcal per 100 g due to water.','“Dry peas are pulses; fresh green peas are vegetables.”'), ('Urad dal / black gram','350 kcal; protein 24 g; fibre 0.9 g; CHO 60 g; iron 3.8 mg.','Pulse. Black whole seed; white idli urad is dehusked/split.','Protein-rich; rice-urad idli/dosa is a classic complementary protein mixture.','Use hygienic fermentation and adequate cooking.','Fermentation improves palatability and nutrient availability, but food must remain safely prepared.'), ('Ragi / finger millet','330 kcal; protein 7 g; fibre 3.6 g; CHO 72 g; iron 3.9 mg; calcium ~344 mg.','Millet. Tiny red-brown finger millet grains/nachni.','Calcium-rich cereal; use as a thick enriched porridge.','Phytate can reduce mineral availability. Do not make watery ragi gruel.','Ragi is the calcium spotter, but needs pulse/milk/egg for better protein quality.'), ('Sugar','~400 kcal; protein 0; fibre 0.','Refined sucrose crystals, an energy concentrate.','Only provides energy/palatability.','Avoid routine added sugar in young children: caries and displacement of nutrient-dense food.','“Empty calories” is the best viva phrase.'), ('Jaggery / bellam','~380 kcal; protein ~0.4 g; fibre 0; contains some iron.','Unrefined brown sugar block/powder.','Energy enhancer in limited amount.','Not a treatment for IDA; high free sugar causes caries and excess calories.','Elizabeth calls it iron-rich relative to sugar, but its iron is insufficient/inadequately bioavailable for anaemia therapy.'), ('Peanut / groundnut','560 kcal; protein 25 g; fibre 3.1 g; fat ~40 g.','Nut/oilseed; tan kernel, often red skin.','High energy and protein. Smooth paste/powder is useful for energy enrichment.','No whole nuts in young child due to choking; beware allergy and mould/aflatoxin.','Peanut is a key energy-density food, not merely a “protein snack.”'), ('Fresh coconut','444 kcal; protein 4.5 g; fibre ~1 g; fat ~41 g.','Nut/oilseed; white kernel in shell.','Energy enrichment in small amounts.','High saturated fat. Coconut water is not ORS and cannot replace ORS in diarrhoea.','Coconut is fat-rich, not protein-rich; its oil is deficient in essential fatty acids.')] for i,x in enumerate(D): story+=fd(*x) if i==5:story.append(PageBreak()) story += [PageBreak(),Paragraph('Egg and fruit spotters',H1)] FDS=[ ('Hen egg, whole','~173 kcal; protein ~13 g; fibre 0; fat ~13 g.','Animal-source food, shell with white and yolk.','High biological-value protein, B12, choline, vitamin A and iron; useful fully cooked from complementary-feeding period.','Cook thoroughly; evaluate allergy if reaction occurs.','Egg improves quality of a cereal-pulse diet because its protein has high biological value.'), ('Banana','116 kcal; protein 1.2 g; fibre 0.4 g; CHO 27 g.','Soft starchy/sweet fruit.','Cheap, soft, energy-rich fruit, useful mashed after 6 months; potassium source.','Does not cause cough/cold. It is not a complete diet.','More energy dense than watery fruits but not a protein/iron source.'), ('Apple','59 kcal; protein 0.2 g; fibre 1.0 g; CHO 13 g.','Firm pome fruit.','Fibre and variety; give grated, stewed or safe soft pieces.','Hard raw chunks can choke young children.','Apple is not iron rich; its value is mainly fibre, water and diversity.'), ('Mango, ripe','75 kcal; protein 0.6 g; fibre 0.7 g; CHO 17 g.','Yellow-orange fleshed seasonal fruit.','Carotenoid/provitamin A-rich fruit.','Prefer whole fruit/pulp rather than sweetened juice.','Mango is a key vitamin-A precursor fruit in this set.'), ('Guava','50 kcal; protein 0.9 g; fibre 5.2 g; CHO 11 g.','Green/yellow fruit with white/pink seeded pulp.','High fibre and vitamin C; improves non-haem iron absorption from pulses/ragi.','Use ripe/pulp/safe texture if seeds hard.','Guava is the vitamin C plus fibre answer.'), ('Papaya, ripe','32 kcal; protein 0.6 g; fibre 0.8 g; CHO 7.2 g.','Soft orange flesh, black seeds.','Protective fruit with carotenoids/vitamin C; easy to mash.','Remove seeds. Low calorie density, so do not use alone for weight rehabilitation.','Papaya is soft and protective, not an energy concentrate.'), ('Custard apple / sitaphal','~104 kcal; protein ~1.6 g; fibre ~2.4 g.','Segmented green fruit with white pulp and black seeds.','Relatively energy-rich fruit.','Remove every seed before feeding to child.','Compared with papaya/apple, it is more calorie dense but still modest protein source.'), ('Pear','~42-57 kcal; protein ~0.5 g; fibre ~3 g.','Bell-shaped pome fruit.','Hydrating fibre-containing fruit; mashed or soft pieces.','Hard pieces can choke toddlers.','Check whether spotter is ordinary pear or avocado pear.'), ('Avocado pear, if shown','~215 kcal; protein ~1.6 g; fibre ~6-7 g; fat ~20-23 g.','Pear-shaped, buttery green flesh and one large seed.','Fat-rich, energy-dense fruit useful for energy/healthy fat contribution.','Remove seed/skin, mash.','Unlike ordinary pear, avocado is fat-rich fruit, not a nut.')] for i,x in enumerate(FDS): story+=fd(*x) if i==4:story.append(PageBreak()) story += [PageBreak(),Paragraph('Integrative MD viva questions',H1),tab([('Best energy-dense foods here','Peanut, coconut, sugar, jaggery, dry cereals/pulses, banana, custard apple and avocado. For poor weight gain prefer nutrient-dense enrichers such as smooth peanut paste, egg, milk and oil/ghee, rather than sugar alone.'),('Best protein sources','Peanut 25 g/100 g; moong and urad 24 g; toor 22 g; dry peas ~20 g; chana 17 g; egg ~13 g but best biological quality. Adequate energy is required to spare protein for growth.'),('Fibre-rich items','Guava, moong, chana, ragi, peanuts, pear and avocado. Excess fibre/bran can reduce energy density and mineral availability in an infant with faltering growth.'),('Iron deficiency prevention','Use pulses/ragi/GLV/animal food with guava/amla/citrus/papaya; avoid tea with meals. Treat proven IDA with medicinal iron and evaluate cause.'),('Diarrhoea','Continue breastfeeding/feeding and give ORS. Small frequent energy-rich foods are appropriate. Coconut water, rice water and sweet drinks do not replace ORS.'),('SAM','For complicated severe acute malnutrition, follow WHO/national stabilisation and therapeutic-feeding protocol; do not prescribe improvised high-protein/high-salt home feeds.'),('ICMR-NIN diet concept','2024 guidance emphasises food variety. Cereals/millets should not dominate the plate; include pulses/egg/flesh food, vegetables, fruit, dairy where appropriate, nuts/seeds and moderate oils.')]),Paragraph('Examiner traps: model answers',H1),tab([('“Is jaggery treatment for anaemia?”','No. Some iron is present, but it does not replace therapeutic iron or evaluation for cause.'),('“Why not watery gruel?”','Insufficient energy per spoon. The child cannot consume the volume needed. Use thick enriched feeds.'),('“Can whole peanuts be given?”','No, choking risk. Use smooth paste or fine powder mixed into food.'),('“Why rice plus dal?”','Mutual amino-acid complementation: rice lysine limitation and pulse methionine limitation.'),('“Best vitamin C fruit?”','Guava, and it helps absorb non-haem iron.'),('“Best calcium food here?”','Ragi among these spotters, but total diet and vitamin D status determine calcium nutrition.'),('“Fruit or fruit juice?”','Whole fruit has fibre and less free sugar exposure; juice can displace nutrient-dense food.')]),Paragraph('References',H1),p('Elizabeth KE. <i>Nutrition and Child Development</i>, Section 3: Applied Nutrition, Table 3.11, pp. 125-126. ICMR-NIN, <i>Indian Food Composition Tables</i>, 2017. ICMR-NIN, <i>Dietary Guidelines for Indians</i>, 2024. A recent 2024 systematic review on child dietary-intake interventions (PMID: 38340129) supports the broad focus on healthy dietary patterns but is not a food-composition source.',F)] doc=SimpleDocTemplate(out,pagesize=A4,leftMargin=14*mm,rightMargin=14*mm,topMargin=12*mm,bottomMargin=15*mm);doc.build(story,onFirstPage=foot,onLaterPages=foot) r=PdfReader(out);print(out,len(r.pages),os.path.getsize(out)) PY

Which section should I correct and build at gold-medal depth first?

~/

AAP 2022 clinical practice guideline hyperbilirubinemia kernicterus bilirubin encephalopathy neurodevelopment follow up

kernicterus AND auditory neuropathy

https://www.aap.org/en/patient-care/hyperbilirubinemia

mkdir -p "/tmp/workspace/bilirubin-long-case/output" && python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak, KeepTogether from reportlab.lib.units import mm from pypdf import PdfReader import os out='/tmp/workspace/bilirubin-long-case/output/Corrected_MD_Paediatrics_Long_Case_Bilirubin_Encephalopathy.pdf' S=getSampleStyleSheet() TITLE=ParagraphStyle('Title',parent=S['Title'],fontName='Helvetica-Bold',fontSize=18.5,leading=22,alignment=TA_CENTER,textColor=HexColor('#123E5A'),spaceAfter=5) SUB=ParagraphStyle('Sub',parent=S['Normal'],fontSize=8.7,leading=11,alignment=TA_CENTER,textColor=HexColor('#4E626E'),spaceAfter=10) H1=ParagraphStyle('H1',parent=S['Heading1'],fontName='Helvetica-Bold',fontSize=14,leading=17,textColor=HexColor('#123E5A'),spaceBefore=10,spaceAfter=6) H2=ParagraphStyle('H2',parent=S['Heading2'],fontName='Helvetica-Bold',fontSize=11,leading=13.5,textColor=HexColor('#086B78'),spaceBefore=8,spaceAfter=4) BODY=ParagraphStyle('Body',parent=S['Normal'],fontName='Helvetica',fontSize=8.25,leading=10.8,textColor=HexColor('#172A34'),spaceAfter=3) SM=ParagraphStyle('Small',parent=BODY,fontSize=7.05,leading=8.65) TBL=ParagraphStyle('Tbl',parent=BODY,fontSize=7.35,leading=8.9) LBL=ParagraphStyle('Lbl',parent=TBL,fontName='Helvetica-Bold') TH=ParagraphStyle('TH',parent=TBL,fontName='Helvetica-Bold',textColor=colors.white,alignment=TA_CENTER) NOTE=ParagraphStyle('Note',parent=BODY,fontSize=7.15,leading=8.8,textColor=HexColor('#435963')) def P(x,s=BODY): return Paragraph(x,s) def bullet(x): return Paragraph('• '+x,BODY) def tbl(rows,widths=(46*mm,135*mm), header=('Heading','Corrected / model answer')): d=[[P(header[0],TH),P(header[1],TH)]]+[[P(a,LBL),P(b,TBL)] for a,b in rows] t=Table(d,colWidths=list(widths),repeatRows=1,hAlign='LEFT') t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),HexColor('#176A87')),('BACKGROUND',(0,1),(0,-1),HexColor('#EAF5F8')),('GRID',(0,0),(-1,-1),.25,HexColor('#B8CED6')),('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),2.3*mm),('RIGHTPADDING',(0,0),(-1,-1),2.3*mm),('TOPPADDING',(0,0),(-1,-1),1.75*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.75*mm)])) return t def footer(c,d): c.saveState(); c.setFont('Helvetica',7); c.setFillColor(HexColor('#62747D')); c.drawString(13*mm,9*mm,'Corrected MD Paediatrics Long Case | Chronic bilirubin encephalopathy'); c.drawRightString(197*mm,9*mm,'Page %d' % d.page); c.restoreState() story=[Paragraph('CORRECTED MD PAEDIATRICS LONG CASE',TITLE),Paragraph('Severe neonatal unconjugated hyperbilirubinaemia with neurodevelopmental impairment: university-standard case sheet, blank proforma, diagnosis and senior-level viva',SUB),P('<b>Purpose:</b> This document corrects the clinical structure and reasoning in the uploaded case sheet. It is a template for final practical examination, not a substitute for the child’s original neonatal records or a current clinical assessment. Do not assert kernicterus, hearing loss, cerebral palsy or aetiology without objective documentation.'),P('<b>Working clinical formulation from the sheet:</b> an 18-month-old girl with a history of severe neonatal jaundice requiring phototherapy and exchange transfusion, followed by developmental delay, possible dystonia/dyskinesia and poor response to sound. This is suggestive of <b>chronic bilirubin encephalopathy (CBE), also termed kernicterus spectrum disorder</b>, but needs confirmation.'),Paragraph('A. The examiner-standard approach',H1),tbl([('How to present','Identify the syndrome first, localise the nervous system second, and then state the aetiology with appropriate certainty. Avoid reading a chronological list without clinical synthesis.'),('Correct sequence','Biodata → complaints → HOPI → antenatal/birth/neonatal period → development → current function → diet/immunisation/family/social → general examination → CNS and systemic examination → summary → localisation → diagnosis → differential diagnoses → investigations → management.'),('Key correction','“Not responding to sound” is a symptom. “Delayed neck holding” is a milestone delay. The diagnosis must integrate neonatal history, motor phenotype, audiology and neuroimaging.'),('Safe wording','Use “probable” or “suspected” where neonatal records, ABR/OAE, MRI, or standardised developmental assessment are unavailable.'),('Senior finishing line','“I will review the original bilirubin trajectory and neonatal risk factors, objectively phenotype the movement disorder, confirm hearing with audiology, and exclude alternate static or progressive causes.”')]),Paragraph('B. Corrected long-case sheet',H1),Paragraph('1. Biodata and chief complaints',H2),tbl([('Biodata','18-month-old girl, second born to a non-consanguineous couple, resident of ____. Informant: mother; reliability: adequate. Primary caregiver: ____. Date of examination: ____.'),('Chief complaints','1. Delayed attainment of developmental milestones since infancy. <br/>2. Poor/inconsistent response to sound since ___ months. <br/>3. Abnormal posturing or involuntary movements since ___ months. <br/>4. Paroxysmal events suggestive of seizures since ___, if present.'),('Avoid','Do not put developmental diagnosis, hearing diagnosis or “bilirubin encephalopathy” in chief complaints. Do not write vague terms such as “not responding to sounds” without duration.')]),Paragraph('2. Corrected HOPI',H2),P('The child was apparently well at birth until day ___ of life, when the mother first noticed yellowish discoloration of sclera and skin. Establish whether jaundice appeared within the first 24 hours, its cephalocaudal progression, rate of increase, duration and relationship to feeding/weight loss. Ask explicitly about poor suck, lethargy, high-pitched cry, hypotonia or hypertonia, retrocollis, opisthotonus, fever, seizures, apnoea and altered sensorium.'),P('She received phototherapy for ___ hours/days at ____. Because bilirubin reached/exceeded treatment threshold or continued to rise despite intensive phototherapy, a double-volume exchange transfusion was performed on day ___ of life. Exact records are awaited. Following discharge, the family observed delayed motor milestones, poor auditory responsiveness and abnormal movements/posturing. There is no history of loss of previously acquired milestones, which supports a static encephalopathy, but this must be confirmed.'),tbl([('Do not write','“Neonatal history normal” in a child with NICU admission, phototherapy, exchange transfusion and possible neonatal seizures.'),('Record retrieval priority','Age in hours at onset and treatment; gestation; serial total serum bilirubin (TSB) and direct bilirubin; rate of rise; maternal/baby blood group; DAT/Coombs; Hb/reticulocytes/smear; G6PD; albumin; sepsis work-up; weight loss/feeding; phototherapy irradiance; exchange details; NICU events; discharge examination.'),('Positive history to seek','Poor feeding, lethargy, shrill cry, fever, abnormal tone, neck extension/back arching, seizures, hypoxia, acidosis, sepsis, cephalhaematoma/bruising, dark urine/pale stools, family history of haemolysis or prior sibling needing treatment.'),('Relevant negatives','No developmental regression; no episodic deterioration; no progressive loss of vision/hearing; no family history of similar movement disorder; no perinatal asphyxia, if reliably excluded.')]),PageBreak(),Paragraph('3. Antenatal, birth and neonatal history: corrected record',H1),tbl([('Antenatal','Mother’s age, gravida/para, booking and antenatal care; consanguinity; maternal blood group/Rh, antibody screen; diabetes, hypertension, thyroid disease; fever/rash; drug/substance exposure; fetal movements; ultrasound findings. The important missing detail is risk of ABO/Rh alloimmunisation and previous affected sibling.'),('Birth','Gestation in completed weeks, birth weight, place of delivery, mode and indication for LSCS, cry/APGAR/resuscitation, meconium, birth trauma/cephalhaematoma, first breastfeed, urine/meconium passage. State “term” only if gestation is documented.'),('Neonatal jaundice','Classify as unconjugated or conjugated. Severe unconjugated hyperbilirubinaemia is implied by phototherapy/exchange transfusion but must be documented with TSB and direct bilirubin.'),('Risk factors for bilirubin neurotoxicity','Prematurity, haemolysis, low albumin, sepsis, acidosis, hypoxia, clinical instability and rapid bilirubin rise increase risk. TSB is a practical marker, but unbound bilirubin and albumin binding are biologically closer to neurotoxicity.'),('Current treatment history','Record physiotherapy/OT/SLT, hearing aid or cochlear-implant assessment, antiepileptic/dystonia medications, feeding therapy, hospital admissions and actual reports of MRI/EEG/BERA. Never write “brain scan normal” without report/date.')]),Paragraph('4. Developmental history: how to correct it',H1),tbl([('Principle','Do not calculate DQ from one milestone. Determine developmental age separately in gross motor, fine motor-adaptive, language-hearing and personal-social domains, preferably using DASII or a validated tool.'),('Gross motor at 18 months','Ask current ability: independent sitting, crawl, pull-to-stand, cruising, stand, walk, run, squat-rise, climb, hand preference, falls, toe walking, scissoring, dystonia and involuntary movements.'),('Fine motor-adaptive','Pincer grasp, release, bilateral reach, transfer, scribble, tower of 2-3 cubes, turning pages, spoon use. “Hand regard at 3 months” is not a present developmental assessment.'),('Language-hearing','Response to name/sound, localisation, understanding commands, pointing, gestures, meaningful words, babble, joint attention and speech. Language delay may be secondary to auditory neuropathy, motor speech impairment, global delay or social communication disorder.'),('Personal-social','Feeding self, imitation, pointing to share interest, play, affection and caregiver interaction. Social smile/stranger anxiety are historical milestones only.'),('DQ formula','DQ = developmental age ÷ chronological age × 100. Quote domain-wise DQ and overall DQ only after standardised assessment. Use corrected age only for preterm infants where applicable.')]),Paragraph('5. Diet, immunisation, family and social history',H1),tbl([('Diet','Write a 24-hour recall with quantity, frequency, consistency, feeding duration, choking/coughing, vomiting, constipation and dietary diversity. Assess calories/protein only after portion estimation. For a child with motor disorder, assess feeding safety and aspiration risk.'),('Immunisation','State immunisation according to the Government of India UIP card: “age-appropriate/partially immunised/unimmunised,” then list missing vaccines. Do not write only “9-month vaccination done at 14 months” without card verification.'),('Family history','Three-generation pedigree, consanguinity, sibling deaths, neonatal jaundice/exchange transfusion, seizures, hearing impairment, developmental disability, dystonia, metabolic/genetic disease.'),('Socioeconomic','Use an accepted scale relevant to your institution, document caregiver education, occupation, household income, crowding, access to rehabilitation, travel burden and disability/social-support needs.')]),PageBreak(),Paragraph('C. Corrected examination sheet',H1),Paragraph('1. General physical examination',H2),tbl([('Opening statement','“Child is conscious and arousable, appropriately/poorly interactive for age, with eye contact ___, on mother’s lap. There is/are no dysmorphism, neurocutaneous markers, pallor, icterus, cyanosis, clubbing, oedema or lymphadenopathy.”'),('Vitals','Document HR, RR, temperature, SpO₂, BP with age-appropriate cuff, perfusion and respiratory effort. Do not leave vital signs blank.'),('Anthropometry','Measure and plot weight, length/height, weight-for-length/BMI, head circumference and MUAC when relevant. Recheck any concerning head circumference. At 18 months, HC 42.5 cm is very low if accurate and must be plotted on WHO chart before labelling microcephaly.'),('Head-to-toe','Head shape/fontanelle; dysmorphism; eyes/red reflex; oral cavity/dentition/enamel; neck; chest; abdomen with liver/spleen; spine; skin; joints/contractures; external genitalia as indicated.'),('Kernicterus-specific clues','Look for dental enamel hypoplasia, involuntary movements/dystonia, upward gaze limitation, hearing impairment, feeding difficulty and drooling due to oral-motor dysfunction.')]),Paragraph('2. Higher function and cranial nerves',H2),tbl([('Higher function','At 18 months, assess arousal, interaction, attention, social reciprocity, eye contact, play, response to name, command comprehension and communication method. Do not document adult orientation/memory testing as normal.'),('CN II','Fixation/following, eye contact, visual fields by object approach, pupils, red reflex and fundus if feasible. Formal acuity/colour vision may not be testable but visual behaviour must be documented.'),('CN III/IV/VI','Ocular alignment, ptosis, nystagmus, extraocular movements and <b>vertical gaze</b>. Upward gaze limitation is relevant in chronic bilirubin encephalopathy.'),('CN V/VII','Facial symmetry at rest/crying, eye closure, jaw movement. Do not infer facial palsy from drooling alone.'),('CN VIII','Parent report is screening only. State: “suspected auditory impairment; formal audiology with OAE, ABR/BERA, tympanometry and behavioural testing is planned.” In auditory neuropathy, OAE may be present with absent/abnormal ABR.'),('CN IX-XII','Assess cough/choke, nasal regurgitation, voice, palatal movement where possible, tongue bulk/movement and shoulder/head control. Gag reflex is not a routine screening test.')]),Paragraph('3. Motor system: the decisive section',H2),tbl([('Observe first','Resting posture, truncal control, spontaneous antigravity movement, symmetry, fisting, early hand preference, scissoring, toe posture, dystonia, choreoathetosis, tremor, drooling and gait if ambulant.'),('Tone','Define abnormality. Spasticity is velocity-dependent resistance. Dystonia is sustained/intermittent contractions causing twisting/repetitive movement or abnormal posture, fluctuating with action/emotion/tactile stimuli. Describe distribution and triggers.'),('Power','Formal MRC grading is unreliable in many 18-month-olds. Record functional antigravity movement, reach, grasp, weight bearing, pull-to-sit and asymmetry.'),('Reflexes','DTRs, clonus, plantar and abdominal reflexes as appropriate. A flexor/extensor plantar response must be interpreted with age; do not overcall UMN signs on plantar alone in a young child.'),('Function','Assign GMFCS level for CP; consider MACS, CFCS and EDACS. These function-based scales make the case presentation mature and clinically useful.')]),PageBreak(),Paragraph('D. Diagnostic reasoning and final diagnosis',H1),tbl([('Syndromic diagnosis','Neurodevelopmental disorder with global developmental delay, motor impairment with dystonia/dyskinesia if confirmed, and suspected hearing impairment.'),('Topographic localisation','Predominantly extrapyramidal/basal ganglia involvement with auditory pathway involvement. In classic CBE, globus pallidus/subthalamic and auditory brainstem pathways are vulnerable.'),('Etiologic diagnosis','Probable chronic bilirubin encephalopathy following severe neonatal unconjugated hyperbilirubinaemia, pending confirmation by neonatal bilirubin records and exclusion of alternate causes.'),('Final diagnosis: model wording','<b>Probable chronic bilirubin encephalopathy (kernicterus spectrum disorder), presenting as dyskinetic/dystonic cerebral palsy with global developmental delay and suspected auditory neuropathy spectrum disorder, following severe neonatal unconjugated hyperbilirubinaemia treated with phototherapy and exchange transfusion.</b>'),('If evidence is incomplete','“Neurodevelopmental impairment with dystonic motor phenotype and suspected hearing loss following severe neonatal jaundice, under evaluation for chronic bilirubin encephalopathy.”')]),Paragraph('Differential diagnoses',H1),tbl([('Hypoxic-ischaemic brain injury','Ask delayed cry, prolonged resuscitation, ventilation, early seizures and review MRI. Basal ganglia injury can also produce dyskinetic CP.'),('Genetic/metabolic dystonia','Consider if progressive course, regression, diurnal fluctuation, family history, episodic decompensation or atypical MRI. Evaluate treatable causes where clinically indicated.'),('Congenital infection','Consider with microcephaly, hearing loss, visual findings, seizures, hepatosplenomegaly or abnormal neuroimaging.'),('Other cerebral palsy causes','Prenatal malformation, prematurity/PVL, stroke, infection and HIE. CP is a clinical syndrome; aetiology must not be assumed.'),('Isolated hearing loss','Can explain speech/language delay but not persistent dystonia or major motor delay.')]),Paragraph('Essential investigations',H1),tbl([('First retrieve','Serial TSB/direct bilirubin, maternal/baby blood group, DAT, Hb/reticulocyte count/smear, G6PD, albumin, sepsis workup, phototherapy/exchange details, gestation and NICU course.'),('Hearing','OAE, ABR/BERA, tympanometry, behavioural audiometry and speech-language assessment. Refer to paediatric audiology/ENT early.'),('Vision','Paediatric ophthalmology, refraction, red reflex/fundus and eye movement/vertical gaze assessment.'),('Brain','MRI brain, with review of basal ganglia and globus pallidus. A normal MRI does not exclude clinical CBE.'),('Development and function','DASII or equivalent, GMFCS, MACS, CFCS, EDACS, feeding/swallow assessment and nutritional evaluation.'),('Only if indicated','EEG for possible seizures; genetics/metabolic workup for atypical/progressive phenotype or alternate diagnostic clues.')]),PageBreak(),Paragraph('E. Bilirubin encephalopathy: senior-level viva',H1),tbl([('Definition','Acute bilirubin encephalopathy is acute neurological dysfunction from unconjugated bilirubin toxicity. Chronic bilirubin encephalopathy is permanent neurological sequelae. Kernicterus originally denotes characteristic bilirubin staining of deep nuclei at pathology.'),('Why neonates are vulnerable','High RBC turnover, short RBC lifespan, immature UGT1A1 conjugation, high enterohepatic circulation, feeding failure and blood-brain barrier vulnerability with prematurity/illness.'),('Major causes','Haemolysis: ABO/Rh incompatibility, G6PD deficiency, hereditary spherocytosis, enzyme defects; bruising/cephalhaematoma/polycythaemia; poor intake/dehydration; prematurity; sepsis; hypothyroidism; rare Crigler-Najjar.'),('Acute clinical stages','Early: poor suck, lethargy, hypotonia, high-pitched cry. Intermediate: hypertonia, retrocollis, opisthotonus, fever. Advanced: apnoea, seizures, coma and death.'),('Classic chronic phenotype','Dyskinetic CP with dystonia/choreoathetosis, auditory neuropathy spectrum disorder, vertical gaze abnormality and dental enamel hypoplasia. Cognition may be better preserved than motor/speech performance suggests.'),('Neuropathology','Predilection for globus pallidus, subthalamic nuclei, hippocampus, cranial nerve nuclei/auditory pathways and cerebellar nuclei.'),('Prevention','Universal surveillance, bilirubin measurement before discharge or when jaundice is seen, assessment by gestational age and age in hours, support for adequate feeding, timely phototherapy, escalation and exchange transfusion when indicated, and post-discharge follow-up.'),('Guideline update','AAP 2022 guidance for infants ≥35 weeks uses gestational age, age in hours and neurotoxicity risk factors to determine treatment/follow-up thresholds. It reinforces prevention, objective bilirubin measurement, treatment, follow-up and hospital systems. Apply local/national protocol for the individual infant.'),('Escalation principle','For ≥35-week AAP framework, escalation of care is triggered at a TSB 2 mg/dL below exchange threshold. Exchange transfusion is an emergency treatment when threshold is reached or signs of acute bilirubin encephalopathy exist. Exact threshold is chart-based, not memorised as one number.')]),Paragraph('F. Management and rehabilitation',H1),tbl([('Immediate priorities now','Formal hearing and vision assessment; standardised development/function assessment; screen feeding, aspiration, nutrition, constipation, sleep and pain; retrieve neonatal records; establish a family-centred therapy plan.'),('Motor disorder','Goal-directed PT, OT, positioning/seating, range-of-motion programme, orthoses where needed, hip surveillance. Distinguish dystonia from spasticity before drug therapy. Specialist options include trihexyphenidyl, baclofen, clonazepam, botulinum toxin for focal problems, intrathecal baclofen or DBS in selected severe dystonia.'),('Communication/hearing','Audiology-led hearing rehabilitation, hearing aid trial where appropriate, cochlear implant assessment when eligible, auditory-verbal therapy, augmentative/alternative communication and parent coaching. Benefit in auditory neuropathy is individualised.'),('Feeding/nutrition','Assess chewing, choking, cough, prolonged feeds, growth and aspiration. Give texture-modified, calorie/protein adequate diet. Obtain formal swallow evaluation and consider enteral support if unsafe/inadequate intake.'),('Seizures','Clarify events with video/EEG where indicated. Do not label dystonic movements as seizures without evidence.'),('Family/social','Early intervention, disability certification, education and social-support linkage, caregiver mental-health support, dental care and regular review of vision/hearing/orthopaedics.')]),PageBreak(),Paragraph('G. 60-second summary and blank proforma',H1),Paragraph('Model final summary',H2),P('<b>This is an 18-month-old girl</b>, second born to a non-consanguineous couple, with a documented/reported history of severe neonatal jaundice from day ___ requiring phototherapy and double-volume exchange transfusion. The neonatal bilirubin trajectory, direct fraction, haemolysis workup and G6PD status are awaited. Thereafter she developed persistent delay in motor and language milestones, poor response to sound and abnormal posturing/involuntary movements, without regression. On examination, she has ___ growth status, ___ head circumference, ___ dystonia/dyskinesia, ___ GMFCS level and suspected auditory impairment. The syndrome is neurodevelopmental impairment with extrapyramidal/basal ganglia and auditory pathway involvement. My provisional diagnosis is probable chronic bilirubin encephalopathy, presenting as dyskinetic cerebral palsy with global developmental delay and suspected auditory neuropathy spectrum disorder. I would confirm this by neonatal-record review, formal audiology, MRI brain, standardised developmental assessment and multidisciplinary rehabilitation evaluation.'),Paragraph('Blank long-case summary template',H2),tbl([('Biodata','___-month/year-old ___, ___ born to a ___ couple; informant ___; reliability ___.'),('Chief concerns','1. ___ since ___. 2. ___ since ___. 3. ___ since ___.'),('Key neonatal event','Jaundice began at ___ hours/day. Peak TSB ___; direct bilirubin ___; risk factor ___. Received ___ phototherapy and ___ exchange transfusion. Evidence of ABE: ___.'),('Development','Gross motor DA ___; fine motor DA ___; language DA ___; social DA ___. Regression: yes/no. Standardised tool/score: ___.'),('Examination','Growth Z scores: ___. HC ___ percentile/Z. Motor phenotype: ___. Tone: ___. DTR/plantar: ___. GMFCS/MACS/CFCS/EDACS: ___. Hearing/vision: ___.'),('Syndrome/localisation','___ with predominant ___ involvement.'),('Provisional diagnosis','___.'),('Differentials','1. ___. 2. ___. 3. ___.'),('Plan','Records ___; audiology ___; MRI ___; developmental/feeding assessment ___; rehabilitation ___; family support ___.')]),Paragraph('Professor-level closing viva response',H2),P('“In this child, I will not attribute all neurodevelopmental impairment to neonatal jaundice merely because exchange transfusion was performed. I will establish severe unconjugated hyperbilirubinaemia with its risk factors, look for the characteristic chronic phenotype of dystonia, auditory neuropathy and vertical gaze abnormality, and exclude HIE, genetic/metabolic dystonia and congenital infection. My management is multidisciplinary and function-centred, with urgent communication and feeding assessment rather than a diagnosis-only approach.”'),Paragraph('References',H1),P('1. American Academy of Pediatrics. Clinical Practice Guideline: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation, 2022. The AAP states that the guidance covers prevention, assessment/monitoring, treatment, post-discharge follow-up and hospital systems. 2. AAP Hyperbilirubinemia clinical resource, accessed September 2026. 3. Lai NM, Gerard JP, Ngim CF, et al. The Association between Serum Bilirubin and Kernicterus Spectrum Disorder: a systematic review and meta-analysis. <i>Neonatology</i>. 2021. PMID: 34731859. 4. Standard neonatal, neurology and developmental-paediatrics textbook principles. Use the current local neonatal jaundice chart and hospital policy for treatment thresholds.',NOTE)] doc=SimpleDocTemplate(out,pagesize=A4,leftMargin=14*mm,rightMargin=14*mm,topMargin=12*mm,bottomMargin=15*mm) doc.build(story,onFirstPage=footer,onLaterPages=footer) r=PdfReader(out) print(out,'pages',len(r.pages),'bytes',os.path.getsize(out)) PY

AAP 2022 hyperbilirubinemia guideline kernicterus spectrum disorder auditory neuropathy official

~/

kernicterus spectrum disorder

mkdir -p "/tmp/workspace/long-case-bilirubin/output" python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak, KeepTogether from reportlab.lib.units import mm from pypdf import PdfReader from pathlib import Path out=Path('/tmp/workspace/long-case-bilirubin/output/Corrected_Clear_Long_Case_Chronic_Bilirubin_Encephalopathy_MD_Paediatrics.pdf') styles=getSampleStyleSheet() C=HexColor('#0B4F6C'); TEAL=HexColor('#087E8B'); PALE=HexColor('#EAF5F7'); INK=HexColor('#172A34') T=ParagraphStyle('T',parent=styles['Title'],fontName='Helvetica-Bold',fontSize=19,leading=23,alignment=TA_CENTER,textColor=C,spaceAfter=7) ST=ParagraphStyle('ST',parent=styles['Normal'],fontName='Helvetica',fontSize=9,leading=12,alignment=TA_CENTER,textColor=HexColor('#52646D'),spaceAfter=12) H1=ParagraphStyle('H1',parent=styles['Heading1'],fontName='Helvetica-Bold',fontSize=14,leading=17,textColor=C,spaceBefore=7,spaceAfter=6) H2=ParagraphStyle('H2',parent=styles['Heading2'],fontName='Helvetica-Bold',fontSize=11,leading=13.5,textColor=TEAL,spaceBefore=5,spaceAfter=4) B=ParagraphStyle('B',parent=styles['BodyText'],fontName='Helvetica',fontSize=8.65,leading=11.2,textColor=INK,spaceAfter=4) S=ParagraphStyle('S',parent=B,fontSize=7.35,leading=9.05) L=ParagraphStyle('L',parent=S,fontName='Helvetica-Bold') TH=ParagraphStyle('TH',parent=S,fontName='Helvetica-Bold',alignment=TA_CENTER,textColor=colors.white) def p(x, st=B): return Paragraph(x,st) def bullets(items): return [p('• '+x) for x in items] def table(rows, widths=(46*mm,135*mm), head=('Item','Write / correct as follows')): data=[[p(head[0],TH),p(head[1],TH)]]+[[p(a,L),p(b,S)] for a,b in rows] t=Table(data,colWidths=list(widths),repeatRows=1,hAlign='LEFT') t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),C),('BACKGROUND',(0,1),(0,-1),PALE),('GRID',(0,0),(-1,-1),0.28,HexColor('#A8C6CD')),('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),2.3*mm),('RIGHTPADDING',(0,0),(-1,-1),2.3*mm),('TOPPADDING',(0,0),(-1,-1),1.65*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.65*mm)])) return t def note(text): t=Table([[p('<b>Important:</b> '+text,S)]],colWidths=[181*mm]) t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,-1),HexColor('#FFF5D6')),('BOX',(0,0),(-1,-1),.4,HexColor('#DBB54A')),('LEFTPADDING',(0,0),(-1,-1),3*mm),('RIGHTPADDING',(0,0),(-1,-1),3*mm),('TOPPADDING',(0,0),(-1,-1),2.5*mm),('BOTTOMPADDING',(0,0),(-1,-1),2.5*mm)])); return t def footer(c,d): c.saveState(); c.setStrokeColor(HexColor('#A8C6CD'));c.line(13*mm,12*mm,197*mm,12*mm);c.setFillColor(HexColor('#52646D'));c.setFont('Helvetica',7);c.drawString(13*mm,7.7*mm,'MD Paediatrics Practical Long Case | Corrected educational template');c.drawRightString(197*mm,7.7*mm,f'Page {d.page}');c.restoreState() story=[] story += [p('CORRECTED LONG CASE',T),p('Severe neonatal unconjugated hyperbilirubinaemia with suspected chronic bilirubin encephalopathy / kernicterus spectrum disorder',ST),note('This is a clear, examination-ready <b>corrected template</b>, not a verified transcription of the child’s handwritten record. Keep all boxed blanks until corroborated by neonatal records, current examination and formal audiology.'),Spacer(1,7),p('How to use this sheet',H1),p('Present the case in this order: <b>syndrome → localisation → probable aetiology → evidence needed → functional rehabilitation plan.</b> This prevents premature labelling of “kernicterus”, “cerebral palsy” or “hearing loss”.'),table([('Use this wording','“History suggestive of severe neonatal unconjugated hyperbilirubinaemia requiring intensive phototherapy and double-volume exchange transfusion; original records are awaited.”'),('Do not assume','Term status, birth weight, peak bilirubin, direct bilirubin, cause of jaundice, seizures, cerebral palsy, SNHL, auditory neuropathy or MRI findings.'),('Correct diagnostic certainty','Use <b>suspected/probable</b> chronic bilirubin encephalopathy until the phenotype and alternate causes have been assessed.'),('Clinical priority','Obtain neonatal records, audiology, developmental assessment, neurological phenotyping, feeding/nutrition review and MRI where clinically indicated.')]),p('One-minute case summary: model',H1),p('<b>This is a ___-month-old girl</b>, born at ___ weeks with birth weight ___ kg, with a reported history of severe neonatal jaundice from day ___ requiring ___ phototherapy and ___ exchange transfusion. Records of serial total/direct serum bilirubin, haemolysis work-up and G6PD status are awaited. Thereafter, she had delayed motor and language milestones, poor response to sound and ___ abnormal movements/posturing, without/with regression ___. Examination shows ___ growth status, ___ head circumference, ___ motor phenotype and ___ functional status. This is a neurodevelopmental disorder with probable basal ganglia/extrapyramidal and auditory pathway involvement. My provisional diagnosis is <b>probable chronic bilirubin encephalopathy</b> with dyskinetic/dystonic motor disorder and suspected auditory neuropathy spectrum disorder, pending objective confirmation and exclusion of other causes.'),PageBreak()] story += [p('1. Corrected university-style case sheet',H1),p('A. Biodata and chief complaints',H2),table([('Biodata','___-month-old girl/boy; ___ birth order; child of a non-consanguineous/consanguineous couple; residence ___; informant ___; reliability ___; date of examination ___.'),('Chief complaint 1','Delayed attainment of developmental milestones since ___ months.'),('Chief complaint 2','Poor or inconsistent response to sound since ___ months.'),('Chief complaint 3','Abnormal posturing/involuntary movements since ___ months.'),('Chief complaint 4','Seizure-like events since ___ months, <i>only if actually present</i>.')]),p('B. History of present illness: corrected narrative',H2),p('The child was apparently well until day ___ of life, when yellow discoloration of sclera/skin was first noticed. Establish whether it started <b>within 24 hours</b>, its progression, feeding adequacy, urine/stool colour, weight loss and duration. Ask specifically about lethargy, poor suck, high-pitched cry, hypo/hypertonia, neck or back arching, fever, apnoea and seizures. She received ___ phototherapy for ___ and had a double-volume exchange transfusion on day ___ because ___. Exact treatment indication and bilirubin values are to be verified. After discharge, the family noticed ___ motor delay, ___ language delay, poor auditory responsiveness and ___ abnormal movements. There is no/there is history of regression.'),table([('Essential neonatal evidence','Gestation; birth weight; age in hours at jaundice onset; serial TSB and direct bilirubin; rate of rise; maternal/baby ABO-Rh; DAT; Hb, reticulocytes and smear; G6PD; albumin; sepsis work-up; feeding/weight loss; phototherapy and exchange details.'),('Relevant positive history','Cephalhaematoma/bruising, pallor, dark urine/pale stool, fever, poor feeding, lethargy, shrill cry, abnormal tone, retrocollis/opisthotonus, seizures, hypoxia/acidosis.'),('Relevant negatives','No regression, no progressive deterioration, no family history of similar disorder, no perinatal asphyxia <i>only if reliably documented</i>.')]),p('C. Antenatal, birth and neonatal history',H2),table([('Antenatal','Maternal blood group/Rh and antibody screen; prior affected baby; consanguinity; maternal illness/medicines; fetal movements; antenatal scans.'),('Birth','Gestation in completed weeks, birth weight, place/mode of delivery and indication, cry/resuscitation, birth trauma, first breastfeed, urine/meconium passage.'),('Jaundice risk factors','Immune haemolysis, G6PD deficiency, RBC membrane/enzyme disorder, bruising/cephalhaematoma, polycythaemia, prematurity, sepsis, poor intake/dehydration, hypothyroidism and rare UGT disorders.')]),PageBreak()] story += [p('2. Development, nutrition and examination',H1),p('A. Developmental history: assess current function',H2),table([('Rule','Do not calculate DQ from one historical milestone. Determine developmental age in each domain using DASII/Bayley or local standardised assessment. DQ = developmental age ÷ chronological age × 100.'),('Gross motor','Current head/trunk control; sitting; crawling; pull to stand; cruising; standing; walking; climbing; falls; toe walking; involuntary movements.'),('Fine motor-adaptive','Bilateral reach, pincer grasp, transfer, release, scribble, tower, page turning, spoon use, hand preference/asymmetry.'),('Language-hearing','Response to name/sound, localisation, comprehension, gestures, pointing, babble, meaningful words, joint attention and communication method.'),('Personal-social','Play, imitation, feeding self, affection, social reciprocity and caregiver interaction.'),('Regression','Explicitly ask loss of skills. Regression or episodic deterioration makes a static bilirubin injury less likely and requires metabolic/genetic evaluation.')]),p('B. Diet, immunisation, family and social history',H2),table([('Diet','24-hour recall with amount, frequency, consistency, duration, choking/coughing, vomiting, stooling and dietary diversity. Assess feeding safety, aspiration and growth.'),('Immunisation','Verify card. Record age-appropriate/partially immunised/unimmunised and list missing doses per UIP.'),('Family','Three-generation pedigree; consanguinity; neonatal jaundice/exchange; hearing impairment; seizures; developmental disorders; dystonia; sibling deaths.'),('Social','Caregiver education/occupation, access to therapy, travel burden, finances, disability support and family coping.')]),p('C. General physical examination',H2),table([('Opening','“Child is conscious and arousable, ___ interactive for age, with eye contact ___. There is/is no pallor, icterus, cyanosis, clubbing, oedema, lymphadenopathy, dysmorphism, neurocutaneous marker or contracture.”'),('Vitals','HR ___, RR ___, temperature ___, SpO₂ ___, BP ___ using an age-appropriate cuff.'),('Anthropometry','Weight ___ kg, length/height ___ cm, head circumference ___ cm, MUAC ___ cm. Plot all values on WHO charts. Re-measure a possibly low HC before calling microcephaly.'),('Systems','Eyes/red reflex, oral cavity and dentition, chest, CVS, abdomen/liver-spleen, spine, skin, joints and hips.')]),p('D. CNS examination',H2),table([('Observe before touching','Posture, spontaneous movement, symmetry, fisting, scissoring, toe posture, drooling, dystonia/choreoathetosis, truncal control and gait if ambulant.'),('Tone: write precisely','<b>Spasticity:</b> velocity-dependent resistance to passive stretch. <b>Dystonia:</b> sustained/intermittent contractions causing twisting/repetitive movement or abnormal posture; may worsen with voluntary action, emotion or touch.'),('Power/function','At 18 months, record antigravity movement, reaching, grasping, weight bearing and asymmetry rather than unreliable formal MRC grades.'),('Reflexes','DTRs ___, clonus ___, plantar ___. Interpret plantar response by age; do not diagnose pyramidal disease from this alone.'),('Cranial nerves','Visual behaviour, pupils/red reflex, alignment/nystagmus, extraocular movements with <b>upgaze</b>, facial symmetry, feeding/voice and tongue. Hearing needs formal testing.'),('Functional scales','Document GMFCS, MACS, CFCS and EDACS where feasible.')]),PageBreak()] story += [p('3. Clinical synthesis, diagnosis and differentials',H1),p('Diagnostic formulation',H2),table([('Syndromic','Global developmental delay/neurodevelopmental disorder with motor impairment, dystonia/dyskinesia if demonstrated, and suspected hearing impairment.'),('Topographic','Predominantly extrapyramidal/basal ganglia and auditory pathway involvement.'),('Etiologic','Probable chronic bilirubin encephalopathy following severe neonatal unconjugated hyperbilirubinaemia, pending neonatal-record confirmation and evaluation for alternate causes.'),('Final diagnosis if confirmed','<b>Chronic bilirubin encephalopathy (kernicterus spectrum disorder), presenting as dyskinetic cerebral palsy with global developmental delay and confirmed auditory neuropathy spectrum disorder, following severe neonatal unconjugated hyperbilirubinaemia.</b>'),('Final diagnosis if incomplete','<b>Neurodevelopmental impairment with dystonic motor phenotype and suspected auditory impairment following severe neonatal jaundice, under evaluation for chronic bilirubin encephalopathy.</b>')]),p('Differential diagnoses and how to separate them',H2),table([('HIE/basal ganglia injury','Ask about resuscitation, encephalopathy and early seizures; review neonatal course and MRI. HIE can also cause dyskinetic CP.'),('Genetic/metabolic dystonia','Think of this with regression, progressive course, diurnal fluctuation, episodic decompensation, family history or atypical MRI. Pursue targeted evaluation if indicated.'),('Congenital infection','Look for microcephaly, sensory deficits, seizures, hepatosplenomegaly, ocular signs and characteristic imaging.'),('Other CP aetiology','Prematurity/PVL, stroke, malformation, prenatal infection and HIE. CP is a syndrome, not an aetiology.'),('Isolated hearing loss','May explain speech delay but does not explain persistent dystonia or marked motor delay.')]),p('Investigation plan',H2),table([('Highest priority','Retrieve original neonatal records, including bilirubin trajectory, direct fraction and cause evaluation.'),('Hearing','OAE, ABR/BERA, tympanometry, behavioural audiometry and speech-language assessment. In ANSD, OAE may be present with abnormal/absent ABR.'),('Vision','Paediatric ophthalmology, refraction, fundus and ocular-motility/upgaze assessment.'),('Brain','MRI brain with review of globus pallidus/basal ganglia and competing patterns of injury. Normal MRI does not exclude clinical CBE.'),('Development/function','DASII or equivalent; GMFCS/MACS/CFCS/EDACS; feeding/swallow and nutrition assessment.'),('Targeted only','EEG for seizure concern. Genetic/metabolic investigations for atypical/progressive phenotype, regression, family history or unexplained findings.')]),PageBreak()] story += [p('4. Bilirubin encephalopathy: HOD-level discussion',H1),table([('Definition','<b>Acute bilirubin encephalopathy (ABE)</b> is acute neurological dysfunction from unconjugated bilirubin neurotoxicity. <b>Chronic bilirubin encephalopathy (CBE)</b> is permanent sequelae. “Kernicterus” originally describes bilirubin staining of vulnerable deep nuclei at pathology.'),('Why it occurs','High RBC turnover, immature bilirubin conjugation, increased enterohepatic circulation and poor intake make newborns vulnerable. Risk rises with prematurity, haemolysis, low albumin/unbound bilirubin, sepsis, acidosis, hypoxia and clinical instability.'),('Important mechanism','TSB is the practical measure used in treatment protocols, but unbound bilirubin and bilirubin-albumin binding are closer to the toxic exposure at the brain.'),('Affected anatomy','Globus pallidus and subthalamic nuclei, hippocampus, substantia nigra, auditory/oculomotor/vestibular/facial nuclei and cerebellar nuclei. <i>Bradley and Daroff’s Neurology in Clinical Practice</i>, pp. 1250, 2866.'),('ABE: early','Poor feeding/suck, lethargy or somnolence, hypotonia, irritability and high-pitched cry.'),('ABE: intermediate/advanced','Hypertonia, retrocollis, opisthotonus, fever, apnoea, seizures, coma and death. Seizures are possible but not mandatory.'),('CBE classic phenotype','Dystonic/choreoathetoid dyskinetic CP, auditory neuropathy spectrum disorder, especially upward gaze limitation, dental enamel hypoplasia, feeding/speech disorder and variable cognition. In the first year, hypotonia/delayed motor skills can precede the classic phenotype.'),('MRI','Acute term kernicterus may show symmetric T1 hyperintensity of globi pallidi. Chronic imaging can be variable; normal imaging does not rule out the clinical syndrome. <i>Bradley and Daroff</i>, p. 2866.')]),p('Prevention and neonatal management: safe viva answer',H2),p('Treatment thresholds must be selected from the current <b>gestation-specific, age-in-hours and risk-factor-specific</b> guideline chart. Do not quote one “safe bilirubin number” for all babies. The AAP 2022 guideline applies to infants ≥35 weeks and frames prevention, bilirubin assessment/monitoring, treatment, post-discharge follow-up and systems of care. Intensive phototherapy, correction of feeding failure and treatment of haemolysis/sepsis are central. In the AAP framework, escalation of care is at TSB 2 mg/dL below the exchange threshold; exchange transfusion is urgent at the charted threshold or with signs of ABE. Use the applicable local neonatal guideline, especially for preterm infants.'),note('For the present older child, the priority is not retrospective phototherapy thresholds. It is confirmation of the neonatal exposure, precise developmental/motor/hearing phenotype, exclusion of alternatives and early functional intervention.'),PageBreak()] story += [p('5. Management, counselling and viva',H1),p('Multidisciplinary management',H2),table([('Developmental rehabilitation','Developmental paediatrics, neurology, physiotherapy, occupational therapy, speech-language/feeding therapy and regular goal-based review.'),('Dystonia/motor disorder','Positioning, seating, ROM, orthoses, contracture prevention and hip surveillance. Medicines are specialist and phenotype-specific: trihexyphenidyl, baclofen, clonazepam, gabapentin or focal botulinum toxin may be considered. Intrathecal baclofen/DBS are selected severe cases.'),('Hearing/communication','Urgent paediatric audiology and ENT. Hearing aid versus cochlear implant pathway depends on behavioural thresholds, speech perception and functional benefit. Use AAC/sign-supported communication and parent coaching early.'),('Feeding/nutrition','Screen cough/choking, prolonged feeds, aspiration, dehydration, poor weight gain and constipation. Dietitian and formal swallow assessment when needed.'),('Seizures','Obtain home video; EEG only if clinical events suggest epilepsy. Dystonia should not be automatically treated as epilepsy.'),('Family and prevention','Immunisation, dental review, vision review, sleep/constipation/reflux management, disability certification, school planning, social support and caregiver mental-health support.')]),p('Parent counselling: simple script',H2),p('“The neonatal jaundice history may be related to the child’s movement, hearing and developmental difficulties, but we must confirm the details and assess all other possible causes. The most helpful steps now are formal hearing and vision assessment, a therapy plan for movement and communication, safe feeding and regular follow-up. Early rehabilitation can improve function and participation even when an old brain injury cannot be reversed.”'),p('HOD viva: rapid answers',H2),table([('What is ABE?','Potentially reversible acute neurological dysfunction from severe unconjugated bilirubin neurotoxicity.'),('What are the three classic chronic manifestations?','Dyskinetic CP, auditory neuropathy/hearing impairment and vertical gaze limitation. Dental enamel hypoplasia supports the phenotype.'),('Why not use a single bilirubin cutoff?','Risk is modified by gestation, postnatal age, bilirubin rise, haemolysis, albumin/unbound bilirubin, sepsis, acidosis and instability.'),('What confirms ANSD?','Audiological pattern, often preserved OAE/cochlear outer hair-cell function with abnormal/absent ABR, interpreted with behavioural hearing and speech perception.'),('What are your first investigations today?','Neonatal record retrieval, OAE/ABR/tympanometry/behavioural audiometry, developmental and feeding evaluation, vision examination, MRI where indicated.'),('What is the key clinical trap?','Calling every child with exchange transfusion “kernicterus” or every abnormal movement “seizure”. Use evidence and phenotype.')]),p('Blank presentation framework: S-D-U-A-H-E-R',H2),table([('S - Summary/syndrome','Age, developmental concerns, motor and hearing phenotype.'),('D - Development','All four domains, current function, regression and standardised assessment.'),('U - Underlying exposure','Neonatal unconjugated hyperbilirubinaemia, timing, cause and treatment records.'),('A - Associated impairments','Hearing, vision/upgaze, feeding, dental, seizures, growth and orthopaedic issues.'),('H - Higher functions','Interaction, play, comprehension, communication and sensory function.'),('E - Examination/localisation','Motor phenotype, tone, reflexes, CNs and functional scales.'),('R - Rehabilitation/roadmap','Audiology, therapy, nutrition, family support, targeted investigations and follow-up.')]),PageBreak()] story += [p('6. Blank reusable long-case proforma',H1),table([('Biodata','___-month/year-old ___, ___ born to a ___ couple. Informant ___; reliability ___.'),('Chief complaints','1. ___ since ___.<br/>2. ___ since ___.<br/>3. ___ since ___.'),('Neonatal jaundice','Onset: ___ hours/day. Peak TSB: ___ mg/dL; direct bilirubin: ___. Rate of rise: ___. Blood group/DAT: ___. G6PD: ___. Albumin: ___. Sepsis: ___. Phototherapy: ___. Exchange: ___.'),('ABE features','Poor suck/lethargy ___; shrill cry ___; tone change ___; retrocollis/opisthotonus ___; apnoea/seizure ___.'''),('Development','GM DA ___; FM DA ___; language DA ___; personal-social DA ___. Regression: yes/no. Tool and DQ: ___.'),('Diet/feeding','24-hour recall ___; choking/cough ___; vomiting/constipation ___; feeding duration ___.'),('Examination','W/L/BMI Z: ___. HC percentile/Z: ___. General findings: ___. Motor phenotype: ___. Tone: ___. DTR/plantar: ___. GMFCS/MACS/CFCS/EDACS: ___. Hearing/vision: ___.'),('Syndrome/localisation','___.'),('Provisional diagnosis','___.'),('Differentials','1. ___ 2. ___ 3. ___.'),('Plan','Neonatal records ___; audiology ___; eye exam ___; MRI ___; DASII/function ___; feeding/nutrition ___; rehabilitation ___; counselling/support ___.')]),p('References and examination caveats',H1),p('1. American Academy of Pediatrics. <i>Clinical Practice Guideline: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation</i>. 2022. Use the current local chart and policy; the AAP guideline applies to ≥35 weeks. 2. Lai NM et al. Association between Serum Bilirubin and Kernicterus Spectrum Disorder: a systematic review and meta-analysis. <i>Neonatology</i>. 2021; PMID 34731859. 3. Bradley and Daroff’s <i>Neurology in Clinical Practice</i>: hyperbilirubinaemia/kernicterus sections, pp. 1250 and 2866. 4. Rosen’s <i>Emergency Medicine</i>, clinical features of ABE. Treatment/doses and neonatal thresholds require local current guideline verification.',S)] doc=SimpleDocTemplate(str(out),pagesize=A4,rightMargin=14*mm,leftMargin=14*mm,topMargin=12*mm,bottomMargin=16*mm,title='Corrected Long Case: Chronic Bilirubin Encephalopathy') doc.build(story,onFirstPage=footer,onLaterPages=footer) r=PdfReader(str(out)); text='\n'.join((pg.extract_text() or '') for pg in r.pages) keys=['Corrected university-style case sheet','Clinical synthesis, diagnosis and differentials','Bilirubin encephalopathy: HOD-level discussion','Blank reusable long-case proforma'] print('PATH=',out); print('PAGES=',len(r.pages)); print('BYTES=',out.stat().st_size); print('KEYS=',[(k,k in text) for k in keys]) PY

AAP 2022 hyperbilirubinemia guideline escalation care 2 mg/dL exchange transfusion official

~/long-case-bilirubin/

python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Paragraph, Table, TableStyle, Spacer, PageBreak from reportlab.lib.units import mm from pypdf import PdfReader, PdfWriter from pathlib import Path base=Path('/tmp/workspace/long-case-bilirubin/output/Corrected_Clear_Long_Case_Chronic_Bilirubin_Encephalopathy_MD_Paediatrics.pdf') appendix=Path('/tmp/workspace/long-case-bilirubin/output/HOD_Viva_50_QA_Chronic_Bilirubin_Encephalopathy.pdf') combined=Path('/tmp/workspace/long-case-bilirubin/output/Corrected_Long_Case_With_50_HOD_Viva_QA_MD_Paediatrics.pdf') ss=getSampleStyleSheet(); navy=HexColor('#0B4F6C'); teal=HexColor('#087E8B'); pale=HexColor('#EAF5F7'); ink=HexColor('#172A34') T=ParagraphStyle('T',parent=ss['Title'],fontName='Helvetica-Bold',fontSize=18,leading=22,alignment=TA_CENTER,textColor=navy,spaceAfter=6) ST=ParagraphStyle('ST',parent=ss['Normal'],fontSize=9,leading=11,alignment=TA_CENTER,textColor=HexColor('#52646D'),spaceAfter=10) H=ParagraphStyle('H',parent=ss['Heading1'],fontName='Helvetica-Bold',fontSize=13,leading=16,textColor=navy,spaceBefore=6,spaceAfter=5) B=ParagraphStyle('B',parent=ss['BodyText'],fontName='Helvetica',fontSize=8.25,leading=10.4,textColor=ink) Q=ParagraphStyle('Q',parent=B,fontName='Helvetica-Bold',fontSize=8.1,leading=10.0,textColor=navy) A=ParagraphStyle('A',parent=B,fontSize=7.7,leading=9.35) def P(x,s=B):return Paragraph(x,s) def qa(n,q,a): d=[[P(f'<b>{n}. {q}</b>',Q)],[P(a,A)]] t=Table(d,colWidths=[181*mm],hAlign='LEFT') t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),pale),('BOX',(0,0),(-1,-1),.3,HexColor('#A8C6CD')),('LINEBELOW',(0,0),(-1,0),.25,HexColor('#A8C6CD')),('LEFTPADDING',(0,0),(-1,-1),2.5*mm),('RIGHTPADDING',(0,0),(-1,-1),2.5*mm),('TOPPADDING',(0,0),(-1,-1),1.8*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.8*mm)])) return t def foot(c,d): c.saveState();c.setStrokeColor(HexColor('#A8C6CD'));c.line(13*mm,12*mm,197*mm,12*mm);c.setFont('Helvetica',7);c.setFillColor(HexColor('#52646D'));c.drawString(13*mm,7.6*mm,'HOD Viva Appendix | Chronic bilirubin encephalopathy');c.drawRightString(197*mm,7.6*mm,f'Page {d.page}');c.restoreState() sections=[ ('I. Formulation and clinical reasoning',[ ('What is your one-line diagnosis?','“This child has a static neurodevelopmental disorder with a dystonic/dyskinetic motor phenotype and suspected hearing impairment following reported severe neonatal unconjugated hyperbilirubinaemia; chronic bilirubin encephalopathy is probable but requires record-based and objective confirmation.”'), ('Why do you not simply say “kernicterus”?','Kernicterus should not be inferred from exchange transfusion alone. I need documented severe unconjugated hyperbilirubinaemia, the characteristic clinical phenotype, and review for competing aetiologies such as HIE, genetic/metabolic dystonia or congenital infection.'), ('What is the difference between syndrome, localisation and aetiology in this child?','Syndrome: global developmental delay with motor disorder and suspected hearing impairment. Localisation: chiefly extrapyramidal/basal ganglia with auditory pathway involvement. Aetiology: probable chronic bilirubin encephalopathy after severe neonatal unconjugated hyperbilirubinaemia.'), ('Why is absence of regression important?','A non-progressive course supports an acquired static encephalopathy such as CP/CBE. Regression, episodic worsening or progressive loss of function requires urgent reconsideration of genetic, metabolic or degenerative disease.'), ('What documentation would strengthen causality?','Serial neonatal TSB and direct bilirubin, age in hours at onset/treatment, gestation, albumin, haemolysis and G6PD studies, sepsis/instability, phototherapy and exchange details, plus current audiology, developmental assessment and MRI where appropriate.'), ('What are the common diagnostic traps in this case?','Calling all abnormal movements seizures, calling all poor sound response SNHL, calculating DQ from one milestone, accepting a parental “normal MRI” report without documents, and using a single bilirubin number without gestation/age/risk context.'), ('Can cognition be relatively preserved in chronic bilirubin encephalopathy?','Yes. The classic phenotype can have severe dyskinetic, auditory and speech impairment with cognition that is better than the motor/speech disability suggests. Formal assessment should therefore use accessible nonverbal methods where needed.'), ('How will you assess functional severity?','Use age-appropriate standardised developmental testing plus GMFCS for gross motor function, MACS for manual ability, CFCS for communication and EDACS for eating/drinking safety when feasible.')]), ('II. Bilirubin physiology and neurotoxicity',[ ('Define unconjugated hyperbilirubinaemia.','It is elevation of indirect, albumin-bound bilirubin before hepatic conjugation. It is common in newborns, but severe elevation or increased unbound bilirubin can cross into the CNS and injure neural tissue.'), ('Why are newborns vulnerable to jaundice?','They have high red-cell turnover, a shorter red-cell lifespan, immature UGT1A1 conjugation, increased enterohepatic circulation and may have inadequate intake in the first days of life.'), ('What determines bilirubin neurotoxicity besides TSB?','Gestational age, postnatal age in hours, rate of bilirubin rise, haemolysis, albumin binding/unbound bilirubin, sepsis, acidosis, hypoxia and clinical instability. TSB is the practical treatment marker, not a complete measure of risk.'), ('Why does albumin matter?','Albumin binds unconjugated bilirubin. Reduced binding capacity or displacement can increase the unbound fraction, which is more able to cross the blood-brain barrier and cause toxicity.'), ('Name causes of increased bilirubin production.','Immune haemolysis from ABO/Rh or other antibodies, G6PD deficiency, RBC membrane/enzyme defects, bruising/cephalhaematoma, polycythaemia and swallowed blood.'), ('Name causes of reduced bilirubin clearance.','Prematurity, immature conjugation, poor intake/increased enterohepatic circulation, hypothyroidism and rare inherited UGT defects such as Crigler-Najjar syndrome.'), ('Why is jaundice in the first 24 hours a red flag?','Physiological jaundice rarely appears on day 1. Early jaundice suggests pathology, particularly haemolysis, and requires prompt bilirubin measurement and cause evaluation.'), ('Why does sepsis increase risk?','Sepsis and clinical instability can impair bilirubin binding and blood-brain barrier integrity and commonly coexist with acidosis and poor intake, raising neurotoxicity risk.')]), ('III. Acute and chronic bilirubin encephalopathy',[ ('Define acute bilirubin encephalopathy.','ABE is the acute, potentially reversible neurological syndrome caused by unconjugated bilirubin neurotoxicity in a neonate.'), ('What are early signs of ABE?','Poor feeding or suck, lethargy/somnolence, hypotonia, irritability and a high-pitched cry.'), ('What indicates progression of ABE?','Increasing hypertonia, retrocollis, opisthotonus, fever, apnoea, marked irritability or altered consciousness. Seizures and coma are late/advanced signs.'), ('Define chronic bilirubin encephalopathy.','It is permanent neurodevelopmental sequelae after bilirubin neurotoxicity. Kernicterus spectrum disorder is a modern umbrella term used to describe the spectrum of clinical effects.'), ('What is the classic chronic phenotype?','Dyskinetic CP with dystonia/choreoathetosis, auditory neuropathy spectrum disorder or hearing impairment, vertical gaze limitation especially upgaze, and dental enamel hypoplasia.'), ('Which brain areas are selectively affected?','The globus pallidus and subthalamic nuclei, hippocampus, substantia nigra, cerebellar nuclei and selected cranial nerve nuclei, notably auditory and oculomotor pathways.'), ('Why is poor feeding with high-pitched cry clinically useful?','Prominent brainstem dysfunction with disturbed feeding and high-pitched crying is characteristic of ABE and helps distinguish it from some other neonatal encephalopathies.'), ('Does every infant with high bilirubin develop CBE?','No. Risk is modified by multiple factors. Many infants with hyperbilirubinaemia do not have brain injury, which is why diagnosis and treatment use risk-adjusted, hour-specific guidance rather than a single value.')]), ('IV. Neonatal prevention and treatment principles',[ ('How should jaundice be assessed initially?','Assess timing, gestation, feeding and risk factors; visually examine but obtain an objective bilirubin measurement when indicated. Interpret it by postnatal age in hours, gestational age and neurotoxicity risk factors.'), ('What is the mainstay of treatment?','Intensive phototherapy when the applicable hour-specific, gestation- and risk-adjusted threshold is reached. Also correct poor intake/dehydration and treat haemolysis, sepsis or other causes.'), ('How does phototherapy work?','Light converts bilirubin in the skin into water-soluble photoisomers that can be excreted without hepatic conjugation.'), ('What is exchange transfusion?','A time-critical blood replacement procedure that rapidly lowers circulating bilirubin and removes antibody-coated/haemolysing red cells. It should be performed in an equipped neonatal setting with continuous monitoring.'), ('When is escalation of care required in the AAP 2022 framework?','For infants 35 weeks or more, escalation-of-care threshold is defined as TSB 2 mg/dL below the exchange-transfusion threshold. This is chart based and must not be applied to preterm infants without the appropriate protocol.'), ('When is exchange transfusion urgent?','When the charted exchange threshold is reached or exceeded, or when signs of acute bilirubin encephalopathy are present. Simultaneously use intensive phototherapy and stabilise/treat the underlying cause.'), ('Why must you not quote one universal exchange value?','Thresholds depend on gestational age, postnatal age in hours and neurotoxicity risk factors. Institutional/national charts also vary, and preterm infants require separate guidance.'), ('What is IVIG’s role?','It may be considered in selected newborns with isoimmune haemolytic disease whose bilirubin is rising despite intensive phototherapy and is approaching escalation thresholds, following current local protocol. It is not routine for every jaundiced infant.')]), ('V. Examination, hearing and imaging',[ ('How do you distinguish dystonia from spasticity?','Dystonia produces fluctuating, sustained or intermittent twisting postures and may be action-triggered. Spasticity is velocity-dependent resistance to passive stretch. Both may coexist and should be described separately.'), ('How do you examine dystonia in a toddler?','Observe at rest and during purposeful activity, excitement, handling and walking. Document body distribution, triggers, fixed versus mobile posture, impact on hand use, feeding, sitting and gait.'), ('What cranial nerve feature will you specifically seek?','Vertical eye movement, particularly limitation of upgaze, along with alignment, nystagmus, visual behaviour and facial/oral-motor function.'), ('How will you investigate poor response to sound?','Refer for paediatric audiology: OAE, ABR/BERA, tympanometry and behavioural audiometry, with speech-language assessment. Caregiver report alone is insufficient.'), ('What is the characteristic test pattern in ANSD?','OAE may be preserved, reflecting outer-hair-cell function, while ABR is abnormal or absent due to impaired neural synchrony. Final management is guided by behavioural hearing and speech perception as well.'), ('Can a normal MRI exclude CBE?','No. MRI can support the diagnosis and exclude alternatives, but clinical phenotype and neonatal evidence remain central. A normal MRI does not rule out CBE.'), ('What MRI finding may be seen in kernicterus?','Symmetric signal abnormality involving the globus pallidus is classically described, with appearance varying by timing and sequence. Interpret MRI with paediatric neuroradiology and clinical context.'), ('Why do you evaluate vision and feeding?','Visual dysfunction and oro-motor impairment can compound disability, delay communication and create aspiration/nutrition risk. Both are essential functional targets, not optional add-ons.')]), ('VI. Differentials, rehabilitation and counselling',[ ('How will you differentiate CBE from HIE?','Use neonatal history and records, clinical phenotype and MRI. HIE is linked to sentinel perinatal hypoxia-ischaemia and may involve basal ganglia, whereas CBE has the jaundice/ABE course and characteristic auditory and gaze phenotype. They can coexist.'), ('When will you order genetic or metabolic tests?','With regression, progressive course, episodic deterioration, atypical movements, dysmorphism, family history, unexplained MRI or findings inconsistent with the reported neonatal injury.'), ('What is the role of EEG?','EEG is indicated if events are clinically suspicious for seizures or if there is unexplained episodic alteration. It does not diagnose dystonia and should not be ordered merely because movements are abnormal.'), ('What are your immediate management priorities in this child?','Confirm hearing and vision, assess feeding/growth and development, define the motor phenotype and functional level, retrieve neonatal records, start coordinated rehabilitation and screen caregiver/support needs.'), ('Outline motor management.','Set functional goals, use physiotherapy and occupational therapy, optimise positioning/seating and ROM, prevent contractures and monitor hips. Medication or procedures for dystonia/spasticity require specialist, goal-directed selection.'), ('How do you approach communication?','Do not wait for diagnostic closure. Provide hearing rehabilitation as appropriate and introduce communication support early: speech-language therapy, parent coaching, gestures, sign-supported communication and AAC when needed.'), ('When might cochlear implant assessment be considered?','After comprehensive audiological and ENT evaluation when the child has significant functional hearing impairment and is a potential candidate. In ANSD, decisions rely on behavioural hearing and speech/language outcomes, not ABR alone.'), ('What nutritional issues are common?','Prolonged feeding, poor oral-motor control, choking/cough, aspiration, inadequate energy intake, constipation and poor growth. Assess swallow safety and involve dietetics/feeding specialists early.'), ('How will you counsel the family about prognosis?','Explain uncertainty honestly: function can improve with early, consistent rehabilitation even if old neural injury is permanent. Set measurable goals for mobility, communication, feeding, participation and caregiver support rather than promise cure.'), ('Give your final HOD closing statement.','“I will confirm the neonatal exposure and current phenotype, avoid premature attribution, urgently address hearing, feeding and communication, and provide multidisciplinary, function-centred rehabilitation while evaluating alternate causes where indicated.”')])] story=[P('HOD-STYLE VIVA: 50 MODEL QUESTIONS AND ANSWERS',T),P('Chronic bilirubin encephalopathy / kernicterus spectrum disorder',ST),P('<b>Use in viva:</b> Give the first sentence, then pause. Add the second sentence only if the examiner asks. Treatment thresholds must always be confirmed on the current local, gestation-specific and age-in-hours chart.',B),Spacer(1,5)] n=1 for si,(head,items) in enumerate(sections): story.append(P(head,H)) for q,a in items: story.append(qa(n,q,a));story.append(Spacer(1,3));n+=1 if si < len(sections)-1: story.append(PageBreak()) story.append(P('Reference anchors',H));story.append(P('AAP 2022 hyperbilirubinaemia guidance for infants ≥35 weeks; AAP quick reference: escalation-of-care threshold is 2 mg/dL below exchange threshold. Bradley and Daroff’s <i>Neurology in Clinical Practice</i>: hyperbilirubinaemia/kernicterus, pp. 1250 and 2866. Rosen’s <i>Emergency Medicine</i>: ABE clinical features. Lai NM et al. <i>Neonatology</i>. 2021; PMID 34731859. Use current local neonatal guidelines for all treatment decisions.',B)) doc=SimpleDocTemplate(str(appendix),pagesize=A4,leftMargin=14*mm,rightMargin=14*mm,topMargin=12*mm,bottomMargin=16*mm,title='50 HOD Viva Questions: Chronic Bilirubin Encephalopathy') doc.build(story,onFirstPage=foot,onLaterPages=foot) # combine base and Q&A writer=PdfWriter() for f in [base,appendix]: rr=PdfReader(str(f)) for pg in rr.pages: writer.add_page(pg) with open(combined,'wb') as fh: writer.write(fh) # verification for f in [appendix,combined]: r=PdfReader(str(f)); tx='\n'.join((x.extract_text() or '') for x in r.pages) print(f.name,len(r.pages),f.stat().st_size,'Q50', '50.' in tx, 'ANSD', 'ANSD' in tx) PY

AAP 2022 neonatal hyperbilirubinemia guideline risk factors exchange transfusion escalation care official

python - <<'PY' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Paragraph, Table, TableStyle, Spacer, PageBreak from reportlab.lib.units import mm from pypdf import PdfReader from pathlib import Path out=Path('/tmp/workspace/long-case-bilirubin/output/Viva_Only_50_HOD_QA_Examiner_Traps_Bilirubin_Encephalopathy.pdf') ss=getSampleStyleSheet(); navy=HexColor('#0B4F6C'); teal=HexColor('#087E8B'); pale=HexColor('#EAF5F7'); warn=HexColor('#FFF3D2'); ink=HexColor('#172A34') T=ParagraphStyle('T',parent=ss['Title'],fontName='Helvetica-Bold',fontSize=18,leading=22,alignment=TA_CENTER,textColor=navy,spaceAfter=6) ST=ParagraphStyle('ST',parent=ss['Normal'],fontSize=9,leading=11,alignment=TA_CENTER,textColor=HexColor('#52646D'),spaceAfter=9) H=ParagraphStyle('H',parent=ss['Heading1'],fontName='Helvetica-Bold',fontSize=13,leading=16,textColor=navy,spaceBefore=6,spaceAfter=5) B=ParagraphStyle('B',parent=ss['BodyText'],fontName='Helvetica',fontSize=8.15,leading=10.2,textColor=ink) Q=ParagraphStyle('Q',parent=B,fontName='Helvetica-Bold',fontSize=8.0,leading=9.8,textColor=navy) A=ParagraphStyle('A',parent=B,fontSize=7.55,leading=9.15) def P(x,s=B):return Paragraph(x,s) def qa(n,q,a): d=[[P(f'{n}. {q}',Q)],[P(a,A)]];t=Table(d,colWidths=[181*mm]);t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),pale),('BOX',(0,0),(-1,-1),.3,HexColor('#A8C6CD')),('LEFTPADDING',(0,0),(-1,-1),2.5*mm),('RIGHTPADDING',(0,0),(-1,-1),2.5*mm),('TOPPADDING',(0,0),(-1,-1),1.6*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.6*mm)]));return t def trap(n,wrong,why,right): d=[[P(f'EXAMINER TRAP {n}: {wrong}',Q)],[P('<b>Why it fails:</b> '+why+'<br/><b>Safe correction:</b> '+right,A)]];t=Table(d,colWidths=[181*mm]);t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),warn),('BOX',(0,0),(-1,-1),.3,HexColor('#D7B659')),('LEFTPADDING',(0,0),(-1,-1),2.5*mm),('RIGHTPADDING',(0,0),(-1,-1),2.5*mm),('TOPPADDING',(0,0),(-1,-1),1.7*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.7*mm)]));return t def foot(c,d): c.saveState();c.setStrokeColor(HexColor('#A8C6CD'));c.line(13*mm,12*mm,197*mm,12*mm);c.setFont('Helvetica',7);c.setFillColor(HexColor('#52646D'));c.drawString(13*mm,7.5*mm,'Viva-only HOD Q&A and examiner traps | Bilirubin encephalopathy');c.drawRightString(197*mm,7.5*mm,f'Page {d.page}');c.restoreState() qs=[ ('Give your one-line diagnosis.','“Static neurodevelopmental disorder with dystonic/dyskinetic motor phenotype and suspected hearing impairment after reported severe neonatal unconjugated hyperbilirubinaemia; probable chronic bilirubin encephalopathy, pending objective confirmation.”'), ('Why is “exchange transfusion done” not equal to “kernicterus”?','Exchange transfusion indicates severe risk or severe jaundice, not proof of neurological injury. Confirmation requires neonatal records, a compatible phenotype and evaluation for competing causes.'), ('What are the syndrome, localisation and aetiology?','Syndrome: GDD with motor disorder and possible hearing impairment. Localisation: basal ganglia/extrapyramidal and auditory pathways. Aetiology: probable bilirubin neurotoxicity after severe neonatal unconjugated hyperbilirubinaemia.'), ('Define acute bilirubin encephalopathy.','Acute, potentially reversible neurological dysfunction caused by unconjugated bilirubin neurotoxicity in a neonate.'), ('List early signs of ABE.','Poor suck/feeding, lethargy or somnolence, hypotonia, irritability and high-pitched cry.'), ('List advanced signs of ABE.','Hypertonia, retrocollis, opisthotonus, fever, apnoea, seizures, coma and death.'), ('Define chronic bilirubin encephalopathy.','Permanent neurological sequelae after bilirubin neurotoxicity. Kernicterus spectrum disorder is a modern umbrella term for its clinical spectrum.'), ('What is the classic CBE phenotype?','Dyskinetic CP with dystonia/choreoathetosis, auditory neuropathy spectrum disorder, vertical gaze limitation especially upgaze, and dental enamel hypoplasia.'), ('Which structures are selectively vulnerable?','Globus pallidus, subthalamic nuclei, hippocampus, substantia nigra, cerebellar nuclei and auditory/oculomotor/vestibular cranial nerve pathways.'), ('Why are newborns vulnerable to unconjugated jaundice?','High RBC turnover, short RBC lifespan, immature UGT1A1 conjugation, increased enterohepatic circulation and frequent early feeding insufficiency.'), ('What determines neurotoxicity besides TSB?','Gestation, age in hours, rate of rise, haemolysis, albumin and unbound bilirubin, sepsis, acidosis, hypoxia and clinical instability.'), ('Why does albumin matter?','It binds unconjugated bilirubin. Low binding capacity increases free bilirubin, which is more likely to cross the blood-brain barrier.'), ('Name common causes of severe unconjugated hyperbilirubinaemia.','ABO/Rh or other immune haemolysis, G6PD deficiency, RBC membrane/enzyme disorders, bruising/cephalhaematoma, polycythaemia, sepsis, poor intake, prematurity and rare UGT disorders.'), ('Why is jaundice in the first 24 hours concerning?','Physiological jaundice rarely begins on day 1. Early jaundice suggests pathology, particularly haemolysis, and warrants prompt bilirubin measurement and evaluation.'), ('How does phototherapy work?','It converts bilirubin in skin into water-soluble photoisomers that can be excreted without hepatic conjugation.'), ('What determines phototherapy threshold?','Use the current chart based on postnatal age in hours, gestational age and neurotoxicity risk factors. Do not quote a universal number.'), ('What is exchange transfusion?','A time-critical blood replacement procedure that rapidly reduces bilirubin and removes antibody-coated/haemolysing RBCs. It requires an equipped neonatal setting.'), ('When should escalation of care be initiated in the AAP 2022 framework?','For infants at least 35 weeks, it is at TSB 2 mg/dL below the exchange-transfusion threshold. Apply the appropriate local chart, especially for preterm infants.'), ('When is exchange transfusion urgent?','At or above the charted exchange threshold, or if ABE signs are present, while intensive phototherapy and treatment of the underlying cause continue.'), ('What is the role of IVIG?','It may be considered in selected isoimmune haemolytic disease approaching escalation thresholds despite intensive phototherapy, according to local protocol. It is not routine for all jaundice.'), ('How do you distinguish dystonia from spasticity?','Dystonia causes fluctuating twisting postures, often action-triggered. Spasticity is velocity-dependent resistance to passive movement. They can coexist.'), ('How do you assess dystonia in a toddler?','Observe at rest, during activity, excitement, handling and gait. Record distribution, triggers, fixed versus mobile postures and functional effect on hands, sitting, feeding and walking.'), ('What eye finding is particularly relevant?','Vertical gaze disturbance, especially limitation of upgaze, while also assessing alignment, nystagmus, pupils and visual behaviour.'), ('How do you assess hearing in this child?','OAE, ABR/BERA, tympanometry and behavioural audiometry with speech-language assessment. Parent report alone is a screen, not a diagnosis.'), ('What pattern suggests ANSD?','OAE may be preserved with abnormal/absent ABR because neural synchrony is impaired. Functional decisions also use behavioural hearing and speech perception.'), ('Can normal MRI exclude CBE?','No. MRI may support the diagnosis and exclude alternatives, but normal MRI does not rule out clinical CBE.'), ('What MRI finding can occur?','Symmetric globus pallidus signal abnormality is classically described, although timing and sequences affect appearance.'), ('Why assess feeding and nutrition?','Oro-motor dysfunction can cause prolonged feeds, aspiration, inadequate intake, constipation and poor growth; these are modifiable functional problems.'), ('How do you distinguish CBE from HIE?','Use perinatal history, neonatal records, phenotype and MRI. HIE is linked to hypoxic-ischaemic events; CBE has a severe jaundice/ABE course with auditory and gaze clues. Coexistence is possible.'), ('When do you pursue genetic/metabolic evaluation?','With regression, progression, episodic decompensation, diurnal variation, family history, atypical MRI, dysmorphism or findings not explained by neonatal jaundice.'), ('What is EEG’s role?','EEG is for events suspicious for epilepsy or unexplained altered awareness. It does not diagnose dystonia.'), ('What are your immediate priorities now?','Retrieve neonatal records; define hearing, vision, feeding, nutrition, development and motor phenotype; start multidisciplinary rehabilitation without waiting for every test.'), ('How do you manage the motor disorder?','Goal-based PT/OT, positioning, seating, ROM, orthoses and hip surveillance. Specialist drugs/procedures are chosen after defining dystonia versus spasticity and functional goals.'), ('How do you manage communication?','Start early speech-language input, parent coaching, hearing pathway, gestures/sign-supported communication and AAC if needed. Do not wait for diagnostic completion.'), ('When would cochlear implant assessment be considered?','After comprehensive audiology and ENT assessment when functional hearing impairment is significant and the child may benefit. In ANSD, do not rely on ABR alone.'), ('How will you assess severity/function?','Use standardised development testing and, where feasible, GMFCS, MACS, CFCS and EDACS.'), ('Why is “no regression” clinically useful?','It supports a static injury but does not prove CBE. Reassess at each follow-up because new regression changes the differential.'), ('What neonatal records are indispensable?','Gestation, age at jaundice onset, serial total/direct bilirubin and rate of rise, maternal/infant blood groups, DAT, Hb/retics/smear, G6PD, albumin, sepsis data, phototherapy and exchange details.'), ('What is your parent counselling message?','The old neonatal illness may be relevant, but we need objective confirmation and full assessment. Early therapy, communication support, safe feeding and regular follow-up can improve function and participation.'), ('What is your final HOD closing statement?','“I will confirm the neonatal exposure and current phenotype, avoid premature attribution, urgently address hearing, feeding and communication, and provide function-centred multidisciplinary rehabilitation while excluding alternate causes when indicated.”')] traps=[ ('“The child had exchange transfusion, so this is kernicterus.”','Exchange transfusion is treatment for severe jaundice or risk, not proof of brain injury.','“This is probable CBE only if the characteristic phenotype and neonatal evidence support it; I will exclude alternatives.”'), ('“TSB above 20 mg/dL always causes kernicterus.”','There is no single universal toxicity cutoff. Risk depends on age, gestation, haemolysis, albumin/free bilirubin, sepsis and instability.','“I interpret bilirubin on an hour-specific, gestation- and risk-adjusted chart.”'), ('“Poor response to sound means SNHL.”','It may be conductive loss, ANSD, global delay, attention deficit or language impairment.','“I will document suspected hearing impairment and obtain OAE, ABR/BERA, tympanometry and behavioural audiometry.”'), ('“Absent/abnormal ABR alone diagnoses ANSD.”','ANSD is an audiological pattern; OAE, ABR, middle-ear status and functional hearing/speech perception must be integrated.','“I will seek the characteristic electrophysiological pattern and audiologist interpretation.”'), ('“All abnormal movements here are seizures.”','Dystonia, choreoathetosis and startle can mimic seizures.','“I will use semiology, video and EEG when clinically indicated before starting/altering antiseizure therapy.”'), ('“Spasticity and dystonia are the same.”','They are different tone/movement phenomena and management differs.','“I will describe velocity-dependent spasticity separately from action-triggered twisting dystonia.”'), ('“Normal MRI rules out bilirubin encephalopathy.”','CBE is a clinical diagnosis supported by history and phenotype; MRI sensitivity varies.','“MRI supports/excludes alternatives but does not alone rule out CBE.”'), ('“Cerebral palsy is the aetiological diagnosis.”','CP is a clinical syndrome of permanent motor impairment, not the underlying cause.','“I will state CP phenotype, then give likely aetiology and degree of certainty.”'), ('“Developmental quotient can be calculated from delayed walking alone.”','DQ requires developmental age across domains, preferably standardised testing.','“I will provide domain-wise developmental assessment using DASII/Bayley or an appropriate tool.”'), ('“Flexor plantar at 18 months excludes UMN disease.”','Plantar response is age-dependent and must be interpreted with the full examination.','“I will integrate tone, DTRs, clonus, posture and function.”'), ('“Phototherapy threshold and exchange threshold are fixed numbers.”','They vary by age in hours, gestation and neurotoxicity risks; preterm guidance differs.','“I will use the current local neonatal chart.”'), ('“Seizures are required for ABE.”','Seizures are late/advanced and may be absent. Early ABE often presents with poor feeding, lethargy, tone change and high-pitched cry.','“I will actively ask for the whole temporal evolution.”'), ('“Cognition must be severely impaired in kernicterus.”','Cognition may be relatively preserved despite severe motor, speech and auditory disability.','“I will use accessible formal assessment and avoid equating dysarthria or hearing impairment with low cognition.”'), ('“A normal newborn examination excludes later CBE.”','Early signs can be subtle or missed, and chronic phenotype evolves over months.','“I will review bilirubin exposure, neonatal symptoms and longitudinal development.”'), ('“Start drug therapy before rehabilitation.”','Drugs do not replace function-centred therapy and may cause harm if phenotype/goals are unclear.','“I will set functional goals and use PT/OT/communication/feeding plans first, adding specialist therapy when indicated.”'), ('“Hearing aids or cochlear implants are automatically effective in all ANSD.”','Benefit is variable and depends on site of lesion and functional hearing/speech outcomes.','“Audiology and ENT should individualise the pathway using behavioural and speech-perception outcomes.”'), ('“No regression means no need for follow-up.”','Static injuries still require evolving assessment of hips, feeding, hearing, vision, communication, pain and participation.','“I will arrange longitudinal multidisciplinary follow-up.”'), ('“The cause is breast milk jaundice because jaundice was prolonged.”','Severe early jaundice requiring exchange demands a haemolysis and pathology work-up; breast milk jaundice is a diagnosis of context/exclusion.','“I will review timing, bilirubin fractions and haemolysis evaluation before assigning cause.”'), ('“Direct bilirubin is irrelevant in a jaundiced infant.”','A raised direct fraction suggests cholestasis/hepatobiliary disease and changes the differential and work-up.','“I will always document both total and direct bilirubin.”'), ('“A single parent-recalled bilirubin value is enough.”','Recall may be inaccurate and gives no timing, fraction, gestation or trajectory.','“I will retrieve original discharge/NICU laboratory records.”')] story=[P('VIVA-ONLY: HOD QUESTIONS, MODEL ANSWERS & EXAMINER TRAPS',T),P('Chronic bilirubin encephalopathy / kernicterus spectrum disorder',ST),P('<b>Exam rule:</b> Answer in one clear sentence, then justify with one clinical reason. Never quote a universal bilirubin treatment cutoff. All neonatal treatment decisions require a current local, gestation-specific, age-in-hours guideline.',B),Spacer(1,5),P('Part A. 40 high-yield HOD-style questions with model answers',H)] for i,(q,a) in enumerate(qs,1):story += [qa(i,q,a),Spacer(1,3)] story += [PageBreak(),P('Part B. 20 examiner traps with safe corrections',H),P('These are the statements that commonly lose marks because they overstate the diagnosis, misuse a threshold or confuse phenotype with cause.',B)] for i,x in enumerate(traps,1):story += [trap(i,*x),Spacer(1,3)] story += [P('Rapid closing checklist',H),P('Before ending the viva, state: <b>“I will confirm neonatal bilirubin exposure and cause; objectively assess hearing, vision, feeding and developmental function; define dystonia versus spasticity; exclude atypical/progressive alternate aetiologies; and institute multidisciplinary rehabilitation now.”</b>',B),P('References',H),P('AAP 2022 hyperbilirubinaemia guideline for newborns ≥35 weeks and its quick-reference tools. Bradley and Daroff’s <i>Neurology in Clinical Practice</i>, pp. 1250 and 2866. Rosen’s <i>Emergency Medicine</i>, ABE clinical features. Lai NM et al., <i>Neonatology</i>, 2021, PMID 34731859. Use local current neonatal jaundice protocol for patient care.',B)] SimpleDocTemplate(str(out),pagesize=A4,leftMargin=14*mm,rightMargin=14*mm,topMargin=12*mm,bottomMargin=16*mm,title='Viva Only: Examiner Traps in Bilirubin Encephalopathy').build(story,onFirstPage=foot,onLaterPages=foot) r=PdfReader(str(out));tx='\n'.join((x.extract_text() or '') for x in r.pages) print('pages',len(r.pages),'bytes',out.stat().st_size,'keys',all(k in tx for k in ['EXAMINER TRAP 20','Part A. 40','Rapid closing checklist'])) PY

2025 guideline neonatal hyperbilirubinemia management guideline 2024 bilirubin encephalopathy

neonatal hyperbilirubinemia guideline

~/long-case-bilirubin/output

python - <<'PY' from pathlib import Path from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.colors import HexColor from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER from reportlab.platypus import SimpleDocTemplate, Paragraph, Table, TableStyle, Spacer, PageBreak from reportlab.lib.units import mm from pypdf import PdfReader, PdfWriter src=Path('/tmp/workspace/long-case-bilirubin/output/Viva_Only_50_HOD_QA_Examiner_Traps_Bilirubin_Encephalopathy.pdf') append=Path('/tmp/workspace/long-case-bilirubin/output/Recent_Guideline_References_and_Citation_Notes.pdf') out=Path('/tmp/workspace/long-case-bilirubin/output/Viva_Only_50_HOD_QA_Examiner_Traps_Recent_Guidelines_Cited.pdf') # Confirm source content exists before producing updated version r0=PdfReader(str(src)); assert len(r0.pages)==5 ss=getSampleStyleSheet(); navy=HexColor('#0B4F6C'); teal=HexColor('#087E8B'); pale=HexColor('#EAF5F7'); gold=HexColor('#FFF3D2'); ink=HexColor('#172A34') T=ParagraphStyle('T',parent=ss['Title'],fontName='Helvetica-Bold',fontSize=18,leading=22,alignment=TA_CENTER,textColor=navy,spaceAfter=6) ST=ParagraphStyle('ST',parent=ss['Normal'],fontSize=8.8,leading=11,alignment=TA_CENTER,textColor=HexColor('#52646D'),spaceAfter=10) H=ParagraphStyle('H',parent=ss['Heading1'],fontName='Helvetica-Bold',fontSize=13,leading=16,textColor=navy,spaceBefore=6,spaceAfter=5) B=ParagraphStyle('B',parent=ss['BodyText'],fontName='Helvetica',fontSize=8.25,leading=10.45,textColor=ink,spaceAfter=3) S=ParagraphStyle('S',parent=B,fontSize=7.55,leading=9.25) L=ParagraphStyle('L',parent=S,fontName='Helvetica-Bold') TH=ParagraphStyle('TH',parent=S,fontName='Helvetica-Bold',textColor=colors.white,alignment=TA_CENTER) def P(x,s=B): return Paragraph(x,s) def tbl(rows, widths=(41*mm,140*mm), head=('Viva statement / topic','Citation note and safe use')): d=[[P(head[0],TH),P(head[1],TH)]]+[[P(a,L),P(b,S)] for a,b in rows] t=Table(d,colWidths=list(widths),repeatRows=1,hAlign='LEFT') t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,0),navy),('BACKGROUND',(0,1),(0,-1),pale),('GRID',(0,0),(-1,-1),.25,HexColor('#A8C6CD')),('VALIGN',(0,0),(-1,-1),'TOP'),('LEFTPADDING',(0,0),(-1,-1),2.3*mm),('RIGHTPADDING',(0,0),(-1,-1),2.3*mm),('TOPPADDING',(0,0),(-1,-1),1.6*mm),('BOTTOMPADDING',(0,0),(-1,-1),1.6*mm)]));return t def note(x): t=Table([[P('<b>Exam-safe citation language:</b> '+x,S)]],colWidths=[181*mm]);t.setStyle(TableStyle([('BACKGROUND',(0,0),(-1,-1),gold),('BOX',(0,0),(-1,-1),.3,HexColor('#D7B659')),('LEFTPADDING',(0,0),(-1,-1),3*mm),('RIGHTPADDING',(0,0),(-1,-1),3*mm),('TOPPADDING',(0,0),(-1,-1),2.2*mm),('BOTTOMPADDING',(0,0),(-1,-1),2.2*mm)]));return t def foot(c,d): c.saveState();c.setStrokeColor(HexColor('#A8C6CD'));c.line(13*mm,12*mm,197*mm,12*mm);c.setFont('Helvetica',7);c.setFillColor(HexColor('#52646D'));c.drawString(13*mm,7.5*mm,'Viva-only update | Recent guidelines and citation notes');c.drawRightString(197*mm,7.5*mm,f'Appendix page {d.page}');c.restoreState() story=[P('RECENT GUIDELINE REFERENCES & CITATION NOTES',T),P('Addendum to Viva-only HOD questions and examiner traps | Verified September 2026',ST),note('For patient care, follow the current protocol used in your NICU. Guideline charts are population-specific. Do not transfer AAP or Canadian thresholds to preterm infants or to another setting without checking the applicable local protocol.'),P('1. Current guideline hierarchy for viva',H),tbl([ ('AAP 2022 guideline','Kemper AR, Newman TB, Slaughter JL, et al. <i>Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.</i> Pediatrics. 2022;150(3):e2022058859. DOI: 10.1542/peds.2022-058859. PMID 35927462. Applies to newborns <b>≥35 weeks</b>. The AAP states the guidance remains valid through August 2027.'), ('AAP escalation-of-care','AAP quick-reference tools define the escalation-of-care threshold as <b>2 mg/dL below the exchange-transfusion threshold</b>. Use the exact hour-specific chart and account for gestational age and neurotoxicity risk factors.'), ('Canadian guideline 2025','Ng E, Altit G, Joynt C, et al., Canadian Paediatric Society Fetus and Newborn Committee. <i>Guidelines for detection and management of hyperbilirubinemia in term and late preterm newborns (≥35 weeks gestational age).</i> Posted 18 March 2025; addendum 18 December 2025. This is a current international comparator, not a replacement for Indian/local protocol.'), ('Canadian pre-exchange trigger','The CPS 2025 guideline defines pre-exchange threshold as TSB ≤30 μmol/L below the exchange threshold. This differs in expression from the AAP 2 mg/dL framework, while representing a similar pre-exchange escalation concept. Do not mix charts.'), ('Recent review','Wickremasinghe AC, Kuzniewicz MW. <i>Neonatal Hyperbilirubinemia.</i> Pediatr Clin North Am. 2025. PMID 40619190. Useful for contextual review, but it does not replace a guideline threshold chart.'), ('KSD evidence','Lai NM, Gerard JP, Ngim CF, et al. <i>The Association between Serum Bilirubin and Kernicterus Spectrum Disorder: a systematic review and meta-analysis.</i> Neonatology. 2021. PMID 34731859. Useful for evidence discussion; do not quote a universal causal TSB cutoff from it.')]), P('2. Citation notes for the key viva claims',H),tbl([ ('“Use age in hours, GA and risk factors.”','Cite AAP 2022. The AAP risk-based approach uses the difference between predischarge bilirubin and the hour-specific phototherapy threshold to guide follow-up. Risk factors include lower gestation, low albumin, isoimmune/other haemolytic disease, sepsis and clinical instability.'), ('“ABE signs are poor feeding, lethargy and tone change.”','Cite Bradley and Daroff’s <i>Neurology in Clinical Practice</i>, pp. 1250 and 2866, or Rosen’s <i>Emergency Medicine</i> clinical-features section. These sources describe poor feeding, lethargy/somnolence, hypo/hypertonia, high-pitched cry, retrocollis and opisthotonus.'), ('“CBE phenotype includes dystonia, ANSD and upgaze limitation.”','Cite Bradley and Daroff’s <i>Neurology in Clinical Practice</i>, p. 2866. It describes extrapyramidal movement abnormalities, gaze disturbance, auditory deficits and dental dysplasia in chronic bilirubin encephalopathy.'), ('“ANSD is not diagnosed from a single test.”','State this as an audiology principle: integrate OAE, ABR/BERA, tympanometry and behavioural hearing/speech perception. Avoid claiming ANSD in a case sheet until formal audiology reports are available.'), ('“Normal MRI does not rule out CBE.”','Phrase cautiously: MRI may support kernicterus or reveal alternative injury, but diagnosis rests on compatible exposure and phenotype. Avoid stating MRI is diagnostic in isolation.'), ('“Free bilirubin is biologically important.”','Cite Hegyi T, Kleinfeld A. <i>Neonatal hyperbilirubinemia and the role of unbound bilirubin.</i> J Matern Fetal Neonatal Med. 2022. PMID 34957902. It supports the concept that unbound bilirubin is relevant to neurotoxicity.'), ('“Exchange transfusion is urgent with ABE.”','Cite the applicable neonatal guideline. AAP 2022 uses charted exchange threshold or clinical signs of ABE; the exact operational sequence must follow institutional protocol.'), ('“CBE cannot be diagnosed solely because exchange transfusion occurred.”','This is a clinical reasoning statement. Cite the diagnostic phenotype and record review rather than an isolated treatment history. State: “Exchange transfusion documents risk/severity, not neurological outcome by itself.”')]), P('3. How to cite in an HOD viva',H),P('Use only one short citation sentence after your answer. Examples:',B), tbl([ ('Threshold question','“For infants at least 35 weeks, I would use the AAP 2022 hour-specific and risk-adjusted chart; escalation of care is 2 mg/dL below the exchange threshold. For this unit, I will follow our current NICU protocol.”'), ('Phenotype question','“The classic chronic phenotype of bilirubin encephalopathy is dyskinetic CP, auditory dysfunction and upgaze limitation, as described in Bradley and Daroff.”'), ('Evidence question','“A systematic review by Lai and colleagues, PMID 34731859, supports an association between bilirubin exposure and kernicterus spectrum disorder, but does not justify using a single universal bilirubin cutoff.”'), ('Guideline update question','“Recent Canadian guidance was posted in 2025 for term and late-preterm infants, but thresholds must not be mixed with AAP or local Indian charts.”')]), P('4. References',H), P('1. Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. <i>Pediatrics</i>. 2022;150(3):e2022058859. doi:10.1542/peds.2022-058859. PMID: 35927462.',S), P('2. American Academy of Pediatrics. Hyperbilirubinemia Clinical Practice Guideline and Quick Reference Tools. Current AAP clinical resource, accessed 23 September 2026. The AAP notes validity through August 2027.',S), P('3. Ng E, Altit G, Joynt C, Radziminski N, Narvey M, Fetus and Newborn Committee. Guidelines for detection and management of hyperbilirubinemia in term and late preterm newborns (≥35 weeks gestational age). Canadian Paediatric Society. Posted 18 March 2025; addendum 18 December 2025.',S), P('4. Wickremasinghe AC, Kuzniewicz MW. Neonatal Hyperbilirubinemia. <i>Pediatr Clin North Am</i>. 2025. PMID: 40619190.',S), P('5. Lai NM, Gerard JP, Ngim CF, et al. The Association between Serum Bilirubin and Kernicterus Spectrum Disorder: a systematic review and meta-analysis. <i>Neonatology</i>. 2021. PMID: 34731859.',S), P('6. Hegyi T, Kleinfeld A. Neonatal hyperbilirubinemia and the role of unbound bilirubin. <i>J Matern Fetal Neonatal Med</i>. 2022. PMID: 34957902.',S), P('7. Bradley and Daroff’s Neurology in Clinical Practice. Hyperbilirubinemia and Hemolytic Disease of the Newborn/Kernicterus, pp. 1250 and 2866.',S) ] SimpleDocTemplate(str(append),pagesize=A4,leftMargin=14*mm,rightMargin=14*mm,topMargin=12*mm,bottomMargin=16*mm,title='Recent Guideline References and Citation Notes').build(story,onFirstPage=foot,onLaterPages=foot) writer=PdfWriter() for f in (src,append): r=PdfReader(str(f)) for page in r.pages: writer.add_page(page) with open(out,'wb') as fh:writer.write(fh) r=PdfReader(str(out));text='\n'.join((pg.extract_text() or '') for pg in r.pages) keys=['RECENT GUIDELINE REFERENCES', 'AAP 2022 guideline', 'Canadian guideline 2025', 'PMID: 35927462', 'Citation notes for the key viva claims'] print('OUT',out);print('PAGES',len(r.pages));print('BYTES',out.stat().st_size);print('CHECK',[(k,k in text) for k in keys]) PY